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Abstract 
 
The 5-hydroxytryptamine (5-HT; serotonin) 5-HT3 receptor is an excitatory ligand-
gated ion channel expressed in for example the brain and the gastrointestinal tract.  
Two major subtypes of the receptor have been studied in the most detail; the 
homomeric 5-HT3A receptor and the heteromeric 5-HT3AB receptor.  5-HT3 receptor 
antagonists are used clinically to treat chemotherapy induced and post-operative 
nausea and vomiting, and demonstrate symptomatic relief in diarrhoea-predominant 
irritable bowel syndrome (IBS-d); but unfortunately, these medications cause adverse 
effects such as constipation or rarely ischemic colitis in the latter condition.  This study 
has characterised the pharmacology of two structurally distinct 5-HT3 receptor partial 
agonists (vortioxetine and CSTI-300); and identified the unique binding properties of 
the cryptic orthosteric modulator 5-chloroindole (Cl-indole) for the human (h) 5-HT3 
receptor. Vortioxetine is a multi-modal antidepressant, which displays affinity for the 
5-HT transporter as well as a multitude of 5-HT receptors, including the 5-HT3 receptor.  
The first part of this study has identified vortioxetine as a relatively high affinity, 
competitive 5-HT3 receptor partial agonist with an intrinsic efficacy of approximately 
40-50% that of 5-HT.  Given the safety of vortioxetine in patients, it has the potential 
to be trialled in other conditions for which 5-HT3 receptor antagonists demonstrate 
efficacy but cause adverse effects, such as IBS-d or even schizophrenia.  The second 
section of this study has identified CSTI-300 as a selective, high affinity 5-HT3 receptor 
partial agonist (intrinsic activity 30-40% that of 5-HT).  Moreover, in a rodent model of 
IBS-d, CSTI-300 demonstrated comparable efficacy to alosetron, a 5-HT3 receptor 
antagonist with established efficacy in treating IBS-d.   CSTI-300 is predicted to be 
able to relieve symptoms of IBS-d in patients without eliciting the side effect profile 
associated with 5-HT3 receptor antagonism.  The final part of this study has 
demonstrated that the binding mechanism of Cl-indole for the 5-HT3A receptor is 
modulated by 5-HT3 receptor agonists, but not 5-HT3 receptor antagonists.  This could 
have implications in designing 5-HT3 receptor allosteric ligands for potentially treating 
conditions such as IBS-d. 
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1 Introduction 
 
1.1 Discovery of 5-HT   
The discovery of 5-hydroxytryptamine (5-HT, serotonin, Figure 1) began with 
Erspamer and colleagues who in 1940 identified a molecule in the gastrointestinal tract 
(GIT), which mediated contraction of smooth muscle (Erspamer et al., 1952).  This 
molecule was found to be secreted by enterochromaffin cells which line the GIT.  
Based on the localisation and chemical structure, this compound was named 
enteramine (entero-from the GIT, amine-due to its monoamine structure).  In 1948, 
Rapport et al identified serotonin (sero-serum, tonin-impacted vascular tone), as a 
plasma-borne mediator of vasoconstriction (Rapport et al., 1948).  Erspamer then 
demonstrated that these two molecules were identical, and the term 5-
hydroxytryptamine was born.  5-HT was found in various brain regions (hippocampus, 
hypothalamus and cortex) (Amin et al., 1954).    Moreover, Twarog and colleagues 
extracted 5-HT from the brains of a variety of animals (rat, rabbit and dog), and 
demonstrated it was active in a functional assay using the isolate heart from venus 
mercenaria (Twarog et al., 1953).  
 
 
 
 
 
 
 
Figure 1. The structure of 5-HT. 
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1.2 Localisation of 5-HT  
The majority of 5-HT within the human body can be found in enterochromaffin cells, 
which reside in the GIT.  Tryptophan is converted into the 5-HT precursor 5-
hyroxytryptohan (5-HTP) by tryptophan hydroxylase (TPH).  5-HT is generated from 
5-HTP by 5-hydroxytryptohan decarboxylase.  5-HT is catabolised into inactive 
metabolite 5-hydroxyindole acetic acid (5-HIAA) by monoamine oxidase (MAO).  TPH 
was initially cloned from rabbit pineal gland (Grenett et al., 1987).  It was discovered 
that knock-out mice for TPH lack peripheral 5-HT, and after screening the human 
genome, a second TPH isoform (TPH2) was discovered on chromosome 12 (Walther 
et al., 2003).  mRNA for Tph1 was predominantly detected in mouse duodenum, whilst 
Tph2 mRNA was found in the mouse brain (Walther et al., 2003).  Moreover, Sakowski 
and colleagues used antibodies selective for TPH1 and TPH2 to elucidate the 
localisation of these enzymes (Sakowski et al., 2006).  To further complement the 
mRNA studies, an antibody recognising TPH1 labelled cells in the basolateral side of 
mouse gastrointestinal mucosa, consistent with enterochromaffin cells in the gut 
(Sakowski et al., 2006).  TPH2 protein was labelled in cell bodies and axons in mouse 
mesencephalon, a pattern consistent with serotonergic neurons (Sakowski et al., 
2006). Although this suggests TPH1 and TPH2 have restricted expression, both 
isoforms have been detected (and shown to be functional) in first trimester placental 
tissue, implying expression of these isoforms maybe more complex than first thought 
(Laurent et al., 2017).    
 
There is also evidence of polymorphisms in TPH correlating with diseases (Jun et al., 
2011; Israelyan et al., 2019).  Indeed, there are associations with TPH1 
polymorphisms and diarrhoeal symptoms in irritable bowel syndrome (Jun et al., 
2011). The R441H polymorphism in human TPH2 has been identified in a selection of 
patients with treatment resistant depression (Israelyan et al., 2019).  Mice expressing 
R439H (the murine homolog of R441H) had reduced brain 5-HT levels and 
demonstrated depressive behaviours (Israelyan et al., 2019).  Interestingly there was 
a reduction in 5-HT immunoreactive cell bodies in the Enteric Nervous System (ENS), 
and these mice had slowed gastrointestinal motility (Israelyan et al., 2019).  This 
implies a potential link between synthesis of central 5-HT with development of 
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peripheral serotonergic neurons and disruption to gastrointestinal function plus mood 
disorders.   
 
In the GIT, 5-HT functions as a local hormone, mediating contraction of intestinal 
smooth muscle, as well as modulating gut activity through neurotransmitter activity 
within the ENS.  In addition, platelets take up 5-HT from the blood through the 
serotonin transporter (SERT).  5-HT is then released by platelets to induce 
vasoconstriction by contracting vascular local smooth muscle during thrombus 
formation.  5-HT also functions as a neurotransmitter in the nervous system.  Within 
the Central Nervous System (CNS), 5-HT-ergic neurons arise from the raphe nuclei 
found within the brainstem (Gothert, 2013).  These serotonergic fibres ascend to 
innervate areas such as the cerebral cortex, hippocampus, limbic areas and 
cerebellum, with 5-HT implicated in mood, emotion, cognition and homeostatic 
functions.  5-HT neurons also descend to the spinal cord and are involved in 
modulating sensory and motor responses (Gothert, 2013).  Similar to other 
monoamines (dopamine and noradrenaline) and acetylcholine, serotonin influences 
the activity of excitatory or inhibitory interneurons, through a plethora of receptors. 
 
1.3 5-HT receptors  
The physiological actions of 5-HT are mediated though interactions with its many 
different receptor subtypes; which are distributed throughout the human body.  The 
first initial description of 5-HT receptors was in the guinea pig intestine by Gaddum 
and Picarelli, who designated receptors depending on their sensitivity to morphine (M) 
or dibenzyline (D) (Gaddum et al., 1957). Bennett and Aghajanian demonstrated that 
rat brain homogenate contained [3H]-Lysergic acid diethylamide ([3H]-LSD) binding 
sites, and the level of [3H]-LSD binding could be reduced by 5-HT (which is structurally 
similar to LSD).  Specific [3H]-LSD binding sites were found in rat cortex, striatum, 
hippocampus, diencephalon, raphe nuclei and the cerebellum (Bennett et al., 1974).  
In 1979, Peroutka and Snyder used different radioligands ([3H]-5-HT, [3H]-LSD or [3H]-
spiroperidol) to distinguish two different 5-HT receptors (named 5-HT1 and 5-HT2 
receptors) based on their differential binding sensitivity to those radioligands ([3H]-5-
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HT bound 5-HT1 receptors, [3H]-spiroperidol bound 5-HT2 receptors and [3H]-LSD 
bound to both receptors with similar affinity) (Peroutka et al., 1979).  More selective 
pharmacological tools and molecular biology has enabled the discovery of 14 distinct 
5-HT receptor subtypes (Table 1).  The majority of 5-HT receptors are G-protein 
coupled receptors (GPCRs). 5-HT1 and 5-HT5A receptors are inhibitory 5-HT 
receptors, coupling to Gi protein to inhibit cyclic adenosine monophosphate (cAMP) 
production and activate K+ channels.  5-HT2 receptors mobilise Ca2+ through 
phospholipase C (PLC) dependent Gq protein stimulation (Hoyer et al., 1989).  The 5-
HT4, 5-HT6 and 5-HT7 receptors all signal through the Gs protein.  The 5-HT3 receptor 
is unusual among monoamine receptors because it is the only ligand-gated ion 
channel (LGIC), permeable to Na+, K+ and Ca2+ ions. 
 
Table 1: 5-HT receptors and their function 
Receptor 
Transduction 
mechanism 
Biological activity Example drug/ligand Side effects 
5-HT1A Gi protein. 
Somatodendritic 
autoreceptor (decrease 5-
HT release). 
Buspirone: partial 
agonist used to treat 
anxiety. 
Light-headiness, nausea 
and vomiting. 
5-HT1B Gi protein. 
Presynaptic autoreceptor 
(decrease 5-HT release). 
Also, vasoconstriction of 
coronary and cerebral 
vasculature. 
Sumatriptan: agonist 
used to treat migraines. 
Dizziness, vertigo, 
sedation. 
5-HT1D Gi protein. 
Autoreceptor (decrease 5-
HT release). 
BRL15572: antagonist. N/a. 
5-ht1e Gi protein. 
Yet to be observed in 
native tissue. 
BRL54443: agonist. N/a. 
5-HT1F Gi protein. 
Inhibits neurogenic dural 
inflammation. 
Lasmiditan: agonist 
used to treat migraines. 
Dizziness, fatigue, 
vertigo. 
5-HT1P Unknown 
Elicits slow depolarisation 
of myenteric neurones. 
5-OHIP: agonist N/a. 
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5-HT2A Gq protein. 
Increase firing of cortical 
glutamatergic and 
GABAergic neurones. 
Pimavanserin: inverse 
agonist/antagonist used 
to treat Parkinson’s 
disease psychosis. 
Somnolence, headache, 
peripheral oedema. 
5-HT2B Gq protein. 
Proliferation and 
differentiation of cardiac 
tissue. 
Anorexigenic. 
Fenfluramine: agonist 
used to treat obesity. 
Cardiac hypertrophy 
(now withdrawn from the 
market). 
5-HT2C Gq protein. 
Stimulate pro-
opiomelanocortin release 
from hypothalamus. 
Lorcaserin: agonist used 
to treat obesity. 
Headache, dizziness, 
nausea. 
5-HT3 
Na+, Ca2+ and 
K+ LGIC. 
Elicit emetic response. 
Stimulate intestinal motility 
and visceral sensation. 
 
Alosetron: antagonist 
used to treat diarrhoea-
predominant irritable 
bowel syndrome. 
Constipation, headache, 
ischemic colitis (rare). 
5-HT4 Gs protein. 
Promote gastric motility. 
Stimulate cortical 
acetylcholine release. 
Cisapride: agonist used 
to treat constipation-
predominant irritable 
bowel syndrome. 
Tachycardia (now 
withdrawn). 
5-HT5A Gi protein. 
Activates K+ channels to 
inhibit neuronal firing in the 
prefrontal cortex. 
ASP5736: antagonist N/a. 
5-HT6 Gs protein. 
Modulate release of 
neurotransmitters 
(acetylcholine, dopamine, 
noradrenaline, glutamate). 
Clozapine: 
antagonist/inverse 
agonist used to treat 
schizophrenia. 
Sedation, hypotension, 
agranulocytosis. 
5-HT7 Gs protein. 
Elicits a hypothermic 
response. 
JNJ18038683: 
antagonist 
N/a. 
 
 
1.3.1 5-HT1A receptors 
The 5-HT1A receptor functions primarily as a somatodendritic autoreceptor on raphe 
neurons, mediating feedback control of 5-HT signalling through inhibition of neuronal 
Table 1 cont. 
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activity (Barnes et al., 1999).  This receptor is also found postsynaptically in the for 
example, hippocampus, septum and cingulate gyrus.  Buspirone, a 5-HT1A receptor 
partial agonist, is used clinically in the treatment of anxiety disorders (Pytliak et al., 
2011).  Side effects are generally mild (light headiness, nausea and vomiting) (Strawn 
et al., 2018). 
 
1.3.2 5-HT1B receptors 
The 5-HT1B receptor is located on presynaptic raphe terminals as an autoreceptor.  
The 5-HT1B receptor is also found as a heteroreceptor, expressed by cholinergic 
neurons (Hoyer et al., 2002).  In addition, activation of this receptor mediates 
vasoconstriction of cerebral and coronary arteries.  Therapeutically, the -triptan class 
of drugs (e.g. sumatriptan) offer relief as anti-migraine agents with few adverse effects 
(dizziness, sedation, vertigo) (Maghbooli et al., 2014).  This is achieved through 
stimulation of 5-HT1B (and 5-HT1D) receptors on cerebral vasculature, which initiates 
vasoconstriction after circulating 5-HT elicits vasodilation (Pytliak et al., 2011). 
 
1.3.3 5-HT1D receptors 
The 5-HT1D receptor has similar pharmacology to the 5-HT1B receptor (both receptors 
display high affinity for sumatriptan) (Nichols et al., 2008).  However, in the human 
brain, 5-HT1D receptor expression is lower in comparison to the 5-HT1B receptor.  The 
5-HT1D receptor can be found in the cortex, hippocampus and substantia nigra (Barnes 
et al., 1999).  The selective antagonist BRL15572 has been used to investigate the 
function of the 5-HT1D receptor in vivo (De Vries et al., 1998). 
 
1.3.4 5-ht1e receptors 
Due to a lack of in vivo functional data, the 5-ht1e receptor is denoted in lower case.  
Expression of the receptor clone in heterologous expression systems has 
demonstrated that the 5-ht1e receptor couples negatively to Gi protein, and so is 
grouped with the other 5-HT1 receptors.  BRL54443, a 5-ht1e antagonist was used to 
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investigate the potential function of the 5-ht1e receptor in rat (Granados-Soto et al., 
2010). 
 
1.3.5 5-HT1F receptors 
Similar to the 5-HT1B and 5-HT1D receptors, the 5-HT1F receptor displays affinity for 
sumatriptan, suggesting a role for this receptor in the antimigraine activity of 
sumatriptan (Pytliak et al., 2011).  5-HT1F binding sites have been discovered in the 
hippocampus and dorsal raphe nucleus, which strongly correlates with its mRNA 
distribution (Barnes et al., 1999).  The 5-HT1F agonist lasmiditan has been approved  
to treat migraines, with dizziness, fatigue and vertigo common side effects (Neeb et 
al., 2010). 
 
1.3.6 5-HT1P receptors 
The 5-HT1P receptor is a novel receptor which has been characterised in vivo but has 
yet to be cloned and studied in recombinant expression systems (Galligan, 2007). [3H]-
5-hydroxyindalpine (5-OHIP) has been shown to label the 5-HT1P in mouse, rabbit and 
guinea pig gut (Branchek et al., 1988). The 5-HT1P receptor has been shown to elicit 
a slow excitatory post synaptic potential in the myenteric plexus of guinea pig and 
increase the frequency of peristalsis in murine colon (Galligan, 2007; Mitchell et al., 
2009).   
 
1.3.7 5-HT2A receptors 
The 5-HT2A receptor is the ‘D’ receptor which Gaddum originally described (Richard 
Green, 2006).  5-HT2A receptor stimulation elicits vascular smooth muscle contraction 
as well as functioning in platelet aggregation (Hoyer et al., 2002).  Within the CNS, this 
receptor is distributed within the cortex, nucleus accumbens and hippocampus.  
Hallucinogenic drugs (e.g. LSD) and atypical antipsychotics such as clozapine 
demonstrate high affinity for this receptor (Bockaert et al., 2006).  Recently, 
pimavanserin has been developed as a  5-HT2A inverse agonist/antagonist used to 
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treat Parkinson’s disease psychosis (Zhang et al., 2019).  Side effects including 
headache, somnolence and peripheral oedema have been experienced by patents 
taking this drug (Zhang et al., 2019). 
 
1.3.8 5-HT2B receptors 
Knock-out of the 5-HT2B receptor is embryonic lethal in mouse, implying this is the only 
essential serotonin receptor.  During neural development, the 5-HT2B receptor is 
involved in neuronal mitosis, although there is low expression of this receptor in the 
adult CNS (Barnes et al., 1999; Berger et al., 2009).  Stimulation of the 5-HT2B receptor 
also appears to trigger mitosis of myofibroblasts in the heart valves.  Fenfluramine, a 
potent 5-HT2B receptor agonist, was used in the treatment of obesity, but was 
withdrawn due to the valvopathies associated with potential 5-HT2B receptor activation 
(Berger et al., 2009; Pytliak et al., 2011).  The 5-HT2B receptor may also be implicated 
in colonic motility in rodent (Barnes et al., 2019. 
 
1.3.9 5-HT2C receptors 
The 5-HT2C receptor is unique amongst serotonergic receptors in the respect it 
undergoes RNA editing to generate a multitude of different splice variants (Pauwels, 
2000).  5-HT2C receptor agonists have been shown to be anxiogenic in vivo (with the 
converse true of antagonists), which correlates with receptor expression in cortical and 
limbic areas of the CNS (Barnes et al., 1999).  Furthermore, lorcaserin, a 5-HT2C 
receptor agonist, has received marketing authorisation (new drug application) by the 
FDA (Food and drugs administration) to reduce food intake of obese patients.  Side 
effects are mild and have been listed as headache, dizziness and nausea (Elhag et 
al., 2019). 
 
1.3.10 5-HT4 receptors 
The 5-HT4 receptor was the first 5-HT receptor to be discovered using functional 
studies (cAMP production) rather than radioligand binding experiments (Barnes et al., 
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1999).  In human, the 5-HT4 gene has 9 splice variants (Bockaert et al., 2006).  In the 
CNS, the 5-HT4 receptor modulates acetylcholine release and facilitates the 
generation of long-term potentiation (LTP), implicating this receptor in cognition, 
learning and memory (Hoyer et al., 2002).  In the colon, 5-HT4 receptors stimulate 
acetylcholine release to contract colonic smooth muscle and elicit peristalsis (Hoyer 
et al., 2002).  5-HT4 partial agonists (e.g. cisapride) were effective in treating 
constipation-predominant irritable bowel syndrome (IBS-c), but induced cardiac side 
effects (tachycardia) due to expression of 5-HT4 receptors by heart muscle (Berger et 
al., 2009). 
 
1.3.11 5-HT5A receptor 
The 5-HT5A receptor has now been recognised as a functional 5-HT receptor, with 
evidence suggesting it couples to the Gi protein to reduce adenylyl cyclase activity 
(Barnes et al, 2019).  Early 5-HT5A receptor knock-out work demonstrated evidence of 
in vivo 5-HT5A receptor activity, and recent ex vivo experiments have suggested 5-
HT5A receptors mediate K+ currents in rodent prefrontal cortex brain slices (Grailhe et 
al., 2001; Goodfellow et al., 2012).  5-HT5A receptors show widespread CNS 
expression and display high affinity for the non-selective 5-HT agonists; LSD and 5-
CT (5-Carboxamidotryptamine) (Tanaka et al., 2012).  The selective 5-HT5A antagonist 
ASP5736 appears to ablate schizophrenic symptoms in an animal model (Yamazaki 
et al., 2014). 
 
1.3.12 5-ht5b receptor 
Expression of the mouse 5-ht5b receptor in a heterologous expression system will yield 
a functional receptor, but with the transduction mechanism not fully understood.  In 
humans, a stop codon in the first exon means the protein is unlikely to be functional 
(Grailhe at al., 2001; Barnes et al, 2019). 
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1.3.13 5-HT6 receptors 
The 5-HT6 receptor is predominantly expressed in CNS regions including the nucleus 
accumbens, striatum and hippocampus.  There is limited expression outside the 
human brain, although mRNA has been found in the stomach and adrenal glands 
(Barnes et al., 1999).  A non-functional splice variant of the human 5-HT6 receptor has 
been discovered (Olsen et al., 1999).  This receptor couples positively to adenylyl 
cyclase, and has been demonstrated to increase acetylcholine release in the CNS, 
implicating the 5-HT6 receptor in cognition (Hoyer et al., 2002).   Clozapine 
demonstrates high affinity for the 5-HT6 receptor, suggesting a role for this receptor in 
schizophrenia (Pytliak et al., 2011).  Patients receiving clozapine report sedation, 
hypotension and agranulocytosis as adverse effects (Zhang et al., 2019). 
 
1.3.14 5-HT7 receptors 
The 5-HT7 receptor is expressed in the hippocampus, thalamus and hypothalamus, 
where for the latter brain region it is believed to be involved in thermoregulation and 
the circadian rhythm (Bockaert et al., 2006).  Three splice variants of the 5-HT7 
receptor exist in humans, with each differing in the length of the C-terminus and 
demonstrate differences in G-protein coupling efficacy and desensitisation (Barnes et 
al., 1999).  Similar to the 5-HT6 receptor, clozapine displays high-affinity inverse-
agonist activity at the 5-HT7 receptor (Nichols et al., 2008). In addition, the selective 
5-HT7 receptor antagonist JNJ18038683 demonstrated some anti-depressant activity 
in mouse, but this was not translated in human studies (Bonaventure et al., 2012). 
 
1.3.15 5-HT3 receptor 
The 5-HT3 receptor is the only serotonergic (and monoaminergic) receptor which is a 
LGIC, eliciting an excitatory response in cells through passage of Na+ and Ca2+ ions.   
The 5-HT3 receptor was originally, designated the ‘M’ receptor by Gaddum, due to the 
fact morphine blocked 5-HT induced muscle contraction in guinea pig ileum (Gaddum 
et al., 1957).  Radioligand binding studies in 1987 first identified 5-HT3 receptor binding 
sites in rat and human brain (Kilpatrick et al., 1987; Barnes et al., 1989).  In 1991, 
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using isolated cDNA from NCB-20 cells, the function of the 5-HT3 receptor was 
explored, and demonstrated it to be an excitatory LGIC with structural similarities to 
the nicotinic acetylcholine receptor (nAChR).  Moreover, it was confirmed to be a 
member of the cys-loop family of ionotropic receptors, which also includes the nAChR, 
GABAA (gamma[γ]-aminobutyric acid) and glycine receptor (Maricq et al., 1991). 
 
1.4 Cys-loop receptors 
Cys-loop receptors are a large family of LGICs conserved across both eukaryotic and 
prokaryotic cells.  In humans, this family includes the nAChR, GABAA receptor, glycine 
receptor and the 5-HT3 receptor.  Briefly, the structure of these proteins can be divided 
into three domains; a large extracellular N-terminus for ligand binding (which 
encompasses the cysteine loop), a transmembrane domain for ion conduction, an 
intracellular loop for receptor trafficking and function, and a small extracellular C-
terminus.  Upon receptor activation by agonist binding, a conformational shift permits 
ion flux across the cell membrane.  To promote excitatory synaptic transfer, 5-HT3 
receptors and nAChR conduct Na+ ions (and possibly Ca2+ ions depending on nAChR 
receptor subtype).  GABAA and glycine receptors on the other hand permit Cl- influx to 
induce fast inhibitory synaptic transfer.   
 
1.5 5-HT3 receptor structure   
5-HT3 receptor binding sites were first identified in rat cortex using the selective 
radioligand [3H]-GR65630.  The affinity of antagonists to compete off [3H]-GR65630 
correlated well with their ability to block depolarisation of rat vagus nerve induced by 
5-HT (Kilpatrick et al., 1987).  The first structural information regarding the 5-HT3 
receptor came in 1991 when Maricq and colleagues isolated 5-HT3 receptor cDNA 
from NCB-20 cells.  It was demonstrated to have 487 amino acids, with a molecular 
weight of 56 kDa.  The 5-HT3 receptor showed sequence similarity to the α7 nAChR, 
with four transmembrane domains and a large N-terminal extracellular loop which 
contained cysteine loops (Maricq et al., 1991). 
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The 5-HT3 receptor is composed of five protein subunits (identical or non-identical) 
surrounding a channel spanning the cell surface membrane (Figure 2).  Homology 
modelling using the closely-related nAChR, along with the acetylcholine binding 
protein (AChBP, secreted by Lymnaea stagnalis at synapses to terminate cholinergic 
transmission) and prokaryotic LGICs have aided in elucidating the structure of these 
subunits.  The large extracellular N-terminus forms the ligand binding domain (where 
the classic cysteine-loops are located) between two juxtaposed subunits.  One protein 
(termed the principle subunit) contributes 3 loops (noted A, B and C) and these loops 
form the binding site for orthosteric ligands with 3 loops (D, E and F) from the adjacent 
complementary subunit.  Research has shown that the majority of the amino acids in 
this structure aid in maintaining the binding pocket as well as playing a part in channel 
gating (Thompson et al., 2006; Barnes et al., 2009).  The structure of the mouse 5-
HT3A receptor has been dissected using crystal structure techniques.  It was 
demonstrated that each receptor subunit was formed by a twisted β-sandwich 
generating the extracellular domain and four helical transmembrane domains (Figure 
2) (Hassaine et al., 2014; Basak et al., 2018). 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. The basic structure of the 5-HT3 receptor.  
This figure highlights the general location of the principle (A, B, C) and 
complementary (D, E, F) loops within the N-terminus of the 5-HT3 receptor.  The 
transmembrane domains can also be seen, with M2 forming the channel pore.  The 
large intracellular loop between M3 and M4 serves as a modulatory domain in 
receptor function; and the small C-terminus is important for receptor trafficking 
(Thompson et al., 2007). 
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Studies have found selective roles for various amino acid residues within the N-
terminal loops.  In the mouse 5-HT3 receptor, Glutamate 106 has a critical role in 5-
HT3 receptor pharmacology.  Mutating this residue to aspartate caused the affinity of 
the radioligand [3H]-GR65630 to be decreased compared to wild-type receptor (Boess 
et al., 1997).  Furthermore, in competition binding assays, the affinity for 5-HT and 
ondansetron, granisetron and renzapride were also decreased at the mutant receptor.  
Although the potency of 5-HT was similar in the mutant receptor compared to wild-
type receptor, the Hill coefficient was reduced to unity in the mutant receptor compared 
to approximately 2 in the wild type receptor, implying a lack of cooperative binding of 
5-HT for the mutant receptor (Boess et al., 1997).  It was suggested that this residue 
may form a hydrogen bond with 5-HT (Boess et al., 1997).  Furthermore, mutating 
asparagine 128 to glycine or lysine caused the potency of 5-HT to be reduced, whilst 
the converse was true when this residue was changed to valine (Price et al., 2008).   
Any mutations to glutamate 129 generated a receptor that failed to respond to 5-HT 
or demonstrate any [3H]-granisetron binding.   It was deduced therefore that 
asparagine 128 is involved in channel gating, meanwhile glutamate 129 is implicated 
in ligand binding, similar to glutamate 106 (Price et al., 2008).  Within loop B, 
tryptophan 183 is thought to be critical in forming a cation-π interaction with 5-HT.  
This was determined by incorporating unnatural amino acids into the 5-HT3 receptor 
and evaluating its function using electrophysiology.  Introducing a fluorine atom into 
tryptophan prevents the formation of cation-π interactions (Beene et al., 2002).  The 
potency of 5-HT is reduced compared to wild type receptor when more fluorine atoms 
are incorporated into tryptophan 183.  Interestingly, the EC50 of 5-HT is not impacted 
when fluorine atoms are added to tryptophan 90 (in loop D), suggesting this residue 
does not form cation-π interactions with 5-HT (Beene et al., 2002). 
 
The most inter-species variability is noticed within loop C, and hence the species-
specific differences in drug action.  Tyrosine residues are thought to be important for 
5-HT3 receptor function (Price et al., 2004).  Mutating tyrosine 50 or tyrosine 91 
generated receptors which did not reach the cell surface and were also not functional 
in electrophysiology experiments.   Moreover, tyrosine 234 in loop C was shown to be 
important in either ligand binding or receptor gating, because mutating this amino acid 
generated a non-functional receptor (Price et al., 2004).  Using a photo-crosslinking 
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granisetron analogue, it was discovered this ligand covalently bound to methionine 
228 in loop C, suggesting an important role for this residue in antagonist binding to the 
5-HT3A receptor (Jack et al., 2018).  The conformation of loop C correlates with 
occupancy of ligand, and functional channel gate (i.e. antagonists leave the loop in an 
open shape, whilst agonists induce a closed shape) (Hassaine et al., 2014; Basak et 
al., 2018).   
 
Within loop D of the complementary subunit, tryptophan 90 is important for ligand 
binding.  Mutating this residue to tyrosine generated a receptor for which 5-HT 
displayed reduced potency and [3H]-granisetron demonstrated reduced affinity.  This 
suggests this residue is important for ligand binding (Spier et al., 2000).  This is also 
true for tryptophan 183, which also displayed slower desensitisation kinetics.  
Tryptophan 95, when mutated to tyrosine, produced a receptor which did not reach 
the cell surface, implicating this amino acid in receptor formation or assembly (Spier 
et al., 2000).  Within loop E, tyrosine residues have been shown to be important for 
ligand binding and 5-HT3 receptor function.  By mutating tyrosine 141 to alanine or 
serine, the 5-HT induced agonist response was similar to wildtype receptor, but the 
affinity for [3H]-granisetron was reduced, implicating this residue in antagonist binding 
and not receptor gating (Beene et al., 2004).  Tyrosine 143 is thought to be involved 
in 5-HT3 receptor function, because 5-HT displayed decreased potency at alanine or 
serine mutants; although [3H]-granisetron binding affinity remains unaffected.  5-HT3 
receptors in which tyrosine 153 is mutated to alanine or serine displayed reduced 
affinity for [3H]-granisetron and an increased EC50 for 5-HT; which implicated this 
residue in both channel gating and ligand binding (Beene et al., 2004). 
 
Like many transmembrane proteins, the 5-HT3 receptor undergoes post-translational 
modifications before cell surface expression.  One example is N-linked glycosylation.  
It has been shown that preventing N-linked glycosylation, either pharmacologically 
(using tunicamycin) or genetically (mutating various asparagine residues within the N-
terminus), causes a reduction in binding of [3H]-granisetron (Monk et al., 2004).  
Immunoreactivity studies showed that cell surface receptor expression is prevented 
by tunicamycin.  It was concluded therefore that N-glycosylation is necessary for 
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stabilising the receptor at the cell surface after transit from the endoplasmic reticulum 
(Monk et al., 2004).     
 
A conserved proline residue (proline 256) in the M1 domain have been shown to be 
essential in 5-HT3 receptor function.  5-HT fails to elicit a response at the 5-HT3 
receptor when this proline residue is mutated to alanine, glycine or leucine probing 
(Dang et al., 2000).  Interestingly, these mutations do not affect the level of [3H]-
granisetron binding.   The M2 domain contains an α-helix which is known to line the 
channel pore and play an essential role in determining ion conductance (both size and 
flux) (Peters et al., 1992; Lummis, 2012). By mutating various residues within the 
transmembrane domain, the charge selectivity can be altered so the 5-HT3 receptor 
now conducts anions (Lummis, 2012).  The M2 domain forms straight helices which 
lie parallel to the pore axis, with aspartate 105 at the extracellular end.  This is then 
followed by hydrophobic rings (isoleucine, valine, leucine), which act as a gate to stop 
ion conduction, and finally threonine, serine and glutamate form the intracellular end 
(Hassaine et al., 2014; Basak et al., 2018).  There is a large intracellular loop between 
the M3 and M4 transmembrane domains.  This loop contains potential phosphorylation 
sites, and serves a modulatory role in receptor trafficking, modulation and ion 
conductance (Walstab et al., 2010; Lummis, 2012).  The M4 transmembrane domain 
lies close to the cys loops and has a role in channel gating.   
 
It was established that the final residues of the C-terminus of the 5-HT3 receptor is 
critical in receptor formation (Butler et al., 2009).  If the last two (glutamine 453 and 
tyrosine 454) residues from the C-terminus are deleted, there is a significant reduction 
in the formation of [3H]-granisetron binding sites (Butler et al., 2009). Moreover, this is 
also replicated when the final alanine amino acid is deleted.  The importance of alanine 
residues in the C-terminus is further strengthened when additional alanine residues 
are added to the C-terminus; or when the before-mentioned glutamine and tyrosine 
are mutated to alanine because these modifications lead to an increase in the 
formation of 5-HT3 receptor binding sites greater than wild type receptor (Butler et al., 
2009).  Cell surface expression of 5-HT3 receptor (visualised by 
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immunocytochemistry) is also diminished when the final residues of the C-terminus 
are deleted (Butler et al., 2009). 
 
1.6 Subunits of the 5-HT3 receptor 
Like the other Cys-loop receptors, the 5-HT3 receptor is composed of 5 protein 
subunits.  In 1991 the first subunit (termed 5-HT3A) was found to be able to generate 
a functional homomeric receptor in expression systems, unlike nAChR which require 
the assistance of chaperone proteins such as RIC-3 (resistance to inhibitors of 
cholinesterase 3) to transit to the cell surface (Lummis, 2012).  It was however noticed 
that the single channel conductance of the 5-HT3A receptor in expression systems 
(e.g. human embryonic kidney [HEK] 293 cells) does not correspond to what is seen 
in native tissue (e.g. rabbit nodose ganglion neurons).  This inconsistency could not 
be explained until 1999 when a second 5-HT3 subunit (termed 5-HT3B) was identified 
by screening the human genome (Dubin et al., 1999). The 5-HT3B subunit is 
approximately 44% identical to the 5-HT3A subunit.  Unlike the 5-HT3A subunit, the 
5-HT3B protein does not form a functional receptor in cell cultures, instead it requires 
the 5-HT3A subunit to form a non-identical heteromeric receptor complex (the 5-
HT3AB receptor) (Davies et al., 1999).  Surface labelling of the 5-HT3B subunit was 
only present when the 5-HT3A protein was co-transfected in HEK293 cells (Monk et 
al., 2001; Reeves et al., 2006).  Co-expression of these two subunits generates a 
receptor with high single channel conductance, and therefore it has similar biophysical 
properties to native tissue.  Since the discovery of the 5-HT3B subunit, the 5-HT3C, 
5-HT3D and 5-HT3E subunits have all been identified (Niesler et al., 2003; Niesler et 
al., 2007; Jensen et al., 2008; Barnes et al., 2009).   
 
The 5-HT3A and 5-HT3AB receptors are the two most commonly studied 5-HT3 
receptor isoforms; and these two subtypes have subtle differences in pharmacology 
and biophysical properties.  One of the biggest differences between the 5-HT3A and 
5-HT3AB receptor is single channel conductance, which is greater in the 5-HT3AB 
receptor compared to the 5-HT3A receptor.  The reason behind this was determined 
using chimeric constructs of 5-HT3A and 5-HT3AB receptors (Kelley et al., 2003).  
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Three arginine residues within the cytoplasmic loop between the M3 and M4 (Figure 
1) transmembrane domains in the 5-HT3A receptor are responsible for the low single 
channel conductance (Kelley et al., 2003).  When these residues are mutated to QDA 
(glutamine, aspartate, alanine) as seen in the 5-HT3AB receptor, the single channel 
conductance of the 5-HT3A receptor matches that of the 5-HT3AB receptor (Kelley et 
al., 2003). The 5-HT3A receptor also has an inwardly rectifying current-voltage 
relationship whereas this correlation is linear for the 5-HT3AB receptor (Davies et al., 
1999; Dubin et al., 1999).  In addition, the 5-HT3A receptor has increased Ca2+ 
permeability and slower desensitisation kinetics when contrasted against the 5-HT3AB 
receptor (Davies et al., 1999; Dubin et al., 1999; Stewart et al., 2003).  An aspartate 
residue in the 5-HT3A receptor may be responsible for this difference in Ca2+ 
conductance.  Mutating aspartate 293 in the 5-HT3A receptor has been shown to 
reduce calcium permeability, to a conductance similar to the 5-HT3AB receptor 
(Livesey et al., 2008). 
 
It is important to note that 5-HT and other orthosteric ligands bind at an A-A interface 
in both the homomeric and heteromeric receptor subtypes (Lochner et al., 2010).  
Therefore, both receptor isoforms show similar pharmacology, although 5-HT has 
slightly higher affinity for the 5-HT3A receptor compared to the 5-HT3AB receptor 
(Brady et al., 2001).  With that, ligands such as picrotoxin show marginally different 
sensitivities to each receptor subtype (Brady et al., 2001; Thompson et al., 2013). The 
compound VUF10166 displayed different pharmacology at the 5-HT3A and 5-HT3AB 
receptors.  This ligand demonstrated lower affinity at the 5-HT3AB receptor compared 
to the 5-HT3A receptor; and whilst it behaved as a competitive ligand at the 5-HT3A 
receptor, VUF10166 appeared to show a non-competitive interaction at the 5-HT3AB 
receptor (Thompson et al., 2012).  Functionally, the 5-HT3A receptor recovered from 
VUF10166 inhibition; yet at the 5-HT3AB receptor the recovery from VUF10166 
inhibition was faster  (Thompson et al., 2012).  The pharmacology of VUF10166 was 
further explored using [3H]-VUF10166.  At the 5-HT3A receptor, [3H]-VUF10166 
labelled a population of saturable binding sites with high affinity and labelled a similar 
density of receptors compared to [3H]-granisetron (Thompson et al., 2014). At the 5-
HT3AB receptor, saturation radioligand binding studies demonstrated that the binding 
of [3H]-VUF10166 did not fit a one site model hypothesis.  Below 3.0 nM, the binding 
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of [3H]-VUF10166 appeared similar at both receptor subtypes.  It was suggested that 
above 3.0 nM, [3H]-VUF10166 interacts with an A-B binding site at the 5-HT3AB 
receptor (Thompson et al., 2014). 
Positive staining for the 5-HT3B subunit has been detected within the rat 
hippocampus, with a diffuse population of cells showing similar morphology and 
distribution to interneurons, which is comparable to the 5-HT3A protein (Monk et al., 
2001; Reeves et al., 2006). mRNA for the 5-HT3B subunit has been detected in the 
human brain (caudate, hippocampus, amygdala, thalamus and cerebral cortex) 
(Davies et al., 1999; Dubin et al., 1999).  Within the  Immunoreactivity for the 5-HT3B 
protein has also been identified in the human hippocampus (Brady et al., 2007). 
 
Recently, novel 5-HT3 receptor subunits (5-HT3C, 5-HT3D and 5-HT3E) have been 
identified and characterised (Niesler et al., 2007).  The HTR3C gene was found on 
chromosome 3 following a search of the human genome using the 5-HT3A and 5-
HT3B protein sequences (Karnovsky et al., 2003).  The two most recent genes, 
HTR3D and HTR3E were cloned from human kidney tissue (Niesler et al., 2003). The 
HTR3C, HTR3D and HTR3E genes are between 82.8-90.1% identical, with each 
protein subunit showing between 64.8-74.3% similarities.  However, when compared 
to the 5-HT3A and 5-HT3B subunits, the similarity is between 26.8-39.8% (Niesler et 
al., 2003).  The 5-HT3C, 5-HT3D and 5-HT3E subunits are conserved across other 
mammalian species (e.g. dog and chimpanzee) but are not present in rodent 
(Holbrook et al., 2009).  Interestingly, the 5-HT3D subunit has a truncated N-terminus 
which is missing the cysteine loops, suggesting this subunit cannot contribute to a 
functional agonist binding site.  The 5-HT3C subunit showed a similar expression 
pattern to 5-HT3A and 5-HT3B mRNA, being found in brain, colon, intestine, lung and 
stomach (Niesler et al., 2003).  mRNA for 5-HT3D and 5-HT3E subunits show more 
of a restrictive expression pattern; with the 5-HT3D mRNA being localised to kidney, 
colon and liver, whilst the 5-HT3E subunit was found in colon, intestine and brain 
(Niesler et al., 2003; Holbrook et al., 2009).  Immunofluorescence studies 
demonstrated expression of the 5-HT3C, 5-HT3D and 5-HT3E subunits within neurons 
of the submucosal and myenteric plexus, and co-localised with the 5-HT3A protein 
19 
 
(Kapeller et al., 2011).  This suggests 5-HT3 receptor function in the gastrointestinal 
tract may be mediated by a plethora of different 5-HT3 receptor subunit combinations. 
Using immunocytochemistry, it was discovered that the 5-HT3C, 5-HT3D and 5-HT3E 
proteins do not reach the cell surface when expressed without the 5-HT3A subunit in 
transfected HEK293 cells (Niesler et al., 2007).  In addition, there is no specific [3H]-
GR65630 binding when the subunits are expressed in HEK293 cells in the absence of 
the 5-HT3A protein.  These subunits cannot elicit a functional response without the 5-
HT3A protein present (Niesler et al., 2007; Holbrook et al., 2009). Niesler and 
colleagues used immunoprecipitation experiments to demonstrate that when these 
novel subunits are expressed in HEK293 cells along with the 5-HT3A subunit, 
heteromeric receptor complexes are generated at the cell surface.  These heteromers 
(5-HT3AC, 5-HT3AD, and 5-HT3AE) all displayed similar affinity for the radioligand [3H]-
GR65630, although there were more binding sites detected in HEK293 cells 
expressing the 5-HT3AD and 5-HT3AE receptors, compared to 5-HT3A and 5-HT3AC 
receptors.  In functional calcium assays, 5-HT and meta-chlorophenylbiguanide 
(mCPBG) had similar potency across the different receptor combinations. However, 
the maximal response generated by 5-HT was greater at the 5-HT3AD and 5-HT3AE 
receptors, and reduced at the 5-HT3AC receptor (compared to the 5-HT3A receptor) 
(Niesler et al., 2007). Conversely, Holbrook and colleagues demonstrated that 5-HT 
responses were reduced at the 5-HT3AC and 5-HT3AE receptors compared to the 5-
HT3A receptor, whilst this response was similar at the 5-HT3D receptor (Holbrook et 
al., 2009). Moreover, mCPBG had higher intrinsic efficacy at the 5-HT3A receptor 
compared to the 5-HT3AC, 5-HT3AD and 5-HT3AE receptors (Price et al., 2017). 
 
1.7 5-HT3 receptor localisation 
Although initially discovered in the GIT, subsequent research has since pinpointed the 
5-HT3 receptor to being located within the human CNS and immune system.  5-HT3 
receptor binding sites have been identified in the human brain using the high-affinity 
radioligand [3H]-(S)-zacopride (Parker et al., 1996). The highest level of specific [3H]-
(S)-zacopride binding was found in the nucleus tractus solitarius and area postrema 
(Barnes et al., 1989; Parker et al., 1996).  Here the 5-HT3 receptor functions within the 
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chemoreceptor trigger zone (CTZ) to elicit the emetic response.  This brainstem area 
serves an important chemosensory role (not being protected by the blood-brain 
barrier), and stimulation of 5-HT3 receptors causes to the vomiting reflex (Thompson 
et al., 2007).  This knowledge contributed to the development of potent and selective 
5-HT3 receptor antagonists (known collectively as the –setrons e.g. ondansetron and 
granisetron) which are utilised therapeutically for post-operative nausea and vomiting 
(PONV) as well as cancer chemotherapy-induced nausea and vomiting (CINV).  
  
In addition, regions of the human forebrain also show discrete expression of the 5-HT3 
receptor.  Specific [3H]-(S)-zacopride binding was identified in the hippocampus 
(specifically the granule layer of the dentate gyrus and CA2 region of pyramidal cells) 
(Parker et al., 1996).  Lower levels of [3H]-(S)-zacopride binding were detected in the 
nucleus accumbens, putamen and caudate nucleus (Parker et al., 1996).  These 
higher brain centres imply a role for the 5-HT3 receptor in cognition, along with 
neuropsychiatric disorders such as schizophrenia, depression, anxiety and addiction.  
Research and clinical trials have been conducted to investigate the potential beneficial 
effects of 5-HT3 receptor antagonists for these before-mentioned neurological 
disorders (Thompson et al., 2007; Walstab et al., 2010). 
 
Within the GIT, the 5-HT3 receptor is localised to vagal afferents, enteric motor 
neurons, interstitial cells of Cajal and intrinsic primary afferent nerves (IPANS) 
(Gershon, 2004; Sanger, 2008; Fakhfouri et al., 2012; Fidalgo et al., 2013). 
Immunohistochemistry and RT-PCR have showed that both the 5-HT3A and 5-HT3B 
subunits are expressed in the submucosal plexus.  Functionally, 5-HT and selective 
5-HT3 receptor agonists induced an excitatory response in gut tissue which can be 
blocked by prior application of a 5-HT3 receptor antagonist (Michel et al., 2005).  
Enterochromaffin cells, which lie in the base of crypts in the GIT, release 5-HT in 
response to various stimuli; including intraluminal distension or vagal nerve 
stimulation.  5-HT can then induce responses through interactions with enterocytes or 
the ENS (Spiller, 2007; Manocha et al., 2012).  The 5-HT3 receptor located on these 
nerve terminals serves a significant role for visceral sensation, plus information 
transfer between the gut and brain via the ENS (Nam et al., 2018).   
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5-HT3 receptors are thought to be implicated in the pathophysiology of diarrhoea-
predominant irritable bowel syndrome (IBS-d); where they appear to be overactive.  
There is also evidence suggesting a genetic component to IBS-d (Niesler, 2011).  The 
c._76G>A variant of the HTR3E gene has been associated with IBS-d in female 
patients (Kapeller et al., 2008). This polymorphism is found in the untranslated region 
of the HTR3E gene, where after being studied in vitro, it was discovered that the 
microRNA miR510 binds to this region of the gene (Kapeller et al., 2008). Interestingly, 
miR510 plays an inhibitory role in HTR3E expression, and the c._76G>A 
polymorphism reduces miR510 binding, leading to increased expression (determined 
by a reporter gene assay) (Kapeller et al., 2008).  In situ hybridisation studies 
demonstrated co-localisation of HTR3E and miR510 in human enterocytes(Kapeller 
et al., 2008).  In addition, the c.-42C>T variant in the HTR3A gene has been shown to 
correlate with worse anxiety symptoms associated with IBS-d and increased amygdala 
activity (Kapeller et al., 2008; Kilpatrick et al., 2011; Niesler, 2011; Celli et al., 2017).  
Similar to the c._76G>A variant of the HTR3E gene, this polymorphism leads to 
increased expression of the 5-HT3A receptor in vitro, suggesting a mechanism behind 
the phenotype associated with this gene variant (Niesler, 2011; Celli et al., 2017).  A 
variant of the HTR3C gene (p.N163K rs6766410) was found to be associated with 
IBS-d patients for whom ondansetron improves stool consistency, implying a potential 
genotype correlating with response to treatment (Gunn et al., 2019). 5-HT3 receptor 
antagonists such as alosetron did provide therapeutic relief but were withdrawn and 
distribution was restricted due to severe side-effects (this will be developed further, 
see section 1.11) (Hoyer et al., 2002; Gershon, 2004; Sanger, 2008).  
 
There is emerging evidence that 5-HT via the actions of multiple receptors (including 
the 5-HT3 receptor) modulates the activity of various cells of the immune system.  
Monocytes and T cells have been shown to express 5-HT3A receptor mRNA (Fiebich 
et al., 2004).  The exact role of the 5-HT3A receptor in immunomodulation remains to 
be elucidated; however, given 5-HT is thought to be pro-inflammatory, this receptor 
may play a key role in inflammation.  Moreover, the intrinsic Ca2+ permeability of the 
5-HT3 receptor could be important for intracellular signalling and potentially cytokine 
expression or synthesis in immune cells.  Indeed, it has been demonstrated that 
tropisetron will decrease IL-2 synthesis in human T-cells stimulated with either phorbol 
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12-myristate 13-acetate (PMA) or Staphylococcal enterotoxin B (Vega et al., 2005).  
Furthermore, tropisetron decreased the production of proinflammatory cytokines (IL-
1β and IL-6) in mouse brain following Lipopolysaccharide-induced neuroinflammation 
(Yu et al., 2018).   
 
In fibromyalgia, a condition with widespread chronic body pain and inflammation, it 
has been evaluated that tropisetron improves pain (measured by visual analogue 
score), and associated depression, anxiety and sleep disturbances (symptoms highly 
associated with fibromyalgia), whilst being well tolerated  (Färber et al., 2000; Haus et 
al., 2000; Marcus, 2009). Furthermore, tropisetron has demonstrated efficacy in 
treating rheumatoid arthritis (Hrycaj, 2004).  In addition, tropisetron reduced 
hyperalgesia and mechanical allodynia in rats with neuropathic pain elicited by spinal 
compression (Nasirinezhad et al., 2016).  Taken together, this suggests a peripheral 
and central role for 5-HT3 receptors in pain and inflammation. 
 
The inflammatory nature of 5-HT in the gastrointestinal tract has been studied using a 
Tph1 knock-out mouse model (Ghia et al., 2009).  Indeed, experimental colitis (elicited 
by application of dextran sulphate) was more severe in wild-type mouse compared to 
Tph1 knock-out mouse (Ghia et al., 2009).  The knock-out mice had reduced 
macrophage infiltration and decreased levels of proinflammatory cytokines (IL-1β, IL-
6, myeloperoxidase and tumour necrosis factor alpha) compared to their wild-type 
counterparts (Ghia et al., 2009).  This anti-inflammatory phenotype was also mirrored 
with pharmacological inhibition of TPH1 using Para-chlorophenylalanine (PCPA) 
(Ghia et al., 2009). This suggests 5-HT plays a major role in the development of 
gastrointestinal inflammation.  Moreover, the levels of IL-1β, IL-6 and tumour necrosis 
factor alpha were decreased by alosetron following experimentally-induced colitis in 
mouse (Motavallian et al., 2019).  Taken together, this suggests the 5-HT3 receptor 
has an important role in both central and systemic inflammation and could be used as 
a drug target for inflammatory conditions. 
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1.8 5-HT3 receptor pharmacology 
As previously mentioned, antagonists at the 5-HT3 receptor (including but not limited 
to: ondansetron, granisetron, palonosetron) are prescribed for CINV and PONV (Billio 
et al., 2010).  As these drugs are relatively safe and expression of the 5-HT3 receptor 
is readily detectable in higher brain centres, studies have been conducted to elucidate 
if 5-HT3 receptor antagonists have potential in various neuropsychiatric conditions.  
These include schizophrenia, anxiety and substance abuse. 
 
Excess levels of 5-HT are thought to be involved in IBS-d (Bearcroft et al., 1998).  
Alosetron (a selective, high affinity 5-HT3 receptor antagonist) was prescribed as a 
treatment and was beneficial in IBS-d patients by improving visceral sensation, gut 
motility and secretions (Manocha et al., 2012).  The mild side effect of constipation 
was noted; however, post-marketing surveillance identified more severe adverse 
effects such as life-threatening ischemic colitis.  The FDA has sternly regulated the 
prescription of alosetron after its withdrawal in 2000, with only a select group of 
patients being allowed access to the drug.  This ‘black box’ approach to prescription 
of alosetron has now been withdrawn by the FDA.  Moreover, cilansetron again 
demonstrated efficacy in treating IBS-d, but similar to alosetron, there were incidences 
of ischemic colitis and so this drug was never marketed (Chey et al., 2005; Grover et 
al., 2014). A structurally different 5-HT3 receptor antagonist ramosetron, which shows 
efficacy in treating IBS-d, has been approved in Japan (Grover et al., 2014; Min et al., 
2015; Fukudo et al., 2016; Qi et al., 2018). 
 
In a clinical trial, the 5-HT3 receptor antagonist tropisetron displayed anxiolytic effects 
(Lecrubier et al., 1993).  In the rodent elevated plus maze model of anxiety, 5-HT3 
receptor antagonists appeared anxiolytic.  This is consistent with data suggesting 5-
HT3A receptor knock-out mice show reduced anxious behaviour in stressful situations  
(Barnes et al., 1999; Thompson et al., 2006). 
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The 5-HT3 receptor could be an attractive target for schizophrenia as it modulates 
midbrain dopamine signalling.  Blocking this receptor will inhibit over-active 
dopaminergic neurons in rats (Hoyer et al., 2002; Nichols et al., 2008).  The atypical 
antipsychotic clozapine potently inhibits 5-HT induced currents at the 5-HT3 receptor 
(Hermann et al., 1996).  Inhibition occurs at concentrations of clozapine which are 
detected in patient plasma, suggesting blockade of 5-HT3 receptors may contribute to 
the clinical efficacy of clozapine (Hermann et al., 1996).  In patients with schizophrenia, 
ondansetron improved p50 auditory gating, without having any benefit on the positive 
or negative symptoms of schizophrenia (E Adler et al., 2005).  Furthermore, 
schizophrenic patients administered with either tropisetron or granisetron in 
combination with the atypical antipsychotic risperidone demonstrated a significant 
improvement in general psychopathy score (specifically an improvement in negative 
symptom score) (Khodaie-Ardakani et al., 2013; Noroozian et al., 2013).  There is also 
evidence of ondansetron improving the cognitive impairment associated with 
schizophrenia (Zheng et al., 2019). 
 
The concept that 5-HT3 receptor antagonists can modulate the dopaminergic system 
has also led to research in substance abuse/addiction.  In animal studies, 5-HT3 
receptor antagonists diminished the increase in midbrain dopamine levels measured 
after administration of morphine or cocaine; which also corresponded behaviourally to 
a decrease in locomotor activity and reduced self-consumption of potentially abusive 
drugs (Thompson et al., 2007; Walstab et al., 2010).  In 5-HT3A receptor knock-out 
mice, the 5-HT3 receptor antagonist LY-278, 584 did not decrease alcohol in-take, this 
was only seen for wild-type mouse, suggesting the 5-HT3A subunit is important for the 
impact of 5-HT3 receptor antagonists on ethanol intake (Hodge et al., 2004).  
Ondansetron also diminished alcohol cravings for early onset alcoholics but not late 
onset alcoholics (Johnson et al., 2002). 
 
1.9 Introduction to allosteric modulation 
Many receptors and proteins (including GPCRs, ion channels, and kinases) have 
multiple ligand-binding sites.  These sites include the orthosteric (competitive) binding 
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site, whereby the endogenous ligand interacts (e.g. 5-HT at the 5-HT3 receptor), and 
any synthetic molecules binding to this site are orthosteric or competitive ligands (e.g. 
ondansetron at the 5-HT3 receptor).  Alternatively, some compounds appear to interact 
with proteins through a non-competitive manner, binding at a site that is distinct from 
the orthosteric site (so-called allosteric ligands/modulators).  The 5-HT3 receptor 
continually transitions between an open and closed state (even in the absence of 
agonist); and agonists shift the equilibrium of the 5-HT3 receptor more towards the 
open state.  Allosteric modulators cannot influence this equilibrium, but instead 
moderate the function of agonist.  Ligands which increase the function of a receptor in 
the presence of orthosteric agonist are positive allosteric modulators (PAMs).  
Molecules which decrease protein activity whilst agonist is bound are negative 
allosteric modulators (NAMs) (Wenthur et al., 2014).  PAMs can also be classified by 
how the affect channel kinetics; type I PAMs do not affect receptor desensitisation, 
whilst type II PAMs slow receptor desensitisation (Thomsen et al., 2012).  Many 
allosteric agents also increase the affinity of orthosteric ligand.  By only subtly 
influencing protein (in this case receptor) function, allosteric modulators offer a new 
and potentially more beneficial area of pharmacology (Thompson, 2013; Wenthur et 
al., 2014).  
 
However, some allosteric ligands function through a more complex mechanism.  For 
example, the GABAB receptor ligand CGP7930 increased the potency and efficacy of 
the endogenous agonist GABA at the GABAB receptor, akin to a PAM (Binet et al., 
2004).  In addition, CGP7930 stimulated functional responses (measured by 
accumulation of Inositol triphosphate 3) at the GABAB receptor in the absence of 
GABA.  Furthermore, whilst the actions of GABA at the GABAB receptor can be 
blocked by the competitive antagonist CGP54626; this is not true for CGP7930 (Binet 
et al., 2004).  It is thought that GABA and CGP7930 bind to different subunits of the 
dimeric GABAB receptor, with GABA interacting with the extracellular domain and 
CGP7930 binding to the heptahelical domain of the GABAB receptor. These ligands 
were then termed ‘orthosteric protomer’ and ‘allosteric protomer’ respectively (Binet et 
al., 2004; Schwartz et al., 2007). 
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Clinical examples of allosteric modulation at Cys-loop receptors are benzodiazepines 
(e.g. diazepam) which demonstrate activity as a PAM at the GABAA receptor.  These 
drugs only increase the activity of the GABAA receptor when GABA is bound (and 
interact with a distinct modulatory site).  Clinically, these drugs are safer than 
barbiturates because of a reduced overdose risk. 
 
1.10 5-HT3 receptor allosteric modulation  
The 5-HT3 receptor has multiple modulatory sites separate from the orthosteric binding 
site (Figure 3).  A diverse range of molecules (endogenous and exogenous, natural 
and synthetic) modulate agonist-induced responses at the 5-HT3 receptor.   
 
 
 
 
 
 
Figure 3. Potential ligand binding sites at the 5-HT3 receptor. 
‘Classic’ orthosteric ligands (e.g. 5-HT, ondansetron) interact within the N-terminus of the 5-
HT3 receptor, whilst allosteric ligands interact with a different site on the 5-HT3 receptor, 
including the transmembrane domain (Walstab et al., 2010). 
 
Ligands acting at the endocannabinoid receptors (CB1 and CB2 receptors) modify the 
activity of the 5-HT3 receptor via allosteric mechanisms.  Synthetic CB1 receptor 
agonists such as WIN55, 212-2 and JWH-015 all inhibited 5-HT-induced inward 
currents at the 5-HT3A receptor in a concentration-dependent manner (Barann et al., 
2002).  This activity is also true for the endocannabinoid anandamide and the plant-
derived ∆9-THC; as well as LY320135 and cannabidiol, both of which are CB1 receptor 
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antagonists (Barann et al., 2002; Yang et al., 2010).  This suggests activity at the 
endocannabinoid receptor does not correlate with allosteric actions at the 5-HT3A 
receptor.  The cannabinoid mechanism of action is not thought to be via channel block  
(Barann et al., 2002; Yang et al., 2010).  Cannabinoid ligands interacted with an 
allosteric site at the 5-HT3 receptor (demonstrated by the ligands not displacing [3H]-
GR65630 in radioligand binding studies) (Barann et al., 2002; Yang et al., 2010).  It is 
known cannabinoids are anti-emetic, and this beneficial therapeutic factor may be 
mediated via interactions at the 5-HT3A receptor (Barann et al., 2002; Walstab et al., 
2010; Yang et al., 2010).  It must also be noted however that CB1 agonists are 
sedative, and this may contribute towards their anti-emetic actions. 
 
Various terpenes and pungent substances display allosteric activity at the 5-HT3A 
receptor.  Both carvacrol and thymol increased the efficacy and potency of 5-HT at the 
5-HT3A receptor, with carvacrol slightly more potent that thymol.  In addition, both of 
these molecules displayed weak activity as partial agonists at the 5-HT3 receptor, with 
intrinsic efficacies approximately 15% of 5-HT (Ziemba et al., 2015).  The responses 
elicited by carvacrol and thymol could be blocked using the selective 5-HT3 receptor 
antagonist tropisetron.  Furthermore, these ligands have no efficacy at the mouse 5-
HT3A receptor.  Both carvacrol and thymol demonstrated activity at chimeric 
mouse/human 5-HT3A receptors (N-terminus of mouse with transmembrane and C-
terminus of human receptor); but had no effect at a chimeric human/mouse 5-HT3A 
receptor (N-terminus of human with transmembrane and C-terminus of mouse 
receptor) (Lansdell et al., 2015).  This suggests that carvacrol and thymol interact with 
the transmembrane or C-terminal domain of the 5-HT3A receptor to elicit a response, 
unlike 5-HT which binds to the N-terminus (Lansdell et al., 2015).  Furthermore, other 
related terpene molecules demonstrated allosteric inhibitory effects, including 
citronellol and linalool, which inhibited 5-HT induced responses by 98% and 93% 
respectively.  Although efficacious, both of these ligands displayed low affinity, with 
functional IC50 concentrations in the high micromolar range (Ziemba et al., 2015).   
 
Using the NCB-20 mouse neuroblastoma cell line, it was shown that ethanol (at 
concentrations considered to be intoxicating) potentiated currents induced by 5-HT 
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and 2-methyl-5-HT at the 5-HT3A receptor.  Ethanol had no functional effect at the 5-
HT3A receptor in absence of agonist.  The impact of ethanol at the 5-HT3A receptor is 
more apparent at lower 5-HT concentrations (below 1.0 μM) compared to higher 
concentrations of 5-HT (10 μM or above).  Ethanol also increased the rate of decay 
for the 5-HT current.  This suggests that pharmacologically relevant concentrations of 
ethanol influenced the activity of the 5-HT3 receptor (Lovinger, 1991).  To further 
investigate the mechanism of action of ethanol at the 5-HT3 receptor, single channel 
electrophysiology was undertaken.  Single channel conductance of the 5-HT3A 
receptor can be measured using a 5-HT3A-QDA mutant, which incorporates the 
glutamine, aspartate and alanine residues from the 5-HT3AB receptor.  Ethanol 
increased the single channel activity and the number of open 5-HT3A-QDA receptors 
(Feinberg-Zadek et al., 2010).  Moreover, at the mouse 5-HT3AB receptor, ethanol 
appeared to have no impact on 5-HT induced currents (Hayrapetyan et al., 2005). 
 
Menthol decreased currents elicited by 5-HT at the h5-HT3A receptor in a 
pharmacologically relevant concentration-dependent manner (Barann et al., 2008; 
Walstab et al., 2014).  The activity of menthol appeared to be allosteric, as menthol 
did not impact 5-HT binding at the 5-HT3A receptor, nor did it compete with [3H]-
GR56630 for 5-HT3A binding sites.  The efficacy of menthol was similar at both the 5-
HT3A and 5-HT3AB receptors (Ashoor et al., 2013).  This may be of interest as menthol 
has been used in the treatment of functional GIT disorders (Walstab et al., 2014). 
 
Although structurally similar to 5-HT, 5-hydroxyindole (5-HI) did not display agonist 
activity at the 5-HT3 receptor expressed endogenously in mouse NIE-115 
neuroblastoma cell line.  Instead, 5-HI increased the efficacy and potency of 5-HT 
through an allosteric mechanism (van Hooft et al., 1997).  5-HI also slowed 
desensitisation of the 5-HT3 receptor. The Hill slope of 5-HT concentration curves 
remains approximately 2 in the presence/absence of 5-HI; implying 5-HI does not 
affect the cooperativity of 5-HT at the 5-HT3A receptor (van Hooft et al., 1997).   
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The intravenous anaesthetic propofol reversibly inhibited 5-HT induced currents in a 
concentration-dependent manner at the 5-HT3A receptor, without having any activity 
in the absence of 5-HT. The rate at which the 5-HT3A receptor desensitised (due to 
activation by 5-HT) is increased by propfol (Barann et al., 2008).   
 
Trattnig and colleagues identified PU02 as a non-competitive inhibitor of 5-HT3 
receptors.  PU02 displayed similar potency at inhibiting 5-HT induced responses at 
the 5-HT3A, 5-HT3AB, 5-HT3AC, 5-HT3AD and 5-HT3AE receptors (Trattnig et al., 
2012).  In addition, PU02 also reduced calcium currents elicited at the α7 nAChR, 
albeit with lower potency compared to 5-HT3 receptors.  PU02 did not displace [3H]-
GR65630 from 5-HT3A receptor binding sites, suggesting an allosteric mechanism of 
action (Trattnig et al., 2012).  Mutagenesis studies identified that PU02 interacted with 
the transmembrane domains of the 5-HT3 receptor (Trattnig et al., 2012). 
 
mCPBG has similar potency as an agonist at the 5-HT3A and 5-HT3AB receptor. 
However, whilst it appeared to be a partial agonist at the 5-HT3A receptor; it 
demonstrated activity as a super-agonist at the 5-HT3AB receptor, with an intrinsic 
efficacy 2.75x greater than that of 5-HT (Miles et al., 2015).  Mutating glutamate 124 
within loop A of the 5-HT3A subunit caused mCPBG to lose all functional activity.  
However, when this mutant subunit is introduced into to the 5-HT3AB receptor, 
mCPBG still retains activity as a partial agonist.  This suggests that mCPBG can act 
at a B-A binding site at the 5-HT3AB receptor, unlike most agonists which appear to 
act at an A-A interface allosteric (Miles et al., 2015). 
 
Current research suggests that 5-chloroindole (Cl-indole) is a potent PAM at the 5-HT3 
receptor (Newman et al., 2013; Powell et al., 2016).  Using functional calcium assays 
and electrophysiology, Cl-indole had no activity at the 5-HT3A receptor in the absence 
of agonist (Powell et al., 2016).  At the 5-HT3A receptor, Cl-indole increased the 
efficacy of 5-HT and 5-HT3 receptor partial agonists.  Moreover, Cl-indole also 
demonstrated similar activity at the 5-HT3AB receptor.  Further, in radioligand binding 
assays, the affinity of 5-HT (but not the 5-HT3 receptor antagonist tropisetron) for 5-
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HT3A receptor binding sites was increased by Cl-indole (Newman et al., 2013).  Cl-
indole did not impact 5-HT3 receptor desensitisation or resensitisation.  Interestingly, 
after 5-HT is removed following co-application of 5-HT and Cl-indole, Cl-indole induces 
a tail current after the initial 5-HT response.  This tail current can be blocked by 
ondansetron (Powell et al., 2016).  Moreover, Cl-indole does not bind to the 5-HT3A 
receptor, but in the presence of 5-HT or other 5-HT3 receptor agonists, Cl-indole will 
compete for [3H]-granisetron occupied 5-HT3A receptor binding site.  This suggests 
that 5-HT can induce Cl-indole to interact with the 5-HT3A receptor through an 
orthosteric mechanism, whilst remaining potentially allosteric in the absence of 5-HT 
(Powell et al., 2016).  Cl-indole was termed a cryptic orthosteric modulator (COM), 
because of its ability to interact with the 5-HT3A receptor in through an orthosteric 
mechanism once 5-HT has activated the receptor. 
 
Furthermore, clinically relevant drugs (including: fluoxetine, flupentixol, fluphenazine, 
haloperidol and levomepromazine) are known to interact with the 5-HT3 receptor 
through non-competitive mechanisms (Choi et al., 2003; Rammes et al., 2004).  
Although fluoxetine has no efficacy at 5-HT3 receptors, it inhibited 5-HT induced 
currents in NCB-20 cells through a concentration-dependent manner (Choi et al., 
2003).  Moreover, fluoxetine also increased the rate of 5-HT3 receptor desensitisation, 
acting through a voltage independent mechanism.  In rat GIT, fluoxetine treatment 
decreased 5-HT3 receptor expression, suggesting a potential impact on receptor 
downregulation (Freeman et al., 2006). In addition, the metabolite norfluoxetine also 
blocked 5-HT3 receptors with higher potency compared to fluoxetine (Choi et al., 
2003).  This suggests some of the therapeutic efficacy of fluoxetine may be due to 5-
HT3 receptor blockade.   
 
It has been shown that various antipsychotics inhibit the 5-HT3 receptor through an 
allosteric mechanism of action.  Typical antipsychotics (including flupentixol, 
fluphenazine, haloperidol and levomepromazine) have been shown to block 5-HT 
induced responses at the 5-HT3 receptor (Rammes et al., 2004).  The inhibition was 
voltage independent, which implies the antagonism is not through channel block.  As 
5-HT3 receptors modulate dopaminergic activity in the mesolimbic and mesocortical 
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pathways; it is suggested that blockade of these receptors by antipsychotics may 
contribute to their therapy (Rammes et al., 2004). 
 
Ginger and its pungent components have been shown to allosterically modulate the 
5-HT3 receptor.  These compounds elicited a concentration-dependent decrease in 5-
HT-evoked calcium responses in HEK293 cells expressing the 5-HT3A or 5-HT3AB 
receptor; and was replicated in electrophysiology experiments with transfected 
oocytes (Walstab et al., 2013; Ziemba et al., 2015).  This was replicated in ex vivo 
experiments using human myenteric plexus.  Moreover, these compounds did not 
displace [3H]-GR65630 from 5-HT3 receptor binding sites, and failed to increase the 
potency of 5-HT; suggesting a non-competitive interaction with the 5-HT3 receptor 
(Walstab et al., 2013).  Interestingly, ginger has been shown to be effective in treating 
CINV and IBS, both of which are thought to involve 5-HT3 receptor activity (Chang et 
al., 2018; Fifi et al., 2018). 
 
1.11 Irritable bowel syndrome  
Irritable bowel syndrome (IBS) is the most prevalent functional gastrointestinal 
disorder, with approximately 11% of the population affected (Canavan et al., 2014; 
Enck et al., 2016; Lacy et al., 2016).  IBS is more common in women and younger 
adults (25-54-year olds) (Canavan et al., 2014; Lacy et al., 2016).  As this condition 
has a multifactorial pathophysiology, there is no definite treatment, rather a symptom-
based management treatment is utilised.  Although no known cause, the symptoms 
are clearly identifiable: pain and altered gut activity as defined by Rome IV criteria 
(Schmulson et al., 2017).  This defines irritable bowel syndrome as recurrent 
abdominal pain for at least one day a week for the last six months; and at least two of 
the following: increased or painful defecation, change in stool frequency and change 
in stool form or appearance (Drossman et al., 2016; Schmulson et al., 2017).  The 
altered gut activity means IBS can be grouped as diarrhoea or constipation 
predominant IBS (IBS-d or IBS-c respectively), which can be defined by the Bristol 
stool scale, or mixed IBS, which is a combination of both (Chey et al., 2015; Lacy et 
al., 2016).  IBS-d is defined by having more than 25% of bowel movement on the 
32 
 
Bristol stool scale subtypes 6-7 (i.e. liquid stool) or less than 25% on the Bristol stool 
scale subtypes 1-2 (i.e. hard stool) (Drossman et al., 2016).  Treatment for IBS-d is 
often symptom based, e.g. loperamide as an antidiarrheal agent.  Often 
antidepressants are prescribed to potentially alleviate the psychological side of IBS-d 
(e.g. depression and anxiety) as well as pain (Enck et al., 2016).   
 
The dysmotility, hypersensitivity and secretomotor abnormalities seen in IBS-d are 
thought to be due to altered enterochromaffin cell activity and the elevated levels of 5-
HT in the gut (Bearcroft et al., 1998; Park et al., 2009).  5-HT plays a major role in the 
communication between the CNS and GIT through the ENS to influence visceral 
sensation and motor function.  The ENS releases 5-HT to initiate motility and visceral 
perception.  5-HT is also secreted following mucosal stimulation, where it activates 
IPANs.  IPANs synapse with excitatory ascending interneurons and descending 
inhibitory interneurons, which activate or inhibit motor neurons respectively.  5-HT3 
receptors are expressed by post synaptic afferent neurons of the PNS.  This pathway 
is thought to be involved in visceral perception and nociception.  5-HT3 receptor 
antagonists such as granisetron or alosetron have been shown to block this pathway 
to reduce sensation (Crowell, 2004).  In IBS-d, there is an increased intestinal motor 
response following meal ingestion or in response to cholecystokinin (CCK).  Visceral 
hypersensitivity is also a factor in IBS-d, with patients showing increased sensation in 
response to stimuli (Chey et al., 2015).   
 
In IBS-d, there is evidence to suggest alteration in gastrointestinal 5-HT signalling.  In 
a study of 8-12-year old children with IBS-d, it was demonstrated that there were 
increased levels of 5-HT in rectal mucosa, which correlated strongly with a reduction 
in the expression of SERT; suggesting the increased 5-HT is due to reduced uptake 
rather than increased synthesis (because levels of TPH1 were consistent between the 
control group and IBS-d cohort (Faure et al., 2010).  Consistent with this, platelets in 
patients with IBS-d show reduced expression and binding affinity of SERT, and the 
ration of 5-HIAA:5-HT is reduced, implying a decrease in the metabolism of 5-HT 
contributes to the elevated levels  (Camilleri, 2009).  Furthermore, SERT in IBS-d 
patients also demonstrated reduced [3H]-5-HT uptake (Foley et al., 2011).  Bearcroft 
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and colleagues used HPLC (high performance liquid chromatography) to evaluate 
plasma 5-HT levels in healthy volunteers and IBS-d patients following ingestion of a 
carbohydrate-rich meal.  It was found that patients with IBS-d had significantly higher 
concentrations of plasma 5-HT compared to healthy controls, and there was a longer 
duration of detectable 5-HT in the plasma of IBS-d patients compared to healthy 
volunteers (Bearcroft et al., 1998; Park et al., 2009).  Indeed, compared to healthy 
control subjects, IBS patients have increased plasma 5-HIAA and reduced urinary 5-
HIAA, suggesting a dysfunction of 5-HT metabolism in IBS patients (Thijssen et al., 
2016; Yu et al., 2016).  Given the knowledge ondansetron is relatively safe in patients 
experiencing nausea and vomiting, and that 5-HT3 receptors are known to influence 
the gastrointestinal tract, it was suggested ondansetron could show promise in treating 
IBS-d.  This idea was then strengthened with the findings that raised plasma 5-HT 
levels are recorded in IBS-d patients (Manning et al., 2011; Moore et al., 2013; Stasi 
et al., 2014).  The use of 5-HT3 receptor antagonists such as alosetron in IBS-d 
appeared to initially be a success, with increased fluid absorption, reduced gut 
movement and improved visceral sensation all reported in IBS-d patients (Thompson 
et al., 2007; Walstab et al., 2010).   
 
Several systemic reviews and meta-analyses have evaluated the efficacy and adverse 
effects of 5-HT3 receptor antagonists in clinical trials for IBS-d.  A meta-analysis 
assessing the impact of ramosetron on IBS-d in 4 randomised clinical trials (821 
patients taking ramosetron and 811 patients receiving placebo) found that compared 
to placebo, ramosetron improved stool consistency, abdominal pain/discomfort, 
abnormal bowel habits to relieve overall IBS-d symptoms (Qi et al., 2018).  65% 
(78/120 patients) who took ondansetron reported relief of IBS-d symptoms (improved 
abdominal pain, reduction in the frequency of loose stool or diarrhoea)  (Garsed et al., 
2014).  Similarly, 54% patients (930/1725) who took alosetron or cilansetron reported 
a global improvement in abdominal pain and IBS-d symptoms (Andresen et al., 2008).  
In addition, 81 out of 132 patients (61.8%) receiving ramosetron reported an overall 
improvement in IBS-d symptoms (Fukudo et al., 2016).  A separate study 
demonstrated that IBS-d symptoms persisted in 49% of patients taking alosetron, 
whilst for placebo this number was 64% (Ford et al., 2009).  Zheng and colleagues 
evaluated 12 studies looking at the impact of alosetron, cilansetron and ramosetron 
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on IBS-d symptoms.  All three drugs had similar efficacy, with 51% (1990 patients) 
describing a global improvement in IBS-d symptoms, compared to 33% (939) patients 
receiving placebo (Zheng et al., 2017).   
 
However, in all of these cases, adverse effects (which in some cases were serious) 
for 5-HT3 receptor antagonists have been reported.  There was an increased incidence 
of hard stool and constipation when IBS-d patients received ramosetron compared to 
placebo (Qi et al., 2018).  24 clinical trials assessing alosetron had been finished by 
November 2000 (around the same time GSK withdrew alosetron from market) (Chang 
et al., 2006).  Some 11,874 patients had received alosetron (3,500 for placebo), and 
there was an incidence of ischemic colitis for 0.15% who took alosetron (none for 
placebo) (Chang et al., 2006; Camilleri, 2017).  In addition, serious constipation was 
seen in 0.1% of patients who were prescribed alosetron, compared to 0.06% who 
received placebo (Chang et al., 2006).  Moreover, it was reported that 24% (604/2526 
patients) taking either alosetron or cilansetron experienced constipation (Andresen et 
al., 2008).  This is a similar proportion to patients receiving ramosetron (19.7%) 
(Fukudo et al., 2016).  Furthermore, Zheng and colleagues reported that whilst 3% of 
those receiving placebo reported constipation, the incidence of constipation was 9%, 
16% and 23% for those taking ramosetron, cilansetron and alosetron respectively; with 
there being 9 cases of ischemic colitis in just the alosetron cohort (Zheng et al., 2017).  
Clearly, 5-HT3 receptor antagonists have efficacy in treating IBS-d, but cause serious 
adverse effects. 
 
Of interest, these cases of ischemic colitis appear to be unique for IBS-d patients 
receiving 5-HT3 receptor antagonists.  5-HT3 receptor antagonists (e.g. ondansetron) 
have been prescribed to treat CINV and PONV, with side effects being mild (Egerton-
Warburton et al., 2014).  A large study examining a variety of clinical trials found that 
none out of 58,412 patients, none reported harm when receiving granisetron, 
ondansetron, palonosetron or tropisetron, despite showing clear efficacy in treating 
CINV (Tricco et al., 2016).  This is also the case for ramosetron and ondansetron, with 
only headache reported as a side effect when being treated for PONV (Yokoi et al., 
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2017).  Constipation has been reported for patients receiving granisetron or 
ondansetron for the treatment of CINV (Billio et al., 2010). 
 
Pumosetrag (DDP, MKC-733), is a high-affinity selective 5-HT3 receptor partial 
agonist, which was also trialled for IBS (both subtypes) (Evangelista, 2007).  
Pumosetrag accelerated gastric emptying in rat, and also enhanced GIT transit in 
guinea pig; displaying an intrinsic efficacy of 40% and 20% (relative to full agonist) 
respectively (Evangelista, 2007). Contractile responses elicited by pumosetrag in rat 
or guinea pig colon were blocked with ondansetron, demonstrating the selectivity of 
pumosetrag for the 5-HT3 receptor (Chetty et al., 2008).  In early phase I trials, 
pumosetrag delayed gastric emptying and small intestinal transit in healthy volunteers 
(Coleman et al., 2003; Evangelista, 2007).  Moreover, in phase II trials, pumosetrag 
increased percentage elimination and stool consistency in IBS-c patients (Fujita et al., 
2005; Evangelista, 2007).  However, side effects (flushing, headache and nausea), 
which are likely to be 5-HT3 receptor mediated, were all reported as adverse effects, 
and lead to the withdrawal of pumosetrag (Coleman et al., 2003; Evangelista, 2007; 
Choung et al., 2014). 
Manning and colleagues have recently developed a series of structurally-related 
ligands which display activity as high-affinity 5-HT3 receptor partial agonists (Manning 
et al., 2011; Moore et al., 2013; Manning et al., 2014).  One of these ligands, CSTI-
300 (Figure 4), has been investigated further in this thesis (Section 3.2), as a potential 
lead candidate drug to treat IBS-d.  
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Figure 4. The structure of CSTI-300 
 
Eluxadoline, a µ receptor agonist and δ receptor antagonist, was approved for IBS-d 
in the USA in May 2015 and Europe in September 2016 (Breslin et al., 2012; Fragkos, 
2017). Opioid receptors are expressed in the ENS and by muscle cells, and µ receptor 
agonists have been known to delay gastric emptying and intestinal transit (Fragkos, 
2017).  Eluxadoline has been shown to decrease contraction of Guinea pig ileum 
(Fragkos, 2017).  Eluxadoline demonstrated efficacy (decreased abdominal pain and 
improved stool constancy) in 2 randomised, double-blind placebo-controlled trials, with 
constipation and nausea listed as common adverse effects.  However due to potential 
additive effects it is not prescribed alongside 5-HT3 receptor antagonists.  Eluxadoline 
demonstrated efficacy after week 4 of being prescribed, relieving symptoms such as 
abdominal pain and bloating, as well as improving stool consistency (Özdener et al., 
2017).  Although common (43.8-60.2% of patients), adverse effects (nausea and 
vomiting, constipation) were well tolerated, with only 0.6-1.7% discontinuing the drug 
(Lacy et al., 2016; Fragkos, 2017).  After-marketing surveillance has reported rare 
cases of pancreatitis, but the prevalence is not yet clear as this drug has only recently 
been introduced to the clinic  (Camilleri, 2017).   
 
Another novel drug of interest for treating IBS-d is the melatonin receptor agonist 
agomelatine.  Enterochromaffin cells produce melatonin, which is thought to modulate 
pain and GIT motility; and IBS-d patients show low salivary levels of melatonin (Ng et 
al., 2018).  Agomelatine, which has higher affinity for melatonin receptors (MT1 and 
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MT2) compared to the endogenous ligand, as well as a longer half-life (~2 hours 
compared to 30-50 minutes for melatonin) is currently used to treat depression.  5 
trials have shown positive results for agomelatine in IBS-d, measured by improved 
abdominal pain (Ng et al., 2018).  This drug could be a novel adjunct for treating IBS-
d.    
 
1.12 Vortioxetine 
Vortioxetine (Figure 5) is a multi-model drug developed by Lundbeck, which was 
approved in 2013 for the treatment of major depressive disorder (MDD) in the USA 
and Europe.  Microdialysis assays showed that vortioxetine raises monoamine (5-HT, 
noradrenaline and dopamine) levels in the medial prefrontal cortex and hippocampus, 
consistent with the actions of some other antidepressant drugs in the clinic.  However, 
it is reported that vortioxetine also antagonises 5-HT3 receptors expressed by 
GABAergic interneurons in the hippocampus, which leads to an increase in 
glutamatergic transmission in pyramidal neurons to potentiate LTP; a relevant 
mechanism that may underlie the improved cognition function evident in elderly 
patients receiving the drug (Dale et al., 2013; Alvarez et al., 2014; Sanchez et al., 
2015).  Vortioxetine, through blockade of SERT and interaction with a multitude of 
monoaminergic receptors, increases the levels of 5-HT, noradrenaline, dopamine, 
acetylcholine and histamine in rat brain (specifically prefrontal cortex and ventral 
hippocampus (Mork et al., 2012).  Chronic treatment with vortioxetine significantly 
increased 5-HT levels (a 2-fold increase compared to vehicle) in the ventral 
hippocampus, and increased social interaction in rats (Mork et al., 2012).  Vortioxetine 
also enhances memory function in rat, which clinically translates to improved cognitive 
performance in elderly patients with MDD (Schatzberg et al., 2014).    
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Figure 5. The structure of vortioxetine. 
 
According to a short-term (6-8 week) clinical trial, vortioxetine appeared to have 
efficacy in treating MDD, with 8 out of 12 trials being positive for vortioxetine against 
placebo (3 trials were non-significant, and 1 trial failed).  Furthermore, it was 
discovered that patients were responding to vortioxetine after two weeks, with a 
maximum response noted during the fourth week of treatment (Alvarez et al., 2014; 
Sanchez et al., 2015).  Longer term trials (12 weeks) demonstrated that the rate of 
MDD relapse was significantly different between vortioxetine and placebo, highlighting 
that the drug maintains its therapeutic activity (Alvarez et al., 2014; Sanchez et al., 
2015).  
 
Several meta-analyses have evaluated the clinical efficacy and tolerability of 
vortioxetine compared against placebo and to other antidepressants.  One such review 
examined 57 studies (18,326 patients in total), and found that all antidepressants 
(including vortioxetine) were beneficial in improving either the Hamilton depression 
rating scale (HAM-D) or the Montgomery–Åsberg Depression Rating Scale (MADRS) 
score (Llorca et al., 2014).  Briefly, both of these scales assess various factors to 
evaluate the level of depression the person is experiencing.  Factors include (but are 
not limited to): depressed mood, suicidal thoughts, insomnia, decreased sleep and 
appetite (Hamilton, 1960; Montgomery et al., 1979).  Moreover, vortioxetine had 
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comparable efficacy when compared against other antidepressants, and was better 
tolerated then desvenlafaxine, sertraline and venlafaxine (Llorca et al., 2014).  In 
separate studies, a statistically significant reduction in MADRS score was seen for 
patients taking vortioxetine compared to placebo (Berhan et al., 2014; Pae et al., 
2015).  Again, there was no difference in efficacy between vortioxetine and other 
antidepressants (serotonin–norepinephrine reuptake inhibitors [SNRI] or agomelatine) 
(Pae et al., 2015).   
 
In a large systematic review, looking at 522 double-blind, randomised, placebo-
controlled trials, vortioxetine was identified as one of the more efficacious 
antidepressants (defined by reduction of over 50% of total score on a standardised 
observer scale for depression e.g. the HAM-D), when compared against placebo and 
other antidepressants (Cipriani et al., 2018).  Moreover, Thase and colleagues 
assessed 11 studies (3,304 patients taking vortioxetine, 1,824 taking placebo).  The 
response rates (measured by an improvement in MADRS score) were significantly 
higher in the 5.0, 10 and 20 mg vortioxetine compared to placebo (Thase et al., 2016).  
655/1783 (36.7%) of patients taking placebo demonstrated an improvement in 
MADRS score.  For vortioxetine; 5.0 mg, n=496/989 (50.2%), 10 mg, n=501/1026 
(48.8%), 15 mg, n=202/436 (46.3%), 20 mg, n=412/799 (51.6%) displayed higher 
rates of response (Thase et al., 2016).  In terms of remission (defined by a MADRS 
score of < 10), only 10 and 20 mg vortioxetine were statistically significant compared 
to placebo (placebo, n=425/1783 (23.8%); vortioxetine 5.0 mg, n=304/989 (30.7%), 
10 mg, n=310/1026 (30.2%), 15 mg, n=125/436 (28.7%), 20mg, n=258/799 (32.3%) 
(Thase et al., 2016).  This pattern of 15 mg vortioxetine not causing an improvement 
in MARDS score was also noted when Baldwin and colleagues assessed the impact 
of vortioxetine on the Hamilton Anxiety Rating Scale (HAM-A) (Baldwin et al., 2016).  
Similar to the HAM-D and MARDS, the HAM-A scale examines a variety of factors 
(e.g. anxious mood, tension, fears, somatic pains) to evaluate the level of anxiety a 
patient is suffering from (Hamilton, 1959).  Furthermore, compared to placebo, 
vortioxetine significantly improved patient functioning (defined by an improvement in 
the Sheehan Disability Scale [SDS]), i.e. symptoms were less likely to disrupt work, 
social life or family life (Sheehan et al., 1996; Florea et al., 2017). 
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However, it was reported that a significantly larger number of patients reported 
adverse effects when taking vortioxetine compared to placebo, with the odds of 
experiencing nausea was 3 x higher for vortioxetine compared to placebo (Berhan et 
al., 2014).  Approximately 25% of patients who took vortioxetine experienced nausea 
(compared to 9% who received placebo), 4% of patients experienced vomiting (3% for 
placebo) and 4% of patients suffered from constipation (1% for placebo).  These 
adverse effects were tolerated, with only 8% of patients who received vortioxetine 
withdrawing from treatment (Schatzberg et al., 2014).  In addition, it was reported that 
the most common adverse effect experienced by those taking vortioxetine (20 mg) 
was nausea (20% compared to 5% for placebo) (Meeker et al., 2015).  In a separate 
analysis, nausea was the biggest reason for discontinuation, with 0.3% of patients 
taking placebo withdrawing, compared to: 1.5%, 1.6%, 2.4% and 4.3% of patients 
taking 5.0, 10, 15 and 20 mg of vortioxetine discontinuing, suggesting the probability 
of experiencing nausea is dose dependent (Baldwin et al., 2016).  In addition, 
vortioxetine had no significant effect on weight gain or sexual dysfunction; both of 
which are issues seen in other antidepressants (Alvarez et al., 2014; Sanchez et al., 
2015). 
 
There appears to be however conflicting data on the tolerability of vortioxetine.  One 
study found the number of people discontinuing due to adverse effects was higher in 
the other antidepressant treatment group (SNRIs and agomelatine) compared to 
vortioxetine (Pae et al., 2015).  Similarly, a large systemic review comparing various 
antidepressants found vortioxetine was also one of the best tolerated drugs, with a low 
dropout rate, when contrasted against placebo and other antidepressants (Cipriani et 
al., 2018). 
 
Vortioxetine has a multi-modal pharmacological profile.  Receptor binding assays 
demonstrated the drug has relatively high affinity (Ki) for the 5-HT3 (3.7 nM) and 5-HT7 
(19 nM) receptors and also the 5-HT transporter, SERT (1.6 nM) (Bang-Andersen et 
al., 2011).  Vortioxetine also interacted with the 5-HT1A (15 nM) and 5-HT1B (33 nM) 
receptors and displayed agonist and partial agonist activity respectively (measured by 
a cAMP assay) (Bang-Andersen et al., 2011; Mork et al., 2012; Dale et al., 2013). In 
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contrast the interaction of vortioxetine with the 5-HT3 receptor was described as being 
an antagonist, although electrophysiological recordings using oocytes expressing the 
5-HT3A receptor demonstrated agonist action on first administration but not for 
subsequent application (Bang-Andersen et al., 2011; Ladefoged et al., 2018).  
Vortioxetine appeared to show a similar binding orientation to 5-HT3 receptor 
antagonists in computational ligand docking assays.  Furthermore, in functional 
membrane potential assays, mutations to valine 202 (located in loop F) appeared to 
impact the potency of vortioxetine as an antagonist, a residue previously not thought 
to play a role in ligand binding (Ladefoged et al., 2018).  Consistent with 5-HT3 receptor 
antagonist activity, vortioxetine (and ondansetron) both inhibited transient bradycardia 
elicited by intravenous administration of 5-HT to rats (Mork et al., 2012).  Given the 
interaction of vortioxetine with the 5-HT3 receptor, the nausea and vomiting 
experienced by patients can be attributed to this pharmacological mechanism of 
action.  Hepatic cytochrome P450 enzymes metabolise vortioxetine (with linear kinetics) 
to an inactive metabolite.  Vortioxetine also does not induce nor inhibit those enzymes 
(Alvarez et al., 2014; Sanchez et al., 2015). 
 
Interestingly, a study has demonstrated anti-inflammatory activity of vortioxetine.  
Nanomolar concentrations of vortioxetine (relevant concentrations to what has been 
found in the plasma of patients taking this drug) inhibit superoxide anion production 
from PMA stimulated human macrophages (Talmon et al., 2018).  Moreover, treating 
monocytes with vortioxetine before differentiating them into macrophages will reduce 
PMA induced superoxide anion production; as well as increasing the expression of an 
anti-inflammatory marker (peroxisome proliferator-activated receptor gamma) and 
decreasing the expression of the proinflammatory cytokine tumour necrosis factor 
alpha (Talmon et al., 2018). 
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1.13 Aims 
The aim of this research is to characterise the pharmacology of two 5-HT3 receptor 
partial agonists (vortioxetine and CSTI-300), and to investigate the binding mechanism 
of Cl-indole at the 5-HT3 receptor. 
 
The first section of this study is an investigation into the pharmacology of vortioxetine, 
a novel antidepressant, at the human (h) 5-HT3A and h5-HT3AB receptors.  This is the 
first detailed examination of vortioxetine in both functional (intracellular calcium 
assays) and receptor binding techniques at the 5-HT3 receptor.  It was also evaluated 
whether vortioxetine could show promise in IBS-d by reducing 5-HT activity in an in 
vitro model of IBS-d. 
 
The next section of this study is a comprehensive assessment of CSTI-300, a selective 
5-HT3 receptor partial agonist with the therapeutic potential to treat IBS-d.  Similar to 
the vortioxetine studies, the pharmacology of CSTI-300 is explored at the h5-HT3A 
and h5-HT3AB receptors using functional and radioligand binding assays.  In addition, 
CSTI-300 is assessed as a potential treatment for IBS-d in a rodent in vivo model, and 
its efficacy compared to a current marketed therapeutic for IBS-d, the 5-HT3 receptor 
antagonist alosetron.  The pharmacokinetics of CSTI-300 in a variety of species 
(mouse, dog, rat and mini-pig) are also explored. 
 
The last section of this work is analysing how 5-HT3 receptor ligands (agonists and 
antagonist) impact how Cl-indole binds to the h5-HT3A and h5-HT3AB receptors. 
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1.14 Hypotheses 
The first hypothesis is that vortioxetine will demonstrate activity as a high-affinity, 
competitive 5-HT3 receptor partial agonist in in vitro assays using recombinant 
expression systems.  This will allow for the speculation that vortioxetine could be a 
viable therapeutic option for treating IBS-d, where there is known 5-HT3 receptor 
dysfunction. 
 
The second hypothesis is that CSTI-300, much like vortioxetine, will display activity in 
in vitro assays as a high-affinity 5-HT3 receptor partial agonist.  Furthermore, in vivo 
studies will demonstrate that CSTI-300 is effective in reducing colonic sensitivity in rat 
and is active in the rat Bezold-Jarisch model.  This will enable conclusions to be drawn 
about whether CSTI-300 is a viable candidate to potentially treat IBS-d. 
 
The third hypothesis is that Cl-indole will demonstrate an unusual binding mechanism, 
in that the presence of 5-HT (or indeed any 5-HT3 receptor ligand) may allow Cl-indole 
to interact with the 5-HT3 receptor differently compared to Cl-indole alone. 
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2 Methods  
 
2.1 Cell culture 
All tissue culture work was carried out under a type II microbiology safety hood to 
ensure sterility.  All reagents used were either purchased sterile or filter sterilised 
through 0.22 µm filters.  HEK293 cells stably expressing the following constructs: h5-
HT3A receptor (HEK3A cells) or the h5-HT3AB receptor (HEK3A3B cells) were cultured 
in Dulbecco’s modified Eagle’s medium (DMEM, Sigma-Aldrich, cat. D5796) 
complemented with (v/v) 10% Foetal Bovine Serum (FBS, Sigma-Aldrich, cat. F7524) 
and   1% Penicillin-Streptomycin (100 units penicillin, 0.1 mg/ml streptomycin, Sigma-
Aldrich, cat. P4333) (Brady et al., 2001).  Cells were passaged when 90% confluent.  
This was achieved by initially aspirating media from the cells and washing with 
phosphate buffered saline (PBS, without calcium and magnesium, Thermo Fisher, cat. 
14200067).  1 ml of trypsin/EDTA (0.5 g/l trypsin and 0.2 g/l EDTA 
[Ethylenediaminetetraacetic acid], Sigma-Aldrich, cat. T3924) was added to the cells 
to detach them from the T75 tissue culture flask (Corning, cat. BC301).  After five 
minutes at 37°C, cells were then resuspended in 9 ml of media (to inactivate the 
trypsin/EDTA).  Generally, the cells were split 1:3 (3 ml of out 9 ml the cells were in 
were added to a new tissue culture flask) and volume made up to 15 ml with DMEM.  
Table 2 lists the selection antibiotics (and concentration) used to maintain protein 
expression in the different cell lines.  These antibiotics were added every 2 weeks.  
After no more than 40 passages, cells were discarded, and new aliquots of cells taken 
from liquid nitrogen. 
 
Table 2: The selection antibiotics which were added to transfected HEK cells to ensure 
target protein expression. 
Cell line  Antibiotic (concentration) 
HEK3A Geneticin (250 µg/ml, Thermo Fisher, cat 10131019) 
HEK3A3B  Geneticin (250 µg/ml) and zeocin (80 µg/ml, Thermo Fisher, cat. R25001) 
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Cells were stored long term in liquid nitrogen.  Briefly, cells were detached from the 
tissue culture flask using trypsin/EDTA before being resuspended in DMEM.  Cells 
were pelleted at 400 x g for 5 minutes with supernatant discarded.  The pellet was 
resuspended in freezing media (90% FBS, 10% dimethyl sulphoxide [DMSO], Sigma-
Aldrich, cat. D2650) and transferred immediately to – 80°C in Mr Frosty (Thermo 
Fisher, cat. 5100-0050).  This enabled a freezing rate of -1°C/minute.  After 24 hours 
cells were stored in the vapour phase of liquid nitrogen. 
 
To recover cell lines from liquid nitrogen, cells were rapidly thawed at 37°C, and 1 ml 
of media was gradually added to the cell suspension, before adding a further 10 ml of 
DMEM.  Cells were pelleted by centrifugation (400 x g, 5 minutes).  Supernatant was 
aspirated, and the pellet was resuspended in fresh media, before being transferred to 
a T-75 tissue culture flask.  After 24 hours, media was replaced (to ensure removal of 
any residual DMSO) and cells were maintained as above.  Antibiotics (for selection) 
were not added until cells had been in culture for at least one week. 
 
2.2 Preparing whole cell lysates 
To generate a whole cell lysate for radioligand binding experiments, media was 
aspirated off confluent cells (HEK3A or HEK3A3B cells) in a T75 tissue culture flask 
and the cells were washed in 5 ml PBS.  Adherent cells were scraped off using a cell 
scraper (Sarstedt, cat. 83.1830) in 5 ml PBS.  Cells were then resuspended in a further 
5 ml of PBS and centrifuged at 400 x g for 5 minutes. The supernatant was discarded, 
and the pellet was stored long-term at -80°C or resuspended in 
Tris(hydroxymethyl)aminomethane buffer pH 7.4 (Tris, Sigma-Aldrich, cat. T1503) and 
lysed by sonication for immediate use. 
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2.3 Bradford assay  
The Bradford protein assay uses the negatively charged Coomassie Brilliant Blue G-
250 dye, which binds to basic amino acids (Bradford, 1976).  In this situation, the 
Bradford reagent absorbs at 595 nm.  A range of Bovine serum albumin (BSA, Sigma-
Aldrich, cat. A9418) standard concentrations (0.1 to 1.4 mg/ml) was used to calibrate 
the Eppendorf BioPhotometer Plus spectrophotometer, enabling the concentration of 
protein in a whole cell lysate to be determined.  20 µl of BSA standard (diluted in 25 
mM tris buffer) was combined with 1 ml of Bradford reagent (Sigma-Aldrich, B6916) in 
a polystyrene cuvette and left to stand for 5 minutes at room temperature.  A blank, 
which was 20 µl of tris buffer, was also included.   Absorbance (at 595 nm) was then 
measured on the spectrophotometer.  For whole cell lysates, the same procedure was 
applied.   
 
2.4 Intracellular calcium assays 
 
2.4.1 Agonist experiments 
To assess the functional activity of the h5-HT3A or h5-HT3AB receptor in vitro, 
intracellular calcium assays were undertaken using a fluorescent calcium binding dye.  
When confluent, HEK3A or HEK3A3B cells were trypsinised and resuspended in 10 
ml DMEM.  Cells were counted using a haemocytometer and diluted to 1x106 cells/ml 
in DMEM.  Finally, 1x105 cells were seeded per well onto poly d-lysine (100 μg/ml, 
Sigma-Aldrich, cat. P7280) coated black-sided, clear-bottomed 96 well plates (Sigma-
Aldrich, cat. CLS3603).  Poly d-lysine was needed to assist in cell adhesion.  Cells 
were left overnight in a humidified incubator at 37°C to reach confluency. 
 
After 24 hours, 300 ml of HBSS (Hank’s Balanced Salt Solution, Thermo Fisher, cat. 
1416506) was prepared from a 10x stock and the pH adjusted to 7.4. After discarding 
the media, cells were washed twice in HBSS.  Fluo-4 acetoxymethyl (AM) ester 
(Thermo Fisher, cat. F14201) was initially dissolved in DMSO before being diluted in 
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HBSS to a final concentration of 5.0 μM (Newman et al., 2013).  Cells were loaded 
with Fluo-4AM for 1 hour at room temperature in the dark on a rotating table.  Fluo-
4AM contains an acetoxymethyl ester, which renders the molecule cell permeant due 
to increased lipophilicity.  Once the Fluo-4AM is inside the cell, non-specific esterases 
cleave the ester group to render the Fluo-4 active (able to bind calcium) and cell 
impermeant.  After the 1 hour incubation, excess extracellular Fluo-4AM was 
discarded and cells washed twice in HBSS, before being incubated for 30 minutes in 
100 μl HBSS to allow complete de-esterification of the Fluo-4AM.   
 
Fluorescence was read at 495 nm/515 nm (excitation/emission spectra) using the Flex 
Station (Molecular Devices); which is an automated pipetting system which also reads 
fluorescence.  The Flex Station applied drugs at three predetermined time points, and 
also reads fluorescence every 3 seconds.  Generally, Cl-indole or vehicle was added 
at 20 seconds, agonist was applied at 80 seconds and ionomycin (750 ng/ml) at 320 
seconds.  Ionomycin punctures holes in the endoplasmic reticulum and thereby 
releases intracellular calcium to bind to cytosolic fluo-4.  Ionomycin showed that the 
cells could still respond at the end of the experiment, as well as demonstrating the 
maximum calcium response the cells could achieve (Figure 6). 
 
For data analysis, maximal response elicited by drug was subtracted from baseline 
(before addition of agonist).  This was then taken as a percentage of the maximal 
agonist response and plotted against drug concentration.   
 
2.4.2 Antagonist studies 
To verify the calcium responses elicited by agonists at the 5-HT3 receptor were 5-HT3 
receptor dependent, cells were preincubated with granisetron (500 nM) 30 minutes 
before they were analysed on the Flex station was above. 
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2.5 Radioligand binding 
 
2.5.1 Competition radioligand binding 
The binding characteristics of various 5-HT3 receptor ligands for the 5-HT3 receptor 
can be studied using receptor binding techniques.  HEK3A or HEK3A3B cell lysates 
were prepared as previously described and kept on ice in a glass beaker. 
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Figure 6: Ionomycin elicits the maximal calcium 
response in HEK3A cells 
The ionomycin (I) response demonstrated that cells at the 
end of the intracellular calcium assay could still respond to 
stimulation and provided the maximum calcium response 
the cells could achieve. 
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Radioligand binding studies were carried out similar to before (Monk et al., 2004).  
Each condition was performed in triplicate.  Each binding tube (Sarstedt, cat. 
55.526.005) contained a final volume of 300 μl after drug(s), radioligand and cell lysate 
were added in that order.  Drugs and radioligand were prepared in tris buffer (25 mM, 
pH=7.4).  The radioligand used, [3H]-granisetron (Perkin Elmer, cat. Net1030250uc), 
is a high-affinity selective radioligand for the 5-HT3 receptor, which was used at a final 
concentration of ~ 0.5 nM.  The selective 5-HT3 receptor antagonist ondansetron (10 
μM) was used to define non-specific binding. 
 
After addition of drug(s), radioligand and cell lysate, samples were left for one hour at 
room temperature to allow [3H]-granisetron or [3H]-vortioxetine binding to reach 
equilibrium before the reaction was terminated rapidly using a Brandel cell Harvester 
onto pre-soaked GF/B filter papers (Brandel, cat. FP105).  The filter papers were 
soaked in 0.3% Tris/polyethyleneimine (PEI, Sigma-Aldrich, cat. 03880) to assist in 
the protein binding to the filter paper.  For [3H]-granisetron, the filter paper was washed 
3 x 3 seconds with ice-cold tris buffer.  4 ml of scintillation fluid (Optiphase Hisafe-3, 
Perkin Elmer, cat. 1200-437) was added to the filter paper and the samples were left 
for at least three hours before being counted on a Liquid Scintillation Counter 
(Packard). 
 
2.5.2 Saturation radioligand binding 
To demonstrate vortioxetine or CSTI-300 is a competitive antagonist, saturation 
radioligand binding was used to assess whether vortioxetine or CSTI-300 decreases 
the affinity of [3H]-granisetron for the 5-HT3 receptor.  Cell lysates were prepared the 
same as for competition radioligand binding.  A range of [3H]-granisetron 
concentrations (0.1 – 30 nM) were used in the absence (vehicle) or presence of 
vortioxetine or CSTI-300, with ondansetron (10 μM) used to define non-specific 
binding.  Samples were then incubated and harvested as above.  Each condition was 
performed in duplicate.  Specific binding (total binding – non-specific binding) was 
plotted against [3H]-granisetron concentration using Kaleidagraph.  Kaleidagraph was 
also used to draw Scatchard plots (Bound vs Bound/Free). 
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2.5.3 Scintillation Proximity Assay 
Scintillation proximity assays (SPA) depend upon copper PVT (Polyvinyltoluene) 
beads which will bind His-tagged proteins which in turn are bound to a radioligand.  
The copper PVT beads contain scintillant which converts the β energy emitted by 3H 
into light.  The light is measured by a scintillation counter and converted back to units 
of radioactivity.  This technique is useful when the protein target is not located within 
the cell surface membrane and so may not be retained by the filter paper used in 
traditional filtration receptor binding techniques. 
 
To investigate the binding characteristics of Cl-indole (±5-HT) or alosetron at the 
A1B2D1w 5-HTBP (5-HT binding protein), SPA experiments were undertaken as has 
been described previously (Kesters et al., 2013).  25 µl of competing drug(s), 25 µl of 
[3H]-granisetron (~8.0 nM), 25 µl of copper His-tagged PVT beads (2 mg/ml, Perkin 
Elmer cat. RPNQ0095) and 25 µl of 5-HTBP (a gift from Chris Ulens, University of 
Leuven, 1.0 µg/ml) were prepared in buffer (10 mM HEPES [Sigma-Aldrich, cat. 
H3375]/0.05 %Tween-20 [Sigma-Aldrich, cat. P1379) and added to white 96 well 
optiPlates (Perkin Elmer cat. 6005290).  The reaction was left for 90 minutes at room 
temperature on a rotating table.  The plate was centrifuged at 400 x g for 1 minute to 
allow the SPA beads to settle.  A TopCount (Perkin Elmer) was used to measure 
radioactivity remaining on the SPA beads.   
 
2.5.4 Single cell electrophysiology  
Approximately 18 hours prior to electrophysiology assays, HEK3A cells were seeded 
directly onto 13 mm diameter glass coverslips coated with poly-L-lysine (100 µg/ml; 
Sigma-Aldrich, cat. P7280) and fibronectin (40 µg/ml; Sigma-Aldrich, cat. F1056), at a 
density of 2 x 104 HEK3A cells per coverslip.  Macroscopic currents were recorded in 
the whole-cell recording mode of the patch-clamp technique.  Cells were superfused 
at 2.0 ml/min with an extracellular solution composed of (in mM) NaCl 140, KCl 2.8, 
CaCl2 1.0, glucose 10, HEPES 10, pH 7.4 adjusted with NaOH.  Patch electrodes were 
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pulled from borosilicate glass (O.D. 1.2 mm, I.D. 0.69 mm; Harvard Apparatus, 
Edenbridge, UK) using a P-97 puller (Sutter, Novato, CA, USA) and filled with 
intracellular solution consisting of (in mM) 140 CsCl, 2.0 MgCl2, 10 HEPES, 1.0 EGTA, 
1.0 Mg-ATP and 0.3 Na-GTP; pH adjusted to 7.3 with CsOH (osmolarity ~285 mOsm).  
Patch electrodes typically had open tip resistances of 4-7 MΩ. Membrane currents 
were recorded using an Axopatch 200B amplifier (Molecular Devices, Wokingham, 
UK), low-pass Bessel filtered at 1.0 kHz and digitized at 10 kHz by a Digidata 1550B 
(Molecular Devices).  Experiments were performed at room temperature with the cells 
voltage-clamped at -60 mV.   
 
Agonist-evoked currents were elicited by pressure ejection (1.3 bar; Picospritzer III; 
Parker Hannifin, Pine Brook, NJ, USA) of agonist from patch pipettes placed ~30 µm 
from the recorded cell. 
 
2.5.5 Rat Bezold-Jarisch model in vivo 
Male Sprague-Dawley rats (233-260 g) were fasted overnight prior to use.  Dose 
volume for all solutions was 10 ml/kg.  For studies investigating a dose-response to 
CSTI-300 (0.1, 0.3, 1.0, 3.0 mg/kg), alosetron (0.1 mg/kg) or vehicle (2.0% Tween-
80), test substance was administered orally (by oral gavage) to each group of six 
animals.  One hour later, 5-HT (0.3 mg/kg, i.v.)-induced bradycardia was recorded in 
anesthetised (1,500 mg/kg urethane, i.p.) animals.  For studies analysing the time 
effect of CSTI-300 (1.0 mg/kg), the drug was administered orally to each group of six 
animals. One, two, four and eight hour(s) later, 5-HT (0.3 mg/kg, i.v.)-induced 
bradycardia was recorded in anesthetised (1,500 mg/kg urethane, i.p.)  animals.  Lead 
II ECG was obtained with subdermal needle electrodes in the upper right shoulder and 
the lower left inner thigh.  The ECG was recorded using a bio amplifier (AD 
Instruments, Australia) and analysed by data acquisition and analytic system (Power 
Lab/8 SP, AD Instruments, Australia) with a frequency of 60 Hz.  Each bradycardia 
event was recorded for 30 seconds after injection of 5-HT.  Following completion of 
the study, terminal blood was collected for subsequent analysis of plasma CSTI-300 
levels.  Olan Ricerca (Concord, Ohio, USA) performed the experiments.  All aspects 
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of this work including housing, experimentation and disposal of animals were 
performed in general accordance with the Guide for the Care and Use of Laboratory 
Animals (National Academy Press, Washington, D. C., 1996). I was given the raw data 
in the form of a report.  I analysed the data by calculating the percentage net decrease 
in bpm (mean±SEM, n=6 rats) and plotting this against either CSTI-300 (or alosetron) 
concentration, or against time.  I also performed statistical analysis (a Shapiro-Wilk 
procedure to test for normality, followed Kruskal-Wallis test with Dunn’s multiple 
comparisons).  The study was not powered. 
 
2.5.6 Rat colon distension model of IBS-d 
A previously described IBS-d model was used to evaluate the activity of CSTI-300 
versus alosetron (Banner et al., 1995; Banner et al., 1995).  This in vivo model applies 
a noxious colo-rectal distension to conscious rats by acute balloon inflation and the 
effects observed as abdominal muscle contraction with the threshold pressure noted 
as the readout. Thus, under ether anaesthesia (ether), a 6-7 cm long latex balloon was 
carefully inserted intra-anally to a position 1 cm beyond the ano-rectal verge.  The 
cannula from the balloon, which was taped to the tail to prevent expulsion of the 
balloon, was connected to a coloured-water filled manometer and via a 3-way tap to a 
syringe pump.  Throughout the procedure the singly housed animals (male Wistar rats; 
180-250 g) were allowed unrestricted movement within a 20x20x14 cm clear acrylic 
box. 
 
After recovery from the balloon insertion procedure, a ramp inflation of the colo-rectal 
balloon at a rate of 20 mm water per minute was performed until the visceromotor 
response (abdominal muscle contraction) was observed.  At this point the pressure 
was noted and released immediately by opening the 3-way tap.  The inflation 
procedure was repeated at 5 minute intervals until 3 stable responses were recorded. 
 
Rats (n=10) were then dosed with 5-HTP (10 mg/kg s.c.), and 5 minutes later a ramp 
inflation of the colo-rectal balloon was performed until the visceromotor response was 
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observed.  The inflation procedure was repeated at 5 minute intervals until 3 stable 
responses were recorded before subsequent treatment; either alosetron (0.01-1.0 
mg/kg; 1.0 ml/kg s.c.), CSTI-300 (0.01-1.0 mg/kg; 1.0 ml/kg s.c.) or vehicle (0.9% 
NaCl; 1.0 ml/kg s.c.).  The colonic distensions were performed at 5 minute intervals 
for a further 45 minutes with effective pressures monitored. As soon as the last time 
point was recorded, blood was collected from the rats to enable the concentration of 
CSTI-300 (or alosetron) to be assessed.  Rats were euthanised (CO2) following 
completion of the study.  The experiments were carried out by Medicilon (Shanghai, 
China).  The protocol complied with and was approved by the Institutional Animal Care 
and Use Committee (Shanghai Medicilon Inc., Shanghai, China) and Shanghai 
Medicilon Inc is accredited by the NIH Office of laboratory Animal Welfare (OLAW; 
https://olaw.nih.gov/home.htm) and AAALAC (www.aaalac.org). I was given the raw 
data in Microsoft Excel, and from this I calculated the percentage response 
(mean±SEM, n=10), and plotted this against time.  I also performed statistical analysis 
(a Shapiro-Wilk procedure to test for normality, followed by a 2-way ANOVA with 
subsequent Tukey’s multiple comparisons test, with Bonferroni correction for multiple 
comparisons).  The study was not powered.  
 
2.5.7 Dog behavioural and emesis model  
A total of 6 naïve male Beagle dogs (10.15-11.45 kg) were administered with CSTI-
300 (1.0 mg/kg; 5.0 ml/kg p.o.) or vehicle (sterile water, 5.0 ml/kg p.o.).  Each animal 
was monitored continuously (by an observer and a video recording) for least 4 hours 
post-treatment (which would have been extended up to 6 hours if any remarkable 
observations had been evident during the first 4 hours post-dose).  During the 
observation period, each animal was observed primarily for signs of behavioural 
disturbances or emesis.  Emesis was defined by retching and vomiting; “retch” was 
defined as the action, and “vomit” was defined as the delivery of gastric content 
through the retching action.  If either or both of these emetic characteristics had 
occurred, they would have been counted independently and recorded on a raw data 
sheet.  Observations for other adverse events were also performed (e.g. abdominal 
contractions, excessive salivation, state of faecal matter [e.g. normal, loose, 
diarrhoea], general distress, vocalising [e.g. excessive barking or whimpering], 
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atypical behaviour, atypical feeding behaviour, atypical drinking behaviour, indication 
of pain, or mortality).  With no emesis or adverse observations, the observation at the 
time point was noted as ‘normal’.  Animals were also observed for 1 hour at 23-24 hrs 
post-dose and the above observations assessed.  If any emesis had been evident or 
any adverse observation, the animals would have been monitored periodically until 
normal behaviour was resumed (with the above observations monitored and 
recorded).  
 
Six hours after treatment, a peripheral venous blood sample was taken (~1 ml/ sample 
into sodium heparin collection tubes) from each animal for bioanalysis of the plasma 
concentrations of CSTI-300 by HPLC-MS. Briefly; plasma samples (30 µl) were mixed 
with 150 µl 0.1% formic acid in water and transferred to a 96-well plate for injection.  
The liquid chromatography system was comprised of a Waters Ultra Performance 
Liquid Chromatography (UPLC, Waters Corporation, USA) equipped with an 
ACQUITY UPLC binary solvent manager, ACQUITY UPLC Autosampler Module, 
ACQUTIY UPLC sample organiser and ACQUITY UPLC column heater HT.  Samples 
(3.0 µl) were injected on to an ACQUITY UPLC BEH C18 1.7 µm (50 mm×2.10 mm) 
column and the mobile phase ran at 600 µl/minute.  Post-column mass spectrometric 
analysis was performed using an API 4000 (triple-quadrupole) instrument from Applied 
Biosystems/MDS Sciex with an ESI Ionsource.  The data acquisition and control 
system were created using Analyst 1.5.1 Software from Applied Biosystems/MDS 
Sciex.  A calibration curve using CSTI-300 was created to enable quantification of 
CSTI-300 levels in the plasma.  At study termination, all animals were transferred to 
the stock animal collection.  Experiments were performed by Medicilon (Shanghai, 
China).  The protocol for the dog behavioural and emesis model complied with and 
was approved by the Institutional Animal Care and Use Committee (Shanghai 
Medicilon Inc., Shanghai, China).  I was given the data in the form presented in this 
thesis (Table 11). 
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2.5.8 Pharmacokinetic studies 
The pharmacokinetics of CSTI-300 was investigated in male CD-1 mice (20-25 g, 
n=3), male Sprague-Dawley rats (288-322 g, n=3), male Beagle dogs (8.0-12 kg, n=3-
4) and Gottingen mini-pigs (8.9-10.0 kg, n=3).  CSTI-300 was administered either 
intravenously (i.v.) or orally (p.o.) in sterile water as vehicle, with blood samples taken 
at pre-determined times into K2 EDTA anti-coagulant tubes.  For oral studies (drug 
administered by oral gavage), the dose volume was: 10 ml/kg, 5.0 ml/kg, 2.0 ml/kg, 
and 5.0 ml/kg for mouse, rat, dog and mini-pig, respectively.  For intravenous studies, 
the dose volume was: 5.0 ml/kg, 1.0 ml/kg, 2.0 ml/kg and 1.0 ml/kg for mouse, rat, dog 
and mini-pig, respectively.  Plasma samples underwent protein precipitation with 
acetonitrile containing 0.1% formic acid.  After sonication for 1 minute followed by 
vortex mixing for 2 minutes and refrigeration for 30 minutes, supernatants were 
transferred to a 96-well filter plate and filtered in a centrifuge.  Filtered extracts (200 
µl) were transferred into separate 96-well plates and blow dried under nitrogen at 
40°C.  The residue was reconstituted in 100 µl of mobile phase and submitted for 
LC/MS/MS analysis.  CSTI-300 was quantified with Analyst 1.4.2 software using a 
calibration curve.  Plasma concentration data were analysed with WinNonlin 5.2 
software using a non-compartmental model to calculate pharmacokinetic parameters.  
Mouse and rat studies were carried out by NoAb Biodiscoveries (Mississauga, Ontario, 
Canada) after approval of procedures by the NoAb BioDiscoveries animal care 
committee and performed in accordance with the principles of the Canadian Council 
on Animal Care.  Following collection of blood from the last time point, mice were 
terminated by cervical dislocation and rats euthanised by CO2.  Dog experiments were 
performed by Covance Laboratories Inc. (Madison, Wisconsin, USA) in compliance 
with Animal Welfare Act Regulations (9 CFR 3).  Following completion of the study, 
the dogs were returned to the stock colony.  Mini-pig studies were undertaken by 
Calvert laboratories (Scott Township, Pennsylvania, USA), and animals were treated 
in accordance with the USDA Animal Welfare Act (9 CFR Parts 1, 2 and 3) and the 
conditions specified in the Guide for the Care and Use of Laboratory Animals (ILAR, 
1996, National Academy Press).  For all pharmacokinetic studies (mice, rat, dog and 
mini-pig), I received the raw data in Microsoft Excel.  I calculated the mean±SEM and 
plotted CSTI-300 concentration against time. 
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2.6 Data analysis and statistics    
The fluorescence responses measured by the Flex station were recorded by Softmax 
Pro software (Molecular Devices, Berkshire, UK).  For radioligand binding, inhibition 
curves and iterative curve fitting were drawn using Kaleidagraph (Synergy, 
Pennsylvania, USA) defined by the four-parameter logistic equation:  
𝑏 =
𝐵𝑚𝑎𝑥[𝐿]
𝑛
[𝐿]𝑛 + 𝐾𝑛
 
Where b=bound radioligand, Bmax=maximum binding, K=the molar concentration of 
competing drug to decrease specific binding by half, L=molar concentration of 
competing compound and n=Hill coefficient. 
 
The Cheng-Prussoff equation was used to calculate the Ki of competing ligand: 
Ki =
IC50
1 +
[RL]
Kd
 
Where the IC50 is from the competing ligand, [RL] is the concentration of free 
radioligand and Kd is the dissociation constant of the radioligand.    
2-way ANOVA with subsequent Tukey’s multiple comparisons test (with Bonferroni 
correction for multiple comparisons) were used to evaluate potential treatment 
differences in the rat IBS-d colon model; a Shapiro-Wilk procedure tested normality.  
A Kruskal-Wallis test with Dunn’s multiple comparisons was used to test any 
differences in the impact of 5-HT3 receptor agonist (5-HT, vortioxetine or CSTI-300) 
upon Cl-indole affinity for the h5-HT3A receptor; and to investigate any differences 
between CSTI-300 or alosetron compared to vehicle in the rat Bezold-Jarisch reflex.  
A Mann-Whitney U test was utilised to determine if the impact of CSTI-300 or 
vortioxetine upon [3H]-granisetron affinity for the h5-HT3 receptor was significant; and 
used to analyse the impact of 5-HT upon rat heart rate in the Bezold-Jarisch reflex.  A 
Mann-Whitney U test was also undertaken to see if the impact of Cl-indole upon 
vortioxetine affinity for the h5-HT3 receptor was significant.  It was also used to 
determine if there was a difference in the kinetics of a 5-HT plus vortioxetine induced 
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response compared to a 5-HT-induced response at the h5-HT3A receptor.  In addition, 
a Wilcoxon signed-rank sum test was utilised to examine any difference caused by Cl-
indole upon the Hill number for vortioxetine at the h5-HT3 receptor in competition 
radioligand binding assays.  Post-hoc tests were only conducted if p was <0.05 and 
the variance of the data was homogenous.  Significance criterion was p<0.05.  Prism 
(GraphPad, California, USA) was used for statistical analysis. 
 
2.7 Drugs  
5-HT (Sigma-Aldrich cat. H7752), alosetron (Albany Molecular Research Inc.), Cl-
indole (Sigma-Aldrich cat. C47604), CSTI-300 (Consynance Therapeutics Inc), DDP 
(Albany Molecular Research Inc.), granisetron (SmithKline Beecham), ionomycin 
(Sigma-Aldrich, cat. I0634), metoclopramide (Research Biomedicals Incorporated, 
cat. M-117), ondansetron (Tocris, cat. 2891), PBG (phenyl biguanide, Sigma-Aldrich, 
cat. 164216), quipazine (Tocris, cat. 0629), s-zacopride (Dalalonde), vortioxetine 
(Richard Myerson, University of Birmingham). 
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3 Results 
 
3.1 The anti-depressant vortioxetine is an agonist at the h5-HT3 
receptor 
 
3.1.1 The affinity of vortioxetine at the h5-HT3 receptor 
In competition radioligand binding studies, vortioxetine competed for [3H]-granisetron 
occupied h5-HT3A and h5-HT3AB receptor binding sites with relatively high affinity 
(Figure 7; Table 3).  The affinity of vortioxetine for the h5-HT3A and h5-HT3AB 
receptors was comparable.  At the h5-HT3A receptor, vortioxetine displayed a 
relatively high Hill number (p<0.05 when compared against unity), indicating this ligand 
demonstrated positive cooperative binding at this receptor.  This was not seen for the 
h5-HT3AB receptor, where the Hill number was approximately unity, which is not 
uncommon for agonists at the 5-HT3AB receptor (Dubin et al., 1999; Brady et al., 
2001).  The affinity of vortioxetine was increased at both the h5-HT3A and h5-HT3AB 
receptors by the COM Cl-indole (30 µM, Figure 8; Table 3, p<0.05). 
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Table 3: Summary data from Figure 7. The affinity (Ki) of vortioxetine at h5-HT3A or h5-
HT3AB receptors.  The affinity of vortioxetine for each receptor isoform was increased by Cl-
indole (30 µM) (*p<0.05 when compared to vortioxetine + vehicle, using Mann-Whitney U test).  
**p<0.05 when compared to unity (i.e. 1.0) using Wilcoxon Signed Rank Test.  Data represents 
mean±SEM, n=7-8 (h5-HT3A receptor) and n=5 (h5-HT3AB receptor). 
 
 
 
 
 
 
 
5-HT3A receptor Ki (nM) Hill number 
Vortioxetine + vehicle (0.1% DMSO) 8.2±1.1 1.43±0.07** 
Vortioxetine + Cl-indole (10 μM) 6.2±0.9 1.46±0.07** 
Vortioxetine + Cl-indole (30 μM) 5.0±0.8* 1.39±0.11** 
5-HT3AB receptor Ki (nM) Hill number 
Vortioxetine + vehicle (0.1% DMSO) 11.4±1.7 0.86±0.06 
Vortioxetine + Cl-indole (10 μM) 10.6±3.0 1.01±0.07 
Vortioxetine + Cl-indole (30 μM) 5.8±0.9* 0.93±0.04 
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It has been demonstrated previously that Cl-indole (up to 100 µM) does not bind to the 
orthosteric site of h5-HT3A receptor.  However, the presence of approximate EC50 
concentrations of 5-HT induce Cl-indole to bind to the h5-HT3A receptor through a 
competitive mechanism (Powell et al., 2016).  It was investigated whether this 
phenomenon could also be replicated with vortioxetine.  Indeed, in the absence of 
agonist, Cl-indole demonstrated non-competitive binding to the h5-HT3A receptor.  
Yet, sub-maximal concentrations of vortioxetine (30 nM and lower), and 5-HT (200 
nM) allow Cl-indole to compete with [3H]-granisetron for the h5-HT3A receptor (Figure 
5; Table 4).  The increase in Cl-indole affinity caused by vortioxetine (30 nM) or 5-HT 
(200 nM) was also statistically significant (p<0.01, Kruskal-Wallis with Dunn’s multiple 
comparisons test).   
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Figure 7. Vortioxetine demonstrated high affinity for 5-HT3 receptors.   
The ability of vortioxetine to compete with [3H]-granisetron for the binding of h5-HT3A (A) or h5-HT3AB 
(B) receptor sites.  Cl-indole, a 5-HT3 receptor selective COM, increased the affinity of vortioxetine at 
both receptor subtypes.  Data represents mean±SEM, n=7-8 (h5-HT3A receptor) and n=5 (h5-HT3AB 
receptor). 
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Ligand Cl-indole IC50 (µM) 
Cl-indole + vehicle 457±70 
Cl-indole + 5-HT (200 nM) 30±5* 
Cl-indole + vortioxetine (1.0 nM) 256±71 
Cl-indole + vortioxetine (3.0 nM) 160±26 
Cl-indole + vortioxetine (10 nM) 85±24 
Cl-indole + vortioxetine (30 nM) 20±4* 
 
  
 
 
 
 
 
 
 
Table 4:  Summary data from Figure 8.  Both vortioxetine and 5-HT (200 
nM) increased the affinity of Cl-indole for the h5-HT3A receptor. 
Data represents mean±SEM of five experiments.  * indicates p<0.01 when 
compared to Cl-indole + vehicle (Kruskal-Wallis with Dunn’s multiple 
comparisons test). 
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3.1.2 Vortioxetine is a competitive drug at the h5-HT3A receptor 
Saturation radioligand binding was undertaken in order to demonstrate that 
vortioxetine interacts with the h5-HT3A receptor through a competitive mechanism.  
From Figure 9 and Table 5 it can be noted that the presence of vortioxetine (10 nM) 
decreased the affinity (Kd) of [3H]-granisetron for the h5-HT3A receptor (p<0.05, Mann-
Whitney U test).  However, the density of receptors labelled by a saturating 
concentration of [3H]-granisetron (Bmax) remained unaffected by the presence of 
vortioxetine (10 nM) when compared to vehicle (Figure 9; Table 5).   
 
Figure 8.  Vortioxetine modulated the 
binding mechanism of Cl-indole.  
Vortioxetine (or 5-HT) converted Cl-indole from 
a non-competitive ligand to a competitive ligand.  
Data represents mean±SEM of 5 independent 
experiments. 
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Treatment Kd (nM) Bmax (fmol/mg) Hill number 
Vehicle 0.52±0.08 3558±404 0.92±0.05 
With vortioxetine 1.61±0.62 3414±537 0.91±0.09 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 9. Vortioxetine is a competitive ligand at the h5-HT3A receptor.  
The affinity of [3H]-granisetron for the h5-HT3A receptor in the absence (vehicle) or presence of vortioxetine 
(10 nM) A: Saturation curve.  B: Scatchard transformation of the data. Representative data of five repeats. 
Table 5: Summary data from Figure 9.  Vortioxetine displayed a competitive binding interaction with the 
h5-HT3A receptor.  
The affinity (Kd) of [3H]-granisetron is approximately trebled by vortioxetine, but the number of labelled binding sites 
(Bmax) is not affected by vortioxetine (mean±SEM, n=5), indicating a competitive interaction at the h5-HT3A receptor.  
The impact of vortioxetine upon the Kd of [3H]-granisetron was statistically significant (p<0.05, Mann-Whitney U 
test) but was not statistically significant for the Bmax. 
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3.1.3 Functional studies of vortioxetine at the h5-HT3 receptor 
Intracellular calcium assays were utilised to investigate the functional activity of 
vortioxetine at the 5-HT3 receptor.  Both 5-HT and vortioxetine activated the h5-HT3A 
and h5-HT3AB receptors as agonists with differing degrees of efficacy and potency 
(Figures 10 and 11; Table 6).  Maximal responses elicited by vortioxetine were 
approximately 50% and 40% relative to 5-HT at the h5-HT3A and h5-HT3AB receptor 
respectively.  The potency of vortioxetine (and 5-HT) was comparable at both receptor 
subtypes, and vortioxetine was ~ 3x more potent than 5-HT (Table 6) at both receptor 
subtypes.  The maximum response elicited by both 5-HT (10 µM) and vortioxetine (10 
µM) was reduced at the h5-HT3AB receptor compared to the h5-HT3A receptor. 
Moreover, the response induced by vortioxetine at the h5-HT3A receptor appeared to 
decay to baseline faster than 5-HT, although at the h5-HT3AB receptor both 5-HT and 
vortioxetine responses returned to baseline at a similar rate (Figures 10 and 11).  30 
minute pre-treatment with the selective 5-HT3 receptor antagonist granisetron (500 
nM), blocked maximal responses elicited by 5-HT and vortioxetine at both of the 
receptor subtypes, demonstrating the selectivity of vortioxetine and 5-HT in this assay.   
 
 
 
5-HT3A receptor EC50 (nM) Emax Hill Number 
5-HT 571±134 103±2 5.19±1.32 
Vortioxetine 195±25 50±7 3.45±0.77 
5-HT3AB receptor EC50 (nM) Emax Hill Number 
5-HT 571±109 102±2 2.34±0.45 
Vortioxetine 195±68 38±2 1.82±0.26 
Table 6: Summary data from Figures 10 and 11.  Vortioxetine is a 5-HT3 receptor agonist. 
Potency (EC50) and efficacy (Emax) of 5-HT and vortioxetine h5-HT3A and h5-HT3AB receptors.  
Emax presented as percentage of 5-HT response.  Data presented as mean±SEM, n=5. 
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Figure 10. At the h5-HT3A receptor, both vortioxetine 
and the endogenous agonist 5-HT displayed agonist 
activity, with differing potency and efficacy.   
A: Concentration-response curve (mean±SEM, n=5) B: 
Representative traces showing changes in calcium 
(fluorescence) over time.  Bar indicates when drugs were 
applied.  Granisetron (500 nM) blocked 5-HT (3.0 µM, C) 
or vortioxetine (3.0 µM, D) elicited responses at the h5-
HT3A receptor, representative traces of 5 independent 
experiments.  E: Bar chart demonstrating ability of 
granisetron to antagonise 5-HT or vortioxetine responses 
at the h5-HT3A receptor (mean±SEM, n=5), presented as 
% 5-HT response. 
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Figure 11. At the h5-HT3AB receptor, both 
vortioxetine and the endogenous agonist 5-HT 
displayed agonist activity, with differing potency 
and efficacy.   
A: Concentration-response curve (mean±SEM, n=5) B: 
Representative traces showing changes in calcium 
(fluorescence) over time.  Bar indicates when drugs 
were applied.  Granisetron (500 nM) to blocked 5-HT 
(3.0 µM, C) or vortioxetine (3.0 µM, D) elicited 
responses at the h5-HT3AB receptor.  Representative 
traces of 5 independent experiments.  E: Bar chart 
demonstrating ability of granisetron to antagonise 5-HT 
or vortioxetine responses at the h5-HT3AB receptor 
(mean±SEM, n=5), presented as % 5-HT response. 
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3.1.4 Vortioxetine inhibited 5-HT-induced responses at the h5-HT3A receptor. 
In functional calcium studies, alosetron (10 µM) completely blocked the 5-HT (1.0 µM) 
elicited response at the h5-HT3A receptor (Figure 12).  Yet, in the presence of 
vortioxetine (10 µM) some h5-HT3A receptor activity is still retained.  However, the 5-
HT response in the presence of vortioxetine decayed faster compared to 5-HT in the 
absence of vortioxetine.  The t1/2 time for the decay was 139±3 s for 5-HT, and 122±2 
s for vortioxetine, which was statistically significant (p<0.01, Mann-Whitney U test).  
This suggests that vortioxetine can reduce h5-HT3A receptor function but still retain 
some receptor activity.   
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Figure 12. The impact of vortioxetine upon a 5-HT-
mediated response at the h5-HT3A receptor.  
Ability of vortioxetine (10 µM) or the selective 5-HT3 
receptor antagonist alosetron (10 µM) to inhibit a 5-
HT (1.0 µM) mediated increase in intracellular 
calcium at the h5-HT3A receptor, when applied 
together.  Mean traces of n=7-8 independent 
experiments presented. 
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3.2 CSTI-300; a novel 5-HT3 receptor partial agonist with potential to 
treat patients with irritable bowel syndrome  
 
3.2.1 CSTI-300 in competition radioligand binding studies 
CSTI-300 and 5-HT competed for h5-HT3A or h5-HT3AB receptor binding sites with 
[3H]-granisetron.  CSTI-300 demonstrated around 100-fold and 350-fold greater affinity 
compared to 5-HT (Figure 13; Table 7) at the h5-HT3A and h5-HT3AB receptor 
respectively.  Both CSTI-300 and 5-HT displayed comparable affinity at both the h5-
HT3A and h5-HT3AB receptors.  The Hill number for CSTI-300, like 5-HT, was above 
unity when competing for the h5-HT3A receptor (Table 7).  This however was not the 
case for the h5-HT3AB receptor.     
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
5-HT3A receptor Ki (nM) Hill Number 
CSTI-300  2.26±0.48 1.19±0.16 
5-HT  327±62 1.49±0.19 
5-HT3AB receptor Ki (nM) Hill Number 
CSTI-300  1.59±0.09 0.70±0.13 
5-HT  563±89 0.91±0.07 
Table 7: Summary data from Figure 13. CSTI-300 is a high-
affinity 5-HT3 receptor ligand. 
The affinity (Ki) of CSTI-300 or 5-HT for the h5-HT3A and h5-
HT3AB receptors.  Data represents mean±SEM, n=5.  
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It has been demonstrated previously that Cl-indole does not compete with [3H]-
granisetron for the h5-HT3A receptor.  However, 5-HT will induce Cl-indole to 
competitively bind to the h5-HT3A receptor (Powell et al., 2016). This phenomenon of 
5-HT is also shared with CSTI-300, and so is able reveal the ability of Cl-indole to 
compete for [3H]-granisetron binding to the h5-HT3A receptor (Figure 14; Table 8).  
The degree to which the affinity of Cl-indole for the h5-HT3A receptor is increased by 
CSTI-300 is concentration-dependent.  The impact of CSTI-300 (3.0 or 5.0 nM) or 5-
HT (200 nM) upon Cl-indole affinity for the h5-HT3A receptor was statistically 
significant (p<0.05-0.01, Kruskal-Wallis test with Dunn’s multiple comparisons test). 
 
 
 
 
 
Figure 13. CSTI-300 displayed high-affinity binding for the h5-HT3 receptor. 
Ability of CSTI-300 or 5-HT to compete for [3H]-granisetron binding to h5-HT3A (A) or h5-HT3AB (B) 
receptors stably expressed in HEK293 cells.  Data represents mean±SEM, n=5. 
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Ligand Cl-indole IC50 (µM) 
Cl-indole alone 500±182 
Cl-indole + 5-HT (200 nM) 25±6* 
Cl-indole + CSTI-300 (1.0 nM) 63±14 
Cl-indole + CSTI-300 (3.0 nM) 30±4* 
Cl-indole + CSTI-300 (5.0 nM) 24±5** 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 8: Summary data from Figure 14.  CSTI-300 and 5-HT (200 
nM) increased the affinity of Cl-indole for the h5-HT3A receptor.   
Data represents mean±SEM, n=5. *p<0.05, **p<0.01, Kruskal-Wallis 
test with Dunn’s multiple comparisons test. 
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Figure 14. CSTI-300 and 5-HT alter the 
binding mechanism of Cl-indole at the h5-
HT3A receptor.  
Both CSTI-300 and 5-HT (200 nM) allowed Cl-
indole to compete with [3H]-granisetron for the 
h5-HT3A receptor. Data presents mean±SEM, 
n=5. 
71 
 
3.2.2 CSTI-300 in saturation radioligand binding studies 
In order to demonstrate that at the h5-HT3A and h5-HT3AB receptors, CSTI-300 is a 
competitive ligand, saturation binding using [3H]-granisetron was undertaken (Figure 
15; Table 9).  At the h5-HT3A and h5-HT3AB receptors, presence of CSTI-300 (3.0 nM 
and 2.0 nM respectively) reduced the affinity of [3H]-granisetron (p<0.05 using Mann-
Whitney U test for both receptor isoforms), without impacting the density of labelled 
receptors, indicating a competitive interaction (Figure 15; Table 9).   
 
 
 
 
 
 
 
 
 
5-HT3A receptor Kd (nM) Bmax (fmol/mg) Hill Number 
Vehicle 0.38±0.05 3414±582 1.16±0.10 
With CSTI-300 1.42±0.19 3264±552 1.52±0.48 
5-HT3AB receptor Kd (nM) Bmax (fmol/mg) Hill Number 
Vehicle 0.95±0.21 769±83 0.66±0.06 
With CSTI-300 3.40±0.84 845±159 0.83±0.06 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 9: Summary data from Figure 15.  CSTI-300 displayed a competitive 
interaction with the h5-HT3 receptor.  
The presence of CSTI-300 decreased the affinity (Kd) of [3H]-granisetron for h5-
HT3A and h5-HT3AB receptors (p<0.05, Mann-Whitney U test), but did not impact 
upon the density of labelled receptors (Bmax).  Data represents mean±SEM, n=5. 
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Figure 15. CSTI-300 is a competitive h5-HT3 receptor partial agonist.  
The impact of CSTI-300 upon the affinity of [3H]-granisetron for h5-HT3A (3.0 nM, upper panels) and 
h5-HT3AB (2.0 nM, lower panels) receptors.  A: Saturation curve.  B: Scatchard transformation of the 
data.  Representative of five repeats. 
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3.2.3 CSTI-300 in functional in vitro assays 
Using functional intracellular calcium assays, both 5-HT and CSTI-300 displayed 
activity as agonists at the h5-HT3A and h5-HT3AB receptors (Figures 16 and 17; Table 
10).  CSTI-300 was approximately 16x more potent at activating the h5-HT3A receptor 
compared to 5-HT, and had an intrinsic efficacy of around 40% relative to 5-HT.  At 
the h5-HT3AB receptor, CSTI-300 displayed intrinsic activity of approximately 30%, 
and was around 40x more potent than 5-HT.  Although the potency of 5-HT was similar 
at both receptor isoforms, the potency of CSTI-300 was marginally higher at the h5-
HT3A receptor compared to the h5-HT3AB receptor.  The Hill slope for CSTI-300 was 
lower than unity for both the h5-HT3A and h5-HT3AB receptors, whereas for 5-HT the 
Hill slope was greater than unity at both receptor isoforms. The calcium response 
induced by CSTI-300 at the h5-HT3A and h5-HT3AB receptors was also slower to 
reach a peak and returned to baseline slower compared to 5-HT.  Maximal responses 
elicited by 5-HT and CSTI-300 at the h5-HT3A and h5-HT3AB receptors were blocked 
by preincubation with the selective 5-HT3 receptor antagonist granisetron (500 nM). 
 
 
 
 
 
 
 
 
5-HT3A receptor Emax EC50 (nM) Hill number 
CSTI-300 41±7 25±5 0.85±0.14 
5-HT 104±1 400±17 3.28±0.46 
5-HT3AB receptor Emax EC50 (nM) Hill number 
CSTI-300 30±4 12±2 0.83±0.17 
5-HT 101±1 525±71 2.30±0.17 
Table 10: Summary data from Figures 16 and 17. CSTI-300 is a potent h5-HT3 
receptor agonist. 
Efficacy (Emax) and potency (EC50) of CSTI-300 or 5-HT at the h5-HT3A and h5-
HT3AB receptors, where efficacy is presented as percentage 5-HT response.  Data 
represents mean±SEM, n=5. 
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Figure 16. Both CSTI-300 or 5-HT displayed agonist activity at the h5-HT3A 
receptor, assessed by an increase in [Ca2+]i.  
A: Concentration-dependent activity of 5-HT and CSTI-300 (mean±SEM, n=5) B: 
Representative traces displaying change in calcium (fluorescence) over time of 5-HT 
(10 µM) or CSTI-300 (1.0 µM).  The responses elicited by 5-HT (3.0 µM, C) or CSTI-
300 (0.3 µM, D) at the h5-HT3A receptor were blocked with granisetron (500 nM, 30 
minutes preincubation). 
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Figure 17. Both CSTI-300 or 5-HT displayed agonist activity at the h5-HT3AB 
receptor, assessed by an increase in [Ca2+]i.  
A: Concentration-dependent activity of 5-HT and CSTI-300 (mean±SEM, n=5) B: 
Representative traces displaying change in calcium (fluorescence) over time of 5-HT (10 
µM) or CSTI-300 (1.0 µM).  The responses elicited by 5-HT (3.0 µM, C) or CSTI-300 
(0.3 µM, D) at the h5-HT3AB receptor were blocked with granisetron (500 nM, 30 minutes 
preincubation). 
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3.2.4 CSTI-300 as a h5-HT3A receptor functional antagonist 
In the presence of a maximal 5-HT concentration (1.0 µM), a saturating concentration 
of CSTI-300 (10 µM) decreased the level of h5-HT3A receptor activity down to 40% 
(compared to 100% for 5-HT alone).  This suggests CSTI-300 could reduce the activity 
of the h5-HT3A receptor in the presence of endogenous agonist 5-HT, but still retain 
some receptor activity (Figure 18).  This is not seen when 5-HT is co-applied with 
alosetron (10 µM), which blocked the 5-HT response completely. 
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Figure 18. CSTI-300 inhibited 5-HT mediated 
responses through the h5-HT3A receptor.  
The selective 5-HT3 receptor antagonist alosetron 
(10 µM) prevented a 5-HT (1.0 µM) induced 
response at the h5-HT3A receptor when applied 
simultaneously.  When 5-HT and CSTI-300 (10 µM) 
are co-applied there was still h5-HT3A receptor 
activity.  Mean traces of n=8 independent 
experiments presented. 
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3.2.5 The kinetics of CSTI-300 at the h5-HT3A receptor 
 
 
Single cell electrophysiology was used to further examine the kinetics of CSTI-300 
(and 5-HT) activation of the h5-HT3A receptor.   At a holding potential of -60 mV, a 
maximal 5-HT concentration (10 μM; 60 second application) elicited an inward current 
of 1,256±231 pA (n=5; Figure 19).  The time constant of the rising phase was 
0.28±0.07 seconds (n=5), which decayed slowly back to baseline.  A two-exponential 
curve fit was best used to model the decay, with time constants of 57.6±26.5 ms and 
245.8±50.3 ms (n=5).  In contrast, a maximal concentration of CSTI-300 (100 nM; 60 
second application) mediated a smaller inward current (248±74 pA; n=9; Figure 17), 
approximately 20% that of 5-HT at the h5-HT3A receptor.  In addition, the rise time 
was slower (3.64±0.29 s; n=9) as was the decay time (one-exponential fit; 260.9±31.9 
ms; n = 9) when compared to 5-HT. 
 
 
 
 
 
 
Figure 19.  The kinetics of a CSTI-300 or 5-HT induced current at the h5-HT3A receptor.     
An inward current in h5-HT3A receptor expressing HEK293 cells was elicited by a maximal concentration of 
CSTI-300 (100 nM, A) or 5-HT (10 µM, B).  Red bar indicates 60 second application of drug using a Picospritzer.  
Data are representative of 5 (5-HT) or 9 (CSTI-300) separate experiments.  Work performed in collaboration 
with Dr Gillian Grafton. 
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3.2.6 The activity of CSTI-300 activity in rat Bezold-Jarisch reflex 
The efficacy of 5-HT3 receptor antagonists has historically been evaluated using the 
Bezold-Jarisch reflex in rat.  Briefly, intravenous administration of 5-HT will induce 
transient bradycardia through stimulation of vagal afferent 5-HT3 receptors (Cote et 
al., 2004).  Prior oral administration of a 5-HT3 receptor antagonist will prevent this 
reflex (Fozard, 1984; Cohen et al., 1989; Eglen et al., 1995).  Transient bradycardia 
was evoked by intravenous administration of 5-HT (0.3 mg/kg) in rats (Bezold-Jarisch 
reflex; basal heart rate 422±15 bpm; maximum decrease of 66±3%; mean±SEM, n=6; 
p<0.01).  Prior oral treatment with alosetron (0.1 mg/kg) or CSTI-300 (0.1-3.0 mg/kg) 
prevented this reflex in a dose-dependent manner (p<0.01; Figure 18).  The effect of 
CSTI-300 (1.0 mg/kg; representing an approximate ED90 dose) to prevent the Bezold-
Jarisch reflex induced by 5-HT was evident for at least 4 hrs following a single oral 
administration (p<0.05-0.01; Figure 18).  At various time points during the study, 
plasma concentration of CSTI-300 were determined to be 16.6±4.5 nM (1 h), 9.1±0.9 
nM (2 h), 9.1±0.8 nM (4 h), and 3.3±0.2 nM (8 h) (mean±SEM, n=6), supporting a 
correlation of the level of inhibition of the Bezold-Jarisch reflex achieved with the CSTI-
300 plasma concentrations when considering the 5-HT3 receptor Ki (approximately 2.0 
nM) and the rat plasma protein binding (17±5%; mean±SEM, n=3) for CSTI-300.  For 
example, the estimated free concentration of CSTI-300 in the plasma at 4 h and 8 h 
was 7.6 nM and 2.7 nM, respectively; concentrations that are on the concentration-
responsive portion of the competition curve generating the Ki value (Figure 13).    
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3.2.7 The activity of CSTI-300 in an in vivo rodent IBS-d model 
A major symptom of IBS-d is increased visceral sensation and perception (Lacy et al., 
2016). To assess the potential of CSTI-300 for treating IBS-d, it was first evaluated in 
a rodent in vivo IBS-d model based on previous studies (Banner et al., 1995; Banner 
et al., 1995).  CSTI-300 was examined alongside the selective 5-HT3 receptor 
Figure 20.  CSTI-300 and alosetron both block the 5-HT-induced Bezold–Jarisch reflex 
in rat in vivo.  
A: There was a dose-dependent inhibition by CSTI-300 (p.o.) upon the 5-HT-induced Bezold-
Jarisch reflex.   The efficacy of CSTI-300 was similar to alosetron (0.1 mg/kg p.o.).  The ability 
of alosetron (0.1 mg/kg) and CSTI-300 (3.0 mg/kg) to prevent the decrease in 5-HT-induced 
heart rate compared to vehicle was statistically significant (**p<0.01; Kruskal-Wallis test with 
Dunn’s multiple comparisons).  B: Even 4 hours after CSTI-300 administration (1.0 mg/kg 
p.o., estimated ED90 dose), the 5-HT-induced Bezold-Jarisch reflex was still being prevented.  
5-HT (0.3 mg/kg i.v.) was used to evoke the bradycardia associated with the Bezold-Jarisch 
reflex.  Data represent mean±SEM, n=6 rats.  The effect of CSTI-300 (1.0 mg/kg) upon heart 
rate at 1, 2 and 4 hours after dosing was also statistically significant (**p<0.01, *p<0.05; 
Kruskal-Wallis test with Dunn’s multiple comparisons) compared to vehicle.  Work outsourced 
to Olan Ricerca Biosciences (http://www.ricerca.com/), data analysed and plotted by myself. 
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antagonist alosetron (which is also currently marketed as a therapeutic for IBS-d).  
Sub-cutaneous application of 5-hydroxytryptophan (5-HTP; 10 mg/kg) markedly 
increased the rat’s sensitivity to abdominal contractions (Figure 21).  Both alosetron 
and CSTI-300 reversed this increase in colonic sensitivity, with CSTI-300 showing 
similar efficacy to alosetron (Figure 19).  The reduction is sensitivity elicited by 
alosetron or CSTI-300 was statistically significant (p<0.01 to p<0.0001, using 2-way 
ANOVA with Bonferroni adjustment; Supplementary Tables 1, 2 and 3 in Appendix).   
 
5-HT3 receptor stimulation induces emesis, and this occurred previously when a 5-HT3 
receptor partial agonist (DDP, MKC-733, pumosetrag) was given to IBS-c patients or 
healthy adults (Coleman et al., 2003; Fujita et al., 2005).  A maximal oral dose of CSTI-
300 (1.0 mg/kg, p.o.) did not induce emesis in dogs (Table 11).  The concentration of 
plasma CSTI-300 six hours after dosing would be saturating the 5-HT3 receptor, 
implying if CSTI-300 did causes emesis it would have done.  Moreover, CSTI-300 did 
not alter the faeces or the behaviour of the dogs. 
 
 
 
 
 
 
 
 
 
 
 
Treatment 
Emetic episodes 
(either retching or 
vomiting) 
State of faeces 
General 
observations 
Plasma [CSTI-300] 
6 hrs post dose 
Mean±SD (range) 
 
CSTI-300 (1.0 
mg/kg p.o.) 
 
No emetic episodes 
for any of the six 
dogs. 
Normal for all six 
dogs [see methods 
for definition]. 
No abnormal 
observations [see 
methods for 
definition]. 
105±87 nM 
(31-227 nM) 
Table 11: An oral dose of CSTI-300 (1.0 mg/kg) did not alter the faeces of dogs, nor did it induce emesis 
or affect the behaviour of the dogs.   
The free plasma concentration taken six hours after oral dosing was between 10 – 70x the Ki for the h5-HT3A 
receptor (dog plasma protein binding 30±3%).  Data from six dogs.  Work outsourced to Medicilon 
(http://www.medicilon.com/). 
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Figure 21.  CSTI-300 and alosetron displayed similar efficacy in a rodent in 
vivo model of IBS-d, measured by a reduction in colonic sensitivity.   
A: The precursor to 5-HT, 5-HTP (10 mg/kg, s.c. arrow indicates administration), 
increased the sensitivity of rats to colon distension.  Alosetron reserved this 
increase in colonic sensitivity (B & C, arrow indicates administration of vehicle or 
alosetron where appropriate) and so did CSTI-300 (C, arrow indicates 
administration of vehicle, CSTI-300 or alosetron where appropriate).  D: Dose-
response curve for CSTI-300, generated by calculating area under the curve from 
graph C, yielded an ED50 of 0.55 mg/kg.  Data plotted as mean±SEM, n=10 rats.  
The impact of alosetron or CSTI-300 was statistically significant (p<0.01 to 
<0.0001).  Work outsourced to Medicilon (http://www.medicilon.com/), data 
analysed and plotted by myself. 
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3.2.8 The pharmacokinetics of CSTI-300 
The pharmacokinetics of CSTI-300 has been evaluated in dog, rat, mouse and mini-
pig (Figures 22, 23, 24 and 25; Table 12).  The t1/2 for CSTI-300 was comparable 
between rat, mouse and dog, with the half-life being faster when CSTI-300 was given 
as an intravenous injection (at 1.0 mg/kg) compared to oral administration.  The half-
life of CSTI-300 was longer in minipig when administered intravenously compared to 
the other species (rat, mouse and dog). Following intravenous administration of CSTI-
300 (1.0 mg/kg), the t1/2 was comparable between rat (1.6±0.2 hrs; n=3), dog (1.6±0.2 
hrs; n=4) and mini-pig (2.4±1.3 hrs, n=3), with the mouse displaying faster 
pharmacokinetics (0.4±0.06 hrs; n=3).  The t1/2 for CSTI-300 was slower following oral 
administration; mouse (10 mg/kg), rat (1.0 and 5.0 mg/kg), dog (10 and 30 mg/kg) and 
mini-pig (10 and 30 mg/kg), with values: 2.4± 0.4, 2.3±0.7 and 4.4±2.7, 3.7±0.8 and 
3.4±0.6, and 3.0±1.2 and 3.0±0.4 hrs, respectively.  The volume of distribution values 
was moderate in the species evaluated (3.0-14.6 L/kg).  The clearance values for all 
species were also moderate, with an inverse relationship between clearance value 
and species size.  Thus, lower clearance values were apparent in the larger species, 
dog and mini-pig (1.3 and 2.2 L/h/kg, respectively), compared to rodent (mouse and 
rat; 8.2 and 6.2 L/h/kg, respectively).  The oral bioavailability was good in mice and rat 
(24-41 %F) and excellent in dog and mini-pig (60-100 %F). The metabolites of CSTI-
300 are not available in the public domain, but no issues have been reported. A supra-
proportional exposure (AUC) of CSTI-300 was apparent with increasing doses of drug 
within the species examined.  After oral administration, the Cmax and AUC are 
increased for matched or similar doses in the larger animals (dog and mini-pig) versus 
the rodent species (mouse and rat). 
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Species 
(n) 
Dose 
(mg/kg) 
AUClast a 
(h*ng/ml) 
Tmaxb 
(hours) 
Cmaxc 
(ng/ml) 
T1/2d 
(hours) 
CLe 
(L/h/kg) 
Vdf 
(L/kg) 
%Fg 
Mouse (3) 1.0, iv 105±5 0.083±0 237±16 0.4±0.1 8.2 12.8  
Mouse (3) 10, po 435±4 0.5±0 172±36 2.4±0.4   41 
Rat (3) 1.0, iv 163±27 0.083±0 235±28 1.6±0.2 6.2±1.0 14.6±4.3  
Rat (3) 1.0, po 39.8±3.0 0.8±0.1 15±10 2.3±0.7   24 
Rat (3) 5.0, po 331±102 0.8±1.1 138±68 4.4±2.7   41 
Dog (4) 1.0, iv 764±135 0.083±0 497±48 1.6±0.2 1.3±0.2 3.0±0.3  
Dog (3) 0.3, po 205±105 0.5±0 86.1±34.4 1.6±0.18   89 
Dog (3) 1.0, po 1010±712 0.5±0 364±157 2.2±1.1   100 
Dog (4) 10, po 12098±1076 0.4±0.1 3498±725 3.7±0.8   100 
Dog (4) 30, po 39115±13049 0.25±0 9223±1464 3.4±0.6   100 
Mini-pig (3) 1.0, iv 444±39 0.083±0 510±109 2.4±1.3 2.2±0.2 7.7±4.9  
Mini-pig (3) 10, po 2669±328 2.67±1.2 568±203 3.0±1.2   60 
Mini-pig (3) 30, po 9180±948 2.0±0 2424±516 3.0±0.4   69 
 
Table 12: Summary data from Figures 22, 23, 24 and 25.  The pharmacokinetics of CSTI-300 in a variety of 
animals.  
Data represented as Mean±SD.  aArea under the plasma concentration versus time curve from 0 to the last time 
point CSTI-300 was quantifiable in plasma.  bTime of maximum observed concentration of CSTI-300 in plasma.  
cMaximum observed concentration of compound in plasma. dApparent half-life of the terminal phase of elimination 
of CSTI-100 from plasma. eTotal body clearance of CSTI-300.  fVolume of distribution.  gOral bioavailability; F = 
(AUClast po x Doseiv)/ (AUClast iv x dosepo). 
 
Species 
(n) 
Dose 
(mg/kg) 
AUClast a 
(h*ng/ml) 
Tmaxb 
(hours) 
Cmaxc 
(ng/ml) 
T1/2d 
(hours) 
CLe 
(L/h/kg) 
Vdf 
(L/kg) 
%Fg 
Mouse (3) 1.0, iv 105±5 0.083±0 237±16 0.4±0.1 8.2 12.8  
Mouse (3) 10, po 435±4 0.5±0 172±36 2.4±0.4   41 
Rat (3) 1.0, iv 163±27 0.083±0 235±28 1.6±0.2 6.2±1.0 14.6±4.3  
Rat (3) 1.0, po 39.8±3.0 0.8±0.1 15±10 2.3±0.7   24 
Rat (3) 5.0, po 331±102 0.8±1.1 138±68 4.4±2.7   41 
Dog (4) 1.0, iv 764±135 0.083±0 497±48 1.6±0.2 1.3±0.2 3.0±0.3  
Dog (3) 0.3, po 205±105 0.5±0 86.1±34.4 1.6±0.18   89 
Dog (3) 1.0, po 1010±712 0.5±0 364±157 2.2±1.1   100 
Dog (4) 10, po 12098±1076 0.4±0.1 3498±725 3.7±0.8   100 
Dog (4) 30, po 39115±13049 0.25±0 9223±1464 3.4±0.6   100 
Mini-pig (3) 1.0, iv 444±39 0.083±0 510±109 2.4±1.3 2.2±0.2 7.7±4.9  
Mini-pig (3) 10, po 2669±328 2.67±1.2 568±203 3.0±1.2   60 
Mini-pig (3) 30, po 9180±948 2.0±0 2424±516 3.0±0.4   69 
 Data represented as Mean±SD.  aArea under the plasma concentration versus time curve from 0 to the last time 
point CSTI-300 was quantifiable in plasma.  bTime of maximum observed concentration of CSTI-300 in plasma.  
cMaximum observed concentration of compound in plasma. dApparent half-life of the terminal phase of elimination 
of CSTI-100 from plasma. eTotal body clearance of CSTI-300.  fVolume of distribution.  gOral bioavailability; F = 
(AUClast po x Doseiv)/ (AUClast iv x dosepo). 
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Figure 23.  The pharmacokinetics of CSTI-300 in rat.   
After administration of CSTI-300 either intravenously (A) or orally (B; C), CSTI-300 was 
metabolised with a half-life of approximately 2 hours for 1.0 mg/kg or 4 hours for 5.0 mg/kg. 
A half-life of 1.6 hours was recorded for intravenous administration.  Data represents 
mean±SD, from 3 rats.  Work outsourced to NoAb BioDiscoveries, data analysed and 
plotted by myself. 
 
Figure 21.  The pharmacokinetics of CSTI-300 in rat.   
Figure 22.  The pharmacokinetics of CSTI-300 in mouse.   
After administration of CSTI-300 either intravenously (A) or orally (B), CSTI-300 was 
metabolised with a half-life of approximately 2.4 hours for oral administration or 0.4 hours for 
intravenous administration.  Data represents mean±SD, from 3 mice.  Work outsourced to NoAb 
BioDiscoveries, data analysed and plotted by myself. 
 
Figure 20.  The pharmacokinetics of CSTI-300 in mouse.   
After administration of CSTI-300 either intravenously (A) or orally (B), CSTI-300 was 
metabolised with a half-life of approximately 2.4 hours for oral administration or 0.4 hours for 
intravenous administration.  Data represents mean±SD, from 3 mice.  Work outsourced to NoAb 
BioDiscoveries, data analysed and plotted by myself. 
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Figure 24.  The pharmacokinetics of CSTI-300 in dog.  
After administration of CSTI-300 either intravenously (A) or orally (B; C), CSTI-300 was 
metabolised with a half-life of approximately 4 hours for oral administration, and 1.6 hours for 
intravenous administration.  Data represents mean±SD, from 4 dogs.  Work outsourced to 
Covance (https://www.covance.com/), data analysed and plotted by myself. 
 
 
Figure 22.  The pharmacokinetics of CSTI-300 in dog.  
After administration of CSTI-300 either intravenously (A) or orally (B; C), CSTI-300 was 
metabolised with a half-life of approximately 4 hours for oral administration, and 1.6 hours for 
intravenous administration.  Data represents mean±SD, from 4 dogs.  Work outsourced to 
Covance (https://www.covance.com/), data analysed and plotted by myself. 
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Figure 25.  The pharmacokinetics of CSTI-300 in mini-pig.   
After administration of CSTI-300 either intravenously (A) or orally (B; C), CSTI-300 was 
metabolised with a half-life of approximately 3 hours for oral administration or 2.4 hours for 
intravenous administration.  Data represents mean±SD, from 3 mini-pigs.  Worked 
outsourced to by Calvert labs (http://calvertlabs.com/), data analysed and plotted by myself. 
 
Figure 23.  The pharmacokinetics of CSTI-300 in mini-pig.   
After administration of CSTI-300 either intravenously (A) or orally (B; C), CSTI-300 was 
metabolised with a half-life of approximately 3 hours for oral administration or 2.4 hours for 
intravenous administration.  Data represents mean±SD, from 3 mini-pigs.  Worked 
outsourced to by Calvert labs (http://calvertlabs.com/), data analysed and plotted by myself. 
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CSTI-300 also has desirable therapeutic characteristics to make it an ideal drug for 
market (Table 13).  CSTI-300 demonstrated no significant efficacy at a range of other 
receptors, transporters or ion channels and does not interact with members of the 
cytochrome P450 enzyme (CYPs) family, suggesting a low chance of drug-drug 
interactions.  CSTI-300 was also well tolerated in a variety of species (dog, rat and 
monkey) (Table 13). 
 
 
 
 
 
 
 
 
3.3 The binding mechanism of Cl-indole at the 5-HT3 receptor 
High affinity and selectivity for 5-HT3 
receptor 
No significant (>50%) off-target activity 
(screened @ 1.0 µM) (See supplementary 
Table 4 in Appendix).   
Low probability of drug/drug 
interactions 
CYPs (1A2, 2B6, 2C9, 2C19, 2D6, 3A4) IC50 
> 100 µM 
Good oral PK in rodent, dog and 
monkey 
Fmice= 42%, t1/2 = 4.2 h 
Fdog = 100%, t1/2 = 3.7 h 
Fmonkey = 26%, t1/2 = 4.9 h 
Large margin of safety 
NOAEL (no-observed-adverse-effect-level) = 
300 mg/kg/day (7 day dosing in rat); ~300 x 
ED90 conc. 
Good tolerability in dog and monkey study; 
no emesis or loose stool at 1.0 mg/kg (~10 x 
ED90) 
Non-mutagenic in micro-Ames Test 
Excellent pharmaceutical/biophysical 
properties 
Molecular Weight < 350 Daltons 
Log P = 1.95 
Water soluble (>400 mg/mL) 
Table 13: Summary of additional pharmacological and pharmaceutical characteristics of 
CSTI-300. 
 
Table 13: Summary of additional pharmacological and pharmaceutical characteristics of 
CSTI-300. 
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3.3.1 5-HT alters the binding mechanism of Cl-indole but not PBG 
Cl-indole is a relatively selective and potent modulator at the 5-HT3 receptor.  It has 
been shown previously to increase the efficacy and potency of 5-HT (plus other 5-HT3 
receptor agonists) at the h5-HT3A receptor (Newman et al., 2013).  Cl-indole also 
displayed non-competitive binding at the h5-HT3A receptor (i.e. it did not displace [3H]-
granisetron from h5-HT3A receptor binding sites).  This has also been replicated 
(Figure 26), and it has been demonstrated that sub-maximal concentrations of 5-HT 
(up to 200 nM) induce Cl-indole to compete with [3H]-granisetron for the h5-HT3A 
receptor and increase the affinity of Cl-indole for the h5-HT3A receptor (Figure 26; 
Table 14).  The impact of 5-HT upon the affinity of Cl-indole for the h5-HT3A receptor 
was statistically significant (p<0.05 to p<0.001, using Kruskal-Wallis test with Dunn’s 
multiple comparisons). Binding of the weak 5-HT3 receptor partial agonist phenyl 
biguanide (PBG) for the h5-HT3A receptor is not impacted by the same concentrations 
of 5-HT. 
[5-HT] (nM)  
IC50 (µM) 
Cl-indole PBG 
0 (Vehicle) 179±20 15±2 
10 77±12 14±1 
30 49±12 14±1 
100 27±6* 15±3 
200 10±1*** 10±2 
Table 14: Summary data from Figure 26.  The affinity of Cl-indole is increased by 5-HT (compared to Cl-
indole in the absence of 5-HT) at the h5-HT3A receptor.   
However, the affinity of PBG for the h5-HT3A receptor was not affected by 5-HT.  *p<0.05, ***p<0.001 when 
compared to Cl-indole + vehicle, using Kruskal-Wallis with Dunn’s multiple comparisons test.  The data 
represents mean±SEM, n=3-8. 
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3.3.2 The affinity of Cl-indole for the h5-HT3A receptor is modulated by a variety 
of 5-HT3 receptor partial agonists. 
In the presence of Cl-indole, the maximal response elicited by a 5-HT3 receptor partial 
agonist is greater compared to the partial agonist alone (Newman et al., 2013).  It was 
therefore evaluated whether 5-HT3 receptor partial agonists (quipazine, DDP and s-
zacopride) could have the same effect as 5-HT and increase the affinity of Cl-indole 
for the h5-HT3A receptor (Figure 27; Table 15).  Despite having lower intrinsic 
efficacies than 5-HT, all three partial agonists caused Cl-indole to compete out [3H]-
granisetron from h5-HT3A receptor binding sites.  To ensure a valid comparison, the 
concentrations of partial agonists used are approximately their Ki. 
 
Figure 26. 5-HT impacted the binding of Cl-indole, not PBG, for the h5-HT3A receptor.  
The affinity of Cl-indole (A), but not the 5-HT3 receptor partial agonist PBG (B) was increased by sub-
maximal concentrations of 5-HT at the h5-HT3A receptor.  Data represents mean±SEM, n=3-8. 
 
Figure 24. 5-HT impacted the binding of Cl-indole, not PBG, for the h5-HT3A receptor.  
The affinity of Cl-indole (A), but not the 5-HT3 receptor partial agonist PBG (B) was increased by sub-
maximal concentrations of 5-HT at the h5-HT3A receptor.  Data represents mean±SEM, n=3-8. 
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Table 15: Summary data from Figure 27.  The affinity of Cl-indole was 
increased by 5-HT (200 nM) and a variety of 5-HT3 receptor partial 
agonists at the h5-HT3A receptor.  Note: Cl-indole + vehicle and Cl-indole 
+ 5-HT (200 nM) were included with each experiment for the different partial 
agonist, so have been included for each different ligand.  The data 
represents mean±SEM, n=3-5. 
Ligand  Cl-indole IC50 (μM) 
Cl-indole + vehicle 187±45 
Cl-indole + 5-HT (200 nM) 30±4 
Cl-indole + quipazine (0.3 nM) 144±30 
Cl-indole + quipazine (1.0 nM) 92±21 
Cl-indole + quipazine (3.0 nM) 32±5 
Ligand Cl-indole IC50 (μM) 
Cl-indole + vehicle 136±16 
Cl-indole + 5-HT (200 nM) 29±3 
Cl-indole + DDP (0.1 nM) 223±82 
Cl-indole + DDP (0.3 nM) 150±30 
Cl-indole + DDP (1.0 nM) 50±6 
Ligand Cl-indole IC50 (μM) 
Cl-indole + vehicle 160±28 
Cl-indole + 5-HT (200 nM) 52±13 
Cl-indole + s-zacopride (1.0 nM) 99±14 
Cl-indole + s-zacopride (2.0 nM) 47±6 
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Figure 27.  The impact of 5-HT upon Cl-indole binding for the h5-HT3A receptor was replicated by 
other 5-HT3 receptor agonists.  
The affinity of Cl-indole was increased by 5-HT (200 nM), and by other 5-HT3 receptor partial agonists, 
quipazine (A), DDP (B) and s-zacopride (C) at the h5-HT3A receptor.  Data represents mean±SEM, n=3-5. 
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The IC50 for Cl-indole at the h5-HT3A receptor in the presence of quipazine (3.0 nM), 
DDP (1.0 nM) or s-zacopride (2.0 nM) is comparable to what was determined for Cl-
indole + 5-HT (200 nM), demonstrating that the affinity of Cl-indole can be increased 
by a variety of 5-HT3 receptor partial agonists with different intrinsic activities. 
 
3.3.3 5-HT3 receptor antagonists do not affect the binding of Cl-indole at the h5-
HT3A receptor 
To determine whether any 5-HT3 receptor ligand (i.e. intrinsic efficacy wasn’t 
necessary) could increase the affinity for Cl-indole at the h5-HT3A receptor, the impact 
of 5-HT3 receptor antagonists (metoclopramide or ondansetron) upon Cl-indole 
binding for the h5-HT3A receptor was investigated (Figure 28; Table 16).  To allow a 
comparison with the 5-HT3 receptor partial agonists (Figure 27; Table 15), 
concentrations approximate to the Ki of antagonists were used.  Whilst the affinity of 
Cl-indole for the h5-HT3A receptor was increased by 5-HT (200 nM), neither 
metoclopramide nor ondansetron altered the affinity of Cl-indole (Figure 28; Table 16).  
In the presence of 5-HT3 receptor antagonist, Cl-indole did not compete with [3H]-
granisetron for the h5-HT3A receptor binding sites. 
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Ligand Cl-indole IC50 (μM) 
Cl-indole + vehicle 302±101 
Cl-indole + 5-HT (200 nM) 30±7 
Cl-indole + metoclopramide (30 nM) 311±38 
Cl-indole + metoclopramide (100 nM) 364±75 
Cl-indole + metoclopramide (300 nM) 361±75 
Cl-indole + metoclopramide (1000 nM) 167±7 
Ligand Cl-indole IC50 (μM) 
Cl-indole + vehicle 187±45 
Cl-indole + 5-HT (200 nM) 30±4 
Cl-indole + ondansetron (0.3 nM) 269±95 
Cl-indole + ondansetron (1.0 nM) 251±67 
Cl-indole + ondansetron (3.0 nM) 239±30 
 
 
 
 
 
 
Table 16: Summary data from Figure 28.  The affinity of Cl-indole was increased 
by 5-HT (200 nM), but not by 5-HT3 receptor antagonists at the h5-HT3A receptor.  
Note: Cl-indole + vehicle and Cl-indole + 5-HT (200 nM) were included with each 
experiment for the different antagonist, so have been included for each different ligand.  
The data represents mean±SEM, n=3-4. 
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3.3.4 Cl-indole binding to the 5-HTBP 
The 5-HTBP was generated by aligning the AChBP (which does bind 5-HT, albeit with 
lower affinity compared to acetylcholine) with the sequence of the h5-HT3A receptor, 
and identifying homologous ligand binding residues in the extracellular domain 
(Kesters et al., 2013).  The following mutations were made in the AChBP: S92E, 
V140L, K141T and Y53W, homologous to E129 in loop A, L178 and T179 in loop B, 
and W90 in loop D of the h5-HT3A receptor (Kesters et al., 2013).  It was determined 
whether the binding mechanism of Cl-indole to the h5-HT3A receptor could be 
replicated using the 5-HTBP.  Due to the lower affinity of the 5-HTBP for [3H]-
granisetron, SPA was used to measure the binding of [3H]-granisetron to the 5HTBP 
rather than traditional filtration methods.  Unlike what was seen for the h5-HT3A 
receptor, Cl-indole displaced [3H]-granisetron from the 5-HTBP, and the affinity of Cl-
indole was not increased by 5-HT (30 µM) (Figure 29; Table 17).  Moreover, 5-HT and 
Figure 28. 5-HT3 receptor antagonists do not have the same effect as 5-HT upon Cl-indole binding 
for the h5-HT3A receptor.   
The affinity of Cl-indole was increased by 5-HT (200 nM), but not by 5-HT3 receptor antagonists, 
metoclopramide (A) and ondansetron (B) at the h5-HT3A receptor.  Data represents mean±SEM, n=3-4. 
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alosetron both competed for [3H]-granisetron occupied 5-HTBP binding sites, albeit 
with lower affinities than what would be seen for the h5-HT3A receptor (Figure 29; 
Table 17) (Hirata et al., 2007). 
IC50 (µM) 
Cl-indole + vehicle Cl-indole + 5-HT (30 µM) Alosetron 5-HT 
55±11 227±43 2.0±0.6 8.5±1.3 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 29. The 5-HTBP does not replicate Cl-indole binding to the h5-HT3A receptor.  
The affinity of Cl-indole was not affected by 5-HT (30 µM) at the 5-HTBP (A).  Alosetron and 5-HT 
compete with [3H]-granisetron for 5-HTBP binding sites with lower affinity compared to what would be 
expected for the 5-HT3A receptor (B).  Data represents mean±SEM, n=3. 
 
Figure 27. The 5-HTBP does not replicate Cl-indole binding to the h5-HT3A receptor.  
The affinity of Cl-indole was not affected by 5-HT (30 µM) at the 5-HTBP (A).  Alosetron and 5-HT 
Table 17: Summary data from Figure 29.  The affinity of Cl-indole was decreased by the presence of 5-HT 
(30 µM) at the 5-HTBP.  
 Alosetron and 5-HT both compete for the 5-HTBP with [3H]-granisetron.  The data represents mean±SEM, n=3. 
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3.3.5 5-HT does not influence Cl-indole binding to the h5-HT3AB receptor 
Cl-indole has similar functional activity at the h5-HT3AB receptor as it does at the h5-
HT3A receptor, increasing the maximal response and potency of 5-HT (Figure 30; 
Table 18).  The potency of 5-HT was approximately doubled at both receptor subtypes 
in the presence of Cl-indole (10 µM).  Moreover, the maximal response elicited by 5-
HT increased 2-fold at the h5-HT3A receptor in the presence of Cl-indole.  At the h5-
HT3AB receptor, the increase in maximal 5-HT response was also apparent in the 
presence of Cl-indole, albeit not quite as dramatic (a 50% increase).  It was 
investigated whether Cl-indole demonstrated the same binding strategy at the h5-
HT3AB receptor as it does at the h5-HT3A receptor.  Cl-indole did not displace [3H]-
granisetron from h5-HT3AB receptor binding sites (Figure 31).  However, the presence 
of sub-maximal 5-HT concentrations did not induce Cl-indole to compete for h5-HT3AB 
receptor binding sites with [3H]-granisetron nor did 5-HT increase the affinity of Cl-
indole for the h5-HT3AB receptor (Figure 31; Table 19). 
 
Table 18: Summary data from Figure 30.  The impact of Cl-indole upon 5-HT potency 
and efficacy at the 5-HT3A and 5-HT3AB receptors.  
At both the h5-HT3A and the h5-HT3AB receptors, Cl-indole (10 µM) increases the potency 
and efficacy of 5-HT in intracellular calcium assays.  Emax presented as percentage 5-HT + 
vehicle, data represents mean±SEM, n=3. 
 
 
5-HT3A receptor Emax EC50 (nM) Hill number 
5-HT + vehicle 119±1.9 329±76 2.65±0.62 
5-HT + Cl-indole (10 µM) 241±33 195±39 2.91±0.20 
5-HT3AB receptor Emax EC50 (nM) Hill number 
5-HT + vehicle 106±1 367±22 1.86±0.25 
5-HT + Cl-indole (10 µM) 156±16 181±33 1.98±0.23 
97 
 
0
10000
20000
30000
40000
50000
60000
0 50 100 150 200 250 300
5-HT (10 µM) + vehicle
5-HT (10 µM) + Cl-indole (10 µM)
Time (seconds)
 5-HT 
 
 
 Cl-indole or vehicle 
 
 
0
50
100
150
200
250
300
350
10
-9
10
-8
10
-7
10
-6
10
-5
10
-4
5-HT + vehicle
5-HT + Cl-indole (10 µM)
[5-HT] (M)
%
 5
-H
T
 R
e
s
p
o
n
s
e
F
lu
o
re
s
c
e
n
c
e
 (
R
F
U
)
%
 5
-H
T
 R
e
s
p
o
n
s
e
0
50
100
150
200
10
-9
10
-8
10
-7
10
-6
10
-5
10
-4
5-HT + vehicle
5-HT + Cl-indole (10 µM)
[5-HT] (M)
0
5000
10000
15000
20000
25000
30000
35000
0 50 100 150 200 250 300
5-HT (10 µM) + vehicle
5-HT (10 µM) + Cl-indole (10 µM)
Time (seconds)
F
lu
o
re
s
c
e
n
c
e
 (
R
F
U
)
 5-HT 
 
  
 Cl-indole or vehicle 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 30. Cl-indole increases the efficacy and potency of 5-HT at the h5-HT3A and 
h5-HT3AB receptors.  
Concentration-response curve (A) and Representative traces showing changes in calcium 
(fluorescence) over time (B) for the h5-HT3A receptor.  Bar indicates when drugs were 
applied.  Concentration-response curve (C) and Representative traces showing changes 
in calcium (fluorescence) over time (D) for the h5-HT3AB receptor.  Bar indicates when 
drugs were applied.  Data represents mean±SEM, n=3, presented as % 5-HT response 
for concentration-response curves. 
 
 
Figure 28. Cl-indole increases the efficacy and potency of 5-HT at the h5-HT3A and 
h5-HT3AB receptors.  
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[5-HT] (nM) Cl-indole IC50 (μM) 
0 (Vehicle) 237±35 
10 345±20 
30 262±62 
100 224±40 
200 240±52 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 19: Summary data from Figure 31.  
The affinity of Cl-indole was unchanged by 
5-HT at the h5-HT3AB receptor.  
Unlike at the h5-HT3A receptor, 5-HT did not 
impact the affinity of Cl-indole at the h5-HT3AB 
receptor.  The data represents mean±SEM, 
n=5. 
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Figure 31. Cl-indole binding at the h5-HT3AB 
receptor.  
The affinity of Cl-indole was unaffected by 5-HT 
at the h5-HT3AB receptor, unlike what was seen 
for the h5-HT3A receptor.  Data represents 
mean±SEM, n=5. 
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4 Discussion  
 
4.1 Vortioxetine is a 5-HT3 receptor partial agonist 
 
4.1.1 The pharmacology of vortioxetine at the h5-HT3 receptor 
From this in vitro study of vortioxetine at the h5-HT3 receptor, it has been discovered 
that vortioxetine is a high affinity, competitive 5-HT3 receptor partial agonist, with 
similar pharmacology (in terms of potency and efficacy) at the h5-HT3A and h5-HT3AB 
receptor isoforms.  Furthermore, the ability of co-applied vortioxetine to reduce (but 
not fully block) a maximal 5-HT-induced response at the h5-HT3A receptor suggests 
this drug may have potential in treating conditions where the 5-HT3 receptor is over-
active, such is the case in IBS-d. 
 
At the time of investigation, the present studied provided the first detailed 
pharmacological investigation into the activity of vortioxetine at h5-HT3 receptors. 
Recent work by Ladefoged and colleagues was published during the end of these 
studies and after the data in this thesis was presented at conferences.  Vortioxetine 
demonstrated high affinity for the h5-HT3A and h5-HT3AB receptors, and similar to the 
endogenous agonist 5-HT, the affinity of vortioxetine for h5-HT3 receptors was 
increased by the COM Cl-indole (Newman et al., 2013).  Moreover, the affinity of Cl-
indole for the h5-HT3A receptor was increased by vortioxetine in a concentration-
dependent manner, similar to what has been shown previously for 5-HT in this thesis.  
These binding characteristics of vortioxetine (which are shared also by 5-HT) support 
the idea that vortioxetine has functional agonist activity at the h5-HT3 receptor. 
 
In functional studies, in which the ability of a 5-HT3 receptor agonist to activate the 5-
HT3 receptor (measured by an increase in [Ca2+]i), vortioxetine displayed partial 
agonist activity, with an intrinsic efficacy (relative to the endogenous full agonist 5-HT) 
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of approximately 50% at the h5-HT3A receptor and 40% at the h5-HT3AB receptor.  As 
may have been expected, the maximal responses are lower for both vortioxetine and 
5-HT at the h5-HT3AB receptor.  This is due to the reduced calcium permeability of the 
h5-HT3AB compared to the h5-HT3A receptor (Davies et al., 1999).  However, because 
these cell lines are not clonal (i.e. each cell does not generate the same number of 
cell surface receptors), the difference in calcium response could apparently be due to 
differences in 5-HT3 receptor expression.  Furthermore, the responses elicited by 5-
HT and vortioxetine were selective for the 5-HT3 receptor, because preincubation with 
the selective 5-HT3 receptor antagonist granisetron blocked 5-HT3 receptor activity.  
Granisetron was used in this assay as a selective 5-HT3 receptor antagonist to verify 
the selectively of the 5-HT and vortioxetine induced responses at the h5-HT3 receptor. 
 
The first initial investigation of vortioxetine used electrophysiology to assess the 
functional activity of vortioxetine at the 5-HT3A receptor (both rat and human isoforms) 
(Bang-Andersen et al., 2011).  It was established that vortioxetine is a 5-HT3 receptor 
partial agonist for the human receptor (it displayed no functional activity at the rat 5-
HT3 receptor).  However, after vortioxetine elicited an inward current at the h5-HT3A 
receptor, subsequent applications of vortioxetine (or 5-HT) fail to evoke any response 
(Bang-Andersen et al., 2011).  This is unlike what occurs when 5-HT activates the h5-
HT3A receptor, where under appropriate conditions, further applications of 5-HT still 
elicit currents of a similar magnitude.  This unusual mechanism of vortioxetine lead to 
the authors describing it as a ‘functional antagonist’, i.e. vortioxetine doesn’t block the 
5-HT3 receptor through a competitive manner (like a classic antagonist, e.g. 
ondansetron), but rather impacts the receptor such that it can no longer respond to 
agonist, possibly by desensitisation or receptor internalisation. 
 
Different studies have shown that the 5-HT3 receptor undergoes 
internalisation/recycling after treatment with selective agonists or antagonists.  Using 
radioligand binding studies, it was demonstrated that treatment of HEK293 cells 
expressing the h5-HT3A receptor with palonosetron (1.0 nM) for 24 hours caused a 
reduction (approximately 50%) in [3H]-palonosetron surface binding sites, suggesting 
internalisation of the receptor (Rojas et al., 2010).  The effect of palonosetron on cell 
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surface h5-HT3A receptor expression was shown to occur after 15 minutes of 
palonosetron treatment (receptor expression was decreased by 30%).  2 hours of 
palonosetron treatment had a similar effect on h5-HT3A receptor surface expression 
as did 24 hour palonosetron treatment (Rojas et al., 2010).  Furthermore, this was 
translated in functional studies, whereby palonosetron treatment caused a decrease 
in the calcium response elicited by 5-HT at HEK293 cells expressing the h5-HT3A 
receptor (Rojas et al., 2010).  Moreover, the potent 5-HT3 receptor agonist mCPBG 
also caused 5-HT3 receptor internalisation (Ilegems et al., 2004).  
Immunocytochemistry studies demonstrated that after 2 hours treatment with mCPBG 
(500 nM), the majority of mouse 5-HT3A receptors were internalised.  It could be 
possible therefore that the inhibitory actions of vortioxetine are due to 5-HT3 receptor 
internalisation, rather than purely a competitive block.   
 
Interestingly, in functional experiments, the calcium response evoked by vortioxetine 
decayed to baseline faster than the response induced by 5-HT at both the h5-HT3A 
and h5-HT3AB receptors. This was not seen for other 5-HT3 receptor partial agonists 
(e.g. DDP, CSTI-300, quipazine), whereby the response appeared to decay slower 
than that of 5-HT in intracellular calcium assays (Newman et al., 2013).  Moreover, 
electrophysiology assays have demonstrated that 5-HT3 receptor partial agonists (e.g. 
mCPBG or SR 57227A) often have similar desensitisation kinetics compared to 5-HT 
(van Hooft et al., 1996; Nakamura et al., 2019).  This could further imply that 
vortioxetine causes a more rapid desensitisation of the h5-HT3 receptor compared to 
other 5-HT3 receptor agonists.   
 
Functional studies were undertaken where a saturating concentration of 5-HT (1.0 µM) 
and vortioxetine (10 µM) were co-applied to the h5-HT3A receptor.  In this assay, 
vortioxetine was compared alongside alosetron as a 5-HT3 receptor antagonist.  
Alosetron was used so vortioxetine can be compared with a marketed therapeutic for 
IBS-d.  Compared to 5-HT alone, the calcium response caused by 5-HT and 
vortioxetine returned to baseline significantly faster than 5-HT alone (as defined by t1/2 
time).  It is interesting to speculate the mechanism behind this.  5-HT could (having 
lower affinity, and so likely to interact with the receptor first) be eliciting the initial 
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response, and then vortioxetine begins to compete out 5-HT and cause the receptor 
to desensitise more rapidly.  However, this must be approached with some caution.  
Firstly, the functional calcium assays are a population measurement, i.e. it is analysing 
average fluorescent responses of a number of cells in a 96 well plate, rather than at 
the single cell level (unlike electrophysiology).  Therefore, actual comments about the 
receptor state (i.e. whether it is desensitised) cannot be said without examining the 
impact of vortioxetine at the single cell or single channel level.  However, this could be 
one of the mechanisms for which vortioxetine causes 5-HT3 receptor antagonism. 
 
5-HT3 receptor agonists will cause receptor desensitisation.  The distinct 
desensitisation kinetics of 5-HT and vortioxetine are consistent with previous findings 
that desensitisation in the presence of partial agonists exhibit a different profile to full 
agonists (Corradi et al., 2014).  The rate of recovery from desensitisation is dependent 
on 5-HT3 receptor agonist (and not dependent on agonist concentration or agonist 
reassociation with the receptor), and it could be speculated that vortioxetine is an 
agonist which simply shifts the 5-HT3 receptor into such a state that it cannot recover 
from desensitisation (van Hooft et al., 1997).  It may be of interest to determine if this 
desensitisation also occurs when vortioxetine is applied to the h5-HT3A receptor in the 
presence of 5-HI, an allosteric modulator which is known to reduce desensitisation 
kinetics (van Hooft et al., 1997). 
 
In addition, the natural agonist 5-HT (at high concentrations) is known to cause 
channel block (Corradi et al., 2014).  It is interesting to think that the small decrease 
in response elicited by vortioxetine at 3.0 and 10 µM compared to 1.0 µM could be 
due to channel block; although this must be resolved using single channel activity to 
assess the open time kinetics (Corradi et al., 2014). 
 
4.1.2 The efficacy and tolerability of vortioxetine in depression 
The efficacy and tolerability of vortioxetine has been studied in depth.  One such 
review assessing 18,326 patients across 57 studies found that vortioxetine had similar 
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efficacy to other antidepressants (e.g. duloxetine, sertraline, escitalopram) using an 
improvement in the HAM-D or MADRS scale as an endpoint in evaluating depression 
(Llorca et al., 2014).  In addition, vortioxetine was demonstrated to be more efficacious 
than placebo in reducing the MADRS score (Berhan et al., 2014).  Moreover, 
vortioxetine is also effective at helping MDD patients achieve remission (which rarely 
occurs for other antidepressants) (Thase et al., 2016).  Vortioxetine is also effective in 
treating anxiety and improving overall patient functioning (Baldwin et al., 2016; Florea 
et al., 2017).  Indeed, a large review (encompassing 194 studies, 34,196 patients) 
identified vortioxetine (alongside escitalopram) as one of the more efficacious drugs 
in treating depression (with fluoxetine and reboxetine amongst the worst performers) 
(Cipriani et al., 2018). 
 
The highest density of 5-HT3 receptor expression in the brain is within the nucleus 
tractus solitarius of the brainstem (Parker et al., 1996).  Activation of 5-HT3 receptors 
(specifically in the chemoreceptor trigger zone) will induce the emetic response (Miner 
et al., 1987; Bermudez et al., 1988).  Therefore 5-HT3 receptor agonists have rarely 
been tested clinically.  Indeed, only low doses of a 5-HT3 receptor agonist (SR 57227A) 
could be used to investigate the impact of 5-HT3 receptor activation on sleep (Staner 
et al., 2001).    This was because higher doses of the drug could elicit an emetic 
response.  Furthermore, in phase II trials of pumosetrag (DDP733, MCK-733), for IBS-
c, nausea and vomiting were regularly described as common adverse effects, with 
over 25% of patients reporting these side effects (Evangelista, 2007; Choung et al., 
2014). 
 
As may have been anticipated, nausea and vomiting are regularly recorded as an 
adverse effect when prescribed vortioxetine.  One meta-analysis calculated the odds 
of experiencing nausea were 3x higher for vortioxetine compared to placebo, which 
has led to a higher drop-out rate for vortioxetine compared to placebo (Berhan et al., 
2014; Pae et al., 2015).  20% of patients receiving vortioxetine (20 mg) reported 
nausea, whilst this was the case for only 5% of patients taking placebo.  Of note, 1.0 
mg vortioxetine caused a similar rate of nausea as placebo, suggesting a dose-
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dependent effect of vortioxetine on nausea (indicative of a receptor driven event for 
this adverse effect, rather than a non-specific effect) (Meeker et al., 2015). 
 
However, despite this clear issue with vortioxetine, many studies have concluded that 
vortioxetine is one of the better tolerated antidepressants.  Indeed, vortioxetine has 
been described as being better tolerated than desvenlafaxine and sertraline (Llorca et 
al., 2014).  Similar to their efficacy, both vortioxetine and escitalopram are the better 
tolerated antidepressants, (as was fluoxetine interestingly, despite its limited 
effectiveness), whilst amitriptyline and reboxetine were poorly tolerated (Cipriani et al., 
2018). 
 
There are various ideas that support targeting the 5-HT3 receptor for treating 
depression.  Presynaptic 5-HT3 receptors in the brainstem trigger release of GABA 
(Kohler et al., 2016).  This will in turn lead to an inhibition of the release of 
neurotransmitters (e.g. dopamine, noradrenaline and 5-HT), which are thought to be 
implicated in the neurobiology of depression.  Therefore blocking 5-HT3 receptors 
could lead to an increase in these neurotransmitters through a disinhibition mechanism 
(Kohler et al., 2016).  Stahl devised a network theory to try and explain why 5-HT3 
receptor antagonism might culminate into antidepressant efficacy.  It relies on the idea 
that 5-HT can regulate its own release through a simple 3 neuron system (Stahl, 2015).  
Serotonergic neurons input onto GABAergic neurons within the hippocampus or 
prefrontal cortex.  5-HT release will stimulate 5-HT3 receptors on these inhibitory 
interneurons within these higher brain centres (Stahl, 2015).  These GABAergic 
neurones will inhibit pyramidal neurons which project back into the raphe nucleus to 
stimulate 5-HT release.  Therefore 5-HT release into the hippocampus or prefrontal 
cortex can lead to a downstream inhibition of 5-HT release through 5-HT3 receptors 
on these GABAergic neurons.  Vortioxetine can have a dual impact on 
neurotransmitter release.  Vortioxetine, through blockade of SERT, will increase 5-HT 
release; and also through antagonism of 5-HT3 receptors will also lead to an increase 
in 5-HT, as well as noradrenaline and acetylcholine (Stahl, 2015).  Moreover, 
vortioxetine can further elevate brain 5-HT levels through desensitisation of raphe 5-
HT1A receptors (Kohler et al., 2016).   It is interesting of note that increasing CNS levels 
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of acetylcholine is thought to be important in cognition, and vortioxetine has been 
demonstrated to improve cognition in elderly patients suffering with MDD (Sanchez et 
al., 2015).   
 
There is also evidence for pharmacological targeting of the 5-HT3 receptor as a 
treatment for depression.  The novel 5-HT3 receptor antagonist QCM-4 (which has 
similar potency as ondansetron in blocking 2-methyl 5-HT induced contractions of 
guinea pig ileum) has been evaluated for depression or anxiety using in vivo mice 
studies (Mahesh et al., 2011; Kurhe et al., 2014; Kurhe et al., 2017).  QCM-4 (and 
reference drug escitalopram) was shown, in a variety of behavioural studies (sucrose 
consumption, forced swim test, tail-suspension test, elevated plus maze and open field 
test) to reverse the anxiogenic effects of sequential application of a variety of mild 
stresses (such as forced swim test, elevated plus maze and tail suspension test) 
(Kurhe et al., 2014).  Moreover, biochemical markers of oxidative stress (e.g. brain 
levels of thiobarbituric acid reactive substance or nitrate levels) were shown to be 
reduced by QCM-4 or escitalopram, having been increased by the stressful 
environment imposed on the mice (Kurhe et al., 2014).  In addition, QCM-4 and 
escitalopram also reduced the depressive-like phenotype caused by feeding mice a 
high-fat diet (Kurhe et al., 2017).  Again, biochemical markers of depression caused 
by a high-fat diet (e.g. decreased hippocampal cAMP, brain derived neurotrophic 
factor [BDNF] and 5-HT) were all reversed by QCM-4 and escitalopram (Kurhe et al., 
2017).  In addition, the number of pyknotic neurons in the hippocampus was increased 
by the high-fat diet, and reversed by QCM-4 and escitalopram, demonstrating that this 
ligand has similar efficacy to a marketed antidepressant on behavioural, biochemical 
and histological markers of anxiety or depression (Kurhe et al., 2014; Kurhe et al., 
2017).  
 
There is recent evidence that the tricyclic antidepressant amitriptyline displays affinity 
for the 5-HT3 receptor.  Using endogenous 5-HT3 receptor expression in the mouse 
NCB-20 neuroblastoma cell line, amitriptyline inhibited 5-HT-induced currents through 
a competitive interaction (Park et al., 2018).  This inhibition occurred at concentrations 
of amitriptyline which have been detected in the plasma of patients receiving this drug 
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(Montgomery et al., 1979).  The mechanism of inhibition was thought to be due to 
increased rate of 5-HT3 receptor desensitisation.  This implies that 5-HT3 receptor 
inhibition may be an important factor in anti-depressant activity, given also fluoxetine 
will reduce 5-HT3 receptor activity at concentrations relevant to its clinical impact (Pato 
et al., 1991; Choi et al., 2003).  
 
Clinically used 5-HT3 receptor antagonists have also been studied for their potential to 
treat depression.  Rats administered ondansetron had reduced immobility in the forced 
swim test compared to rats treated with placebo (Betry et al., 2015).  Moreover, 
ondansetron and paroxetine combined caused a greater reduction still in time spent 
immobile in the same assay.  In biochemical studies, ondansetron and paroxetine 
caused a greater increase in hippocampal 5-HT release compared to paroxetine (or 
ondansetron) alone; an effect which was also noted when ondansetron was combined 
with citalopram (Mork et al., 2012; Betry et al., 2015).  
 
Some studies have assessed 5-HT3 receptor antagonists in treating depression or 
anxiety disorders in humans.  Dépôt and colleagues looked at the impact of 
ondansetron on CCK induced behavioural changes in healthy subjects.  Administration 
of CCK is known to produce anxiety and panic attacks in people.  Acute administration 
of ondansetron (2.0 mg) caused a decrease in PSS (Panic associated symptom scale) 
score (which like HAM-A measures behaviours including dizziness, trembling/shaking, 
abdominal distress etc.) (Argyle et al., 1991; Depot et al., 1999).  Moreover, plasma 
levels of adrenocorticotropic hormone (a biochemical marker for stress) were 
decreased in the ondansetron treatment group compared to the placebo cohort.  
Furthermore, ondansetron abolished the emotion potentiated startle effect in healthy 
volunteers (Harmer et al., 2006).  In all studies, ondansetron was well tolerated and 
did not affect mood.  It is apparent that 5-HT3 receptor antagonists are efficacious in 
treating depression and anxiety.  Whereas these drugs simply provide a competitive 
block at the 5-HT3 receptor, vortioxetine appears to inhibit a 5-HT3 receptor mediated 
response through a slightly different mechanism of action, by increasing the rate at 
which the response decays.     
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4.1.3 5-HT3 receptor antagonists in treating schizophrenia 
5-HT3 receptor antagonists may have use in other neuropsychiatric conditions, 
including schizophrenia.  A variety of animal and clinical trial data supports this theory.  
In a small trial of 22 schizophrenic patients (currently receiving antipsychotics such as 
olanzapine or risperidone), tropisetron (a high-affinity 5-HT3 receptor antagonist with 
α7 nAChR partial agonist activity) was found to decrease the p50 auditory gating, 1 
hour after administration (Macor et al., 2001; Koike et al., 2005).  Furthermore, patients 
receiving tropisetron as an adjunct to risperidone (an atypical antipsychotic with no 5-
HT3 receptor activity) demonstrated a reduction in negative symptom score; which 
corresponded into a decrease in general psychopathy score (Noroozian et al., 2013).  
Tropisetron interestingly did not appear to have any impact on the positive symptoms 
of schizophrenia.  Side effects were mild, and consistent with what might be expected 
with 5-HT3 receptor antagonism; constipation was experienced in 30% of patients 
receiving tropisetron (Noroozian et al., 2013).   
 
This impact of 5-HT3 receptor antagonists on psychosis is mirrored with other 5-HT3 
receptor antagonists too.  Granisetron (which unlike tropisetron does not display 
relevant α7 nAChR pharmacology), when prescribed along with risperidone to 
schizophrenic patients resulted in a significant improvement in negative symptoms 
when compared to placebo; yet did not have a significant effect on the positive 
symptoms of schizophrenia (Khodaie-Ardakani et al., 2013).  Like tropisetron and 
granisetron, ondansetron combined with risperidone significantly improved the 
negative symptoms of schizophrenia which culminated in a significant improvement in 
psychopathology compared to placebo (Akhondzadeh et al., 2009).  Moreover, as 
before, ondansetron (and risperidone) did not impact on the positive symptoms 
compared to risperidone alone (Akhondzadeh et al., 2009).  Given that vortioxetine 
has a complicated pharmacological profile (akin to clozapine), it may be speculated 
that vortioxetine could also target the positive symptoms of schizophrenia (Warnez et 
al., 2014).  
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Ondansetron has also demonstrated efficacy in treating psychosis when administered 
alongside a typical antipsychotic (haloperidol).  A 12-week trial with 58 patients 
receiving haloperidol and ondansetron, and 63 patients receiving haloperidol and 
placebo was conducted (Zhang et al., 2006).  Those who were administered 
ondansetron with haloperidol showed an improvement in negative symptoms and an 
improved PANSS (positive and negative syndrome scale) score compared to placebo. 
The PANSS examines a variety of positive symptoms (including delusions, 
conceptional disorganisation and hallucinatory behaviour), as well as negative 
symptoms (e.g. blunted affect, emotional withdrawal and stereotyped behaviour) and 
general psychopathology (such as disorientation, poor attention and a lack of 
judgement and insight) (Kay et al., 1987).  Moreover, the clinical response rate 
(defined as a greater than 30% reduction in PANSS score) was 62.5% for patients 
receiving ondansetron alongside haloperidol, compared to 40.3% for placebo and 
haloperidol (Zhang et al., 2006).  Similar to tropisetron and risperidone, more patients 
receiving ondansetron experienced constipation compared to placebo; however, the 
frequency of nausea and vomiting was reduced for those receiving ondansetron 
compared to placebo (Zhang et al., 2006).  Of course, given vortioxetine is a 5-HT3 
receptor partial agonist, it may elicit nausea and vomiting as an adverse effect (as has 
been recorded in clinical trials) (Berhan et al., 2014; Pae et al., 2015). 
 
A review conducted by Kishi and colleagues investigating 6 randomised control trials 
(311 patients) found that there was a significant effect for 5-HT3 receptor antagonists 
for treating the negative symptoms of schizophrenia when co-administered with 
antipsychotics  (Kishi et al., 2014).  This resulted in a significant decrease in PANSS.  
Although constipation was more common with 5-HT3 receptor antagonists, the dropout 
rate was similar to placebo, suggesting these drugs are well tolerated by patients with 
schizophrenia (Kishi et al., 2014).   
 
What is of most interest regarding 5-HT3 receptor antagonism and schizophrenia is 
the ability of these ligands to treat the negative symptoms of schizophrenia.  These 
symptoms have similarities with symptoms of depression (e.g. diminished emotional 
responsiveness, emotional and social withdrawal).  These clinical manifestations  are 
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not thought to be due to hyperdopaminergic activity (which antipsychotics target to 
treat the classic positive symptoms); and often are not treatable by typical and atypical 
antipsychotics (Remington et al., 2016).  Vortioxetine could offer therapy for these 
affective symptoms experienced in schizophrenia through 5-HT3 receptor antagonism 
and its intrinsic ability to treat depression; whilst being generally very well tolerated.  
As it appears vortioxetine can reduce a 5-HT3 receptor mediated response, it could be 
trialled as an adjunct to treat schizophrenia, just as other 5-HT3 receptor antagonists 
have been tried with some success (Kishi et al., 2014).     
 
4.1.4 5-HT3 receptor antagonists as a therapy for IBS-d 
As was previously mentioned in the introduction, current treatment for IBS-d is limited 
and does not meet the patient need for symptom relief.  There is evidence to suggest 
5-HT3 receptor antagonist could prove useful in treating this condition.  However, 
although these ligands demonstrated efficacy in treating the symptoms of IBS-d, a 
number of patients experienced constipation; and more rarely ischemic colitis 
(approximately 1:750 patients taking alosetron) (Chang et al., 2006; Camilleri, 2017).  
Patient advocacy lead to the reinstatement of alosetron, albeit with a ‘black-box’ 
warning label, which has now been lifted (FDA.gov, 2016).  Given the ability of 
vortioxetine to reduce a 5-HT3 mediated response, it could have potential to treat IBS-
d, without the manifestation of severe adverse effects. 
 
However, there is a clear hypothesis to treat IBS-d using a 5-HT3 receptor partial 
agonist.  A 5-HT3 receptor partial agonist, in the presence of excess endogenous 5-
HT, would demonstrate activity as an antagonist, whilst preventing full blockade of 5-
HT3 receptor function, which therefore should prevent the associated side effects 
experienced by patients with IBS-d when taking 5-HT3 receptor antagonists(Nam et 
al., 2018).  Vortioxetine, which displays activity as a 5-HT3 receptor partial agonist, 
could be a viable therapeutic for IBS-d.  It is interesting to note of a case study whereby 
a female patient expressing depression with IBS-d was prescribed vortioxetine (Aydin 
et al., 2018).  She suffered from IBS-d and was diagnosed with MDD.  After being 
prescribed paroxetine and sertraline (both drugs were withdrawn due to adverse side 
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effects), she was offered vortioxetine.  Vortioxetine treated her depression (her HAM-
D score was decreased by almost half), and also influenced her IBS-d (Aydin et al., 
2018).  After 4 weeks of treatment, her IBS-d was in remission with abdominal pain, 
cramping and frequency to defecate all being reduced.  After 7 months of treatment, 
there was no sign of IBS-d or depression.  Indeed, vortioxetine was shown to improve 
quality of life in IBS patients, although impact on bowel function was not investigated 
(Seddighnia et al., 2020). Furthermore, Manning and colleagues have developed a 
number of high-affinity 5-HT3 partial agonists which show potential in treating IBS-d 
(see also CSTI-300 discussion section) (Manning et al., 2011; Moore et al., 2013). 
 
There is a strong link between depression and IBS-d.  A review used an IBS quality of 
life questionnaire (IBS-QOL) and the Beck Depression Inventory (BDI) to assess the 
link between depression in IBS-d patients.  The IBS-QOL evaluates how IBS-d 
patients feel, examining food avoidance, social reaction etc, and the BDI, similar to 
HAM-D and MARDS, scores on feelings such as feeling sad, suicidal thoughts, sexual 
interest (Beck et al., 1961; Patrick et al., 1998).     Depression was diagnosed more 
frequently in IBS-d (46%, 40 patients) compared to healthy controls (9%, 5 patients) 
(Kopczynska et al., 2018).  In addition, the IBS-QOL was worse in IBS-d patients 
compared to control subjects (Kopczynska et al., 2018).  There is therefore 
precedence for using vortioxetine to treat IBS-d, if not for treating any depressive 
symptoms alone.  Moreover, as vortioxetine is well tolerated by patients, and so safety 
is unlikely to be an issue (Cipriani et al., 2018).   
 
Further studies to identify this could involve treating 5-HT3 receptor transfected 
HEK293 cells with vortioxetine, and assessing its functional activity using 
electrophysiology, before then visualising cell surface h5-HT3A receptor expression by 
immunocytochemistry or flow cytometry.  This would allow a correlation between 
actual functional vortioxetine response and any potential impact it has on 5-HT3 
receptor internalisation.  In addition, simply examining whether treatment with 
vortioxetine causes receptor downregulation (measured by immunocytochemistry or 
flow cytometry) could help to elucidate its mechanism of action.  Moreover, given the 
complexity of the 5-HT3 receptor architecture, it may be of importance to study the 
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pharmacology of vortioxetine at other 5-HT3 receptor subtypes (e.g. 5-HT3AC, 5-
HT3AD, 5-HT3AE).  Given there is speculation about whether vortioxetine could be 
efficacious in treating schizophrenia or IBS-d, it may be relevant to study the in vivo 
effect of vortioxetine (and compare to clinically-used drugs) in animal models for these 
conditions (Banner et al., 1995; Banner et al., 1995; Marcotte et al., 2001). 
 
A limitation of this study is only two 5-HT3 receptor isoforms have been studied (5-
HT3A and 5-HT3AB), and given there is at least 5-HT3AC, 5-HT3AD, 5-HT3AE (plus 
potentially other subunit combinations), these need to be considered, especially given 
expression of these receptors in human GIT and possibly brain (Holbrook et al., 2009).  
Similarly, conclusions about the effectiveness of vortioxetine in schizophrenia or IBS-
d cannot be substantiated without testing in in vivo models. 
 
In summary, vortioxetine has been characterised as relatively high affinity, competitive 
h5-HT3 receptor partial agonist.  The antagonist nature of vortioxetine (as reported in 
the literature) could be due to vortioxetine desensitising the 5-HT3 receptor into a state 
whereby agonist can no longer activate the receptor; or possibly by internalising the 
receptor. The activity of vortioxetine (and the fact it is a well-tolerated therapeutic used 
clinically) means it could be used to treat other disorders where 5-HT3 receptor 
blockade is useful.  These disorders include the negative symptoms of schizophrenia, 
depression/anxiety and IBS-d.   
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4.2 Evaluating the pharmacology of a novel 5-HT3 receptor partial 
agonist CSTI-300  
 
4.2.1 The in vitro and in vivo pharmacology of CSTI-300 
This study presents the results of an in-depth pharmacological investigation of CSTI-
300, at the 5-HT3 receptor.  In vitro assays were utilised to establish the affinity, 
potency and efficacy of CSTI-300 at the h5-HT3 receptor; with CSTI-300 
demonstrating a near-identical pharmacological profile at the two most studied 5-HT3 
receptor subtypes, the 5-HT3A and 5-HT3AB receptors.  Moreover, in vivo (rat Bezold-
Jarisch reflex and rat colon distension model) assays highlight the ability of CSTI-300 
to attenuate a 5-HT3 receptor mediated response (transient bradycardia and colonic 
sensitivity respectively) with similar efficacy to alosetron, suggesting the potential of 
CSTI-300 to treat IBS-d and carcinoid syndrome, conditions whereby there the 
pathology is thought to be due to excessive 5-HT3 receptor activity (Bearcroft et al., 
1998). 
 
In radioligand binding assays, CSTI-300 displayed relatively high affinity 
(approximately 100-fold higher than the endogenous ligand 5-HT) for the h5-HT3A and 
h5-HT3AB receptor.  Moreover, whilst in the absence of agonist Cl-indole fails to 
interact with the orthosteric binding site of the h5-HT3A receptor; both CSTI-300 (and 
5-HT) were able to allow Cl-indole to compete for [3H]-granisetron occupied h5-HT3A 
receptor binding sites (Powell et al., 2016).  CSTI-300 also displayed a competitive 
interaction with the h5-HT3A and h5-HT3AB receptors, demonstrated by its ability to 
reduce the affinity of [3H]-granisetron for these 5-HT3 receptors without influencing the 
density of labelled 5-HT3 receptor binding sites.  The affinity of CSTI-300 for the h5-
HT3 receptor is similar to the ondansetron, a first-generation 5-HT3 receptor antagonist 
(used to treat CINV and PONV, and used ‘off-label’ to treat IBS-d) as well as being 
~10x lower affinity compared to the very high affinity 5-HT3 receptor antagonist, 
alosetron (Hirata et al., 2007).  This may be an advantageous property of CSTI-300, 
as it is speculated that the serious constipation that some IBS-d patients experience 
when taking alosetron is due to the high 5-HT3 receptor affinity.  In functional in vitro 
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assays, CSTI-300 demonstrates potent partial agonist efficacy (approximately 30-40% 
of 5-HT), with responses elicited being selective for the h5-HT3 receptor. Granisetron 
was used in this assay as a selective 5-HT3 receptor antagonist to verify the selectively 
of the 5-HT and CSTI-300 induced responses at the h5-HT3 receptor.  
 
In electrophysiology assays examining the kinetics of h5-HT3A receptor activation by 
CSTI-300 or 5-HT, it was determined that the decay rate of the h5-HT3A receptor 
current was approximately 4x slower for CSTI-300 compared to 5-HT.  This is of 
interest because should CSTI-300 cause rapid 5-HT3 receptor desensitisation (akin to 
5-HT), then this may replicate the impact of 5-HT3 receptor antagonists upon 5-HT3 
receptor activity in IBS-d patients, which could potentially cause  constipation, which 
is associated with 5-HT3 receptor antagonists. 
 
CSTI-300 demonstrated activity in the rat Bezold-Jarisch reflex.  In this assay, rapid 
transient bradycardia is elicited by intravenous administration of 5-HT stimulating 5-
HT3 receptors on cardiac vagal terminals (Cote et al., 2004).  This bradycardia can be 
prevented with prior oral administration of 5-HT3 receptor antagonists, and so has 
been used historically to characterise many selective 5-HT3 receptor antagonists 
(Eglen et al., 1995).  Both alosetron and CSTI-300 were able to reverse the 5-HT-
induced bradycardia event, demonstrating that these ligands both engage 5-HT3 
receptors in vivo.  Furthermore, this also reinforces the concept that in the presence 
of excess 5-HT, CSTI-300 displays activity as a 5-HT3 receptor antagonist.  The ability 
of CSTI-300 to behave as an antagonist and block the 5-HT-induced reflex in this 
model is consistent with structurally different 5-HT3 receptor partial agonists (Campiani 
et al., 1997; Lopez-Tudanca et al., 2003; Butini et al., 2009).  In previous studies using 
a mouse model of the Bezold-Jarisch reflex, CSTI-300 displayed similar efficacy in its 
ability to block the 5-HT dependent bradycardia (Moore et al., 2013; Manning et al., 
2014).  Furthermore, when administered intravenously, CSTI-300 was able to evoke 
the Bezold-Jarisch reflex, with efficacy approximately 40% of 5-HT (Moore et al., 2013; 
Manning et al., 2014).  Furthermore, oral administration of alosetron was able to block 
the CSTI-300 evoked bradycardia (unpublished work).  This reinforces the selectivity 
of CSTI-300 for the 5-HT3 receptor.  Given CSTI-300 also does not interact with 
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several other receptors or ion channels, this suggests CSTI-300 is less likely to elicit 
off-target side effects, important in any marketed therapeutic. 
 
After demonstrating that CSTI-300 engages 5-HT3 receptors in vivo, an established 
rat model designed to replicate the visceral sensitivity experienced by IBS-d patients 
was used to investigate the efficacy of CSTI-300 (Houghton et al., 2002).  This assay 
was selected to investigate the efficacy of CSTI-300 (and to compare against the 
clinically effective drug, alosetron) because the most debilitating factor in IBS-d is 
visceral pain.  A comparable rodent model was used previously to establish the 
efficacy of 5-HT3 receptor antagonists (e.g. granisetron, bemesetron) in reducing 
visceral sensitivity (Banner et al., 1995; Banner et al., 1995).  In this assay, slow 
inflation of an intra-colonic balloon delivers a noxious stimulus to rats, which respond 
with a visceromotor reflex.  The pressure required to deliver this visceromotor 
response is the quantitative readout (Banner et al., 1995; Banner et al., 1995).  
Subcutaneous administration of the precursor of 5-HT (5-HTP) increased the 
sensitivity of the rats to colonic distension, i.e. lower balloon pressures evoked the 
visceromotor response.  5-HTP will be converted to 5-HT in the colon thus increasing 
gastrointestinal 5-HT, which is evident in patients with IBS-d (Bearcroft et al., 1998; 
Dunlop et al., 2005; Enck et al., 2016).  Again, similar to what was shown before, a 5-
HT3 receptor antagonist (the clinically validated alosetron in this case) reversed the 
increase in colonic sensitivity induced by 5-HTP.  This also supports the concept that 
increased 5-HT3 receptor activity is primarily responsible for the visceral pain and 
discomfort experienced by IBS-d patients.  CSTI-300 displayed comparable efficacy 
to alosetron to reduce the colonic distension elicited by 5-HTP.  To elicit a comparable 
response, the dose of CSTI-300 was approximately 10-fold that of alosetron, which 
mirrors the difference in affinity these two drugs have for the 5-HT3 receptor (Hirata et 
al., 2007).  
 
Functional intracellular calcium assays were used as an in vitro model to try and 
replicate the gut microenvironment with excess endogenous 5-HT.  Thus, a maximal 
concentration of CSTI-300 (or alosetron for comparison) was applied to HEK293 cells 
expressing the h5-HT3A receptor in the presence of a saturating 5-HT concentration.  
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Alosetron was used so CSTI-300 can be compared with a marketed therapeutic for 
IBS-d.  Whilst alosetron ablated the 5-HT activity, the 5-HT response in the presence 
of CSTI-300 was approximately 40% that of 5-HT alone.  This suggests that CSTI-300 
can, in the presence of 5-HT, reduce 5-HT3 receptor activity whilst still retaining some 
tone upon the 5-HT3 receptor.  This may be of importance for CSTI-300 to not cause 
constipation or ischemic colitis in IBS-d patients, which is thought to arise from 
complete 5-HT3 receptor blockade caused by 5-HT3 receptor antagonists.  
Theoretically, by the presence of CSTI-300 still allowing 5-HT3 receptor activity, gut 
activity can be restored to ‘normal’ (Figure 32).   
 
 
4.2.2 The 5-HT3 receptor is a viable target for treating IBS-d 
There is well established evidence that pharmacologically targeting the 5-HT3 receptor 
is beneficial in IBS-d (Enck et al., 2016; Camilleri et al., 2017).  A diverse variety of 
selective 5-HT3 receptor antagonists demonstrate efficacy in treating IBS-d.  In a 
randomised trial investigating the potential for ondansetron to treat IBS-d, it was 
discovered 65% of patients reported relief from IBS-d symptoms (including average 
urgency scores and average frequency of defecation) (Garsed et al., 2014).  
Furthermore, over 50% of patients reported a global improvement in abdominal pain 
and discomfort as well as stool consistency when talking either alosetron, cilansetron 
or ramosetron (Andresen et al., 2008; Ford et al., 2009; Fukudo et al., 2016; Zheng et 
al., 2017; Qi et al., 2018).  However, a common adverse effect consistently associated 
with these drugs in IBS-d patients is constipation, and in the case of alosetron and 
cilansetron, rare ischemic colitis.  The statistics regarding occurrences of constipation 
has been studied most in alosetron, following its initial withdrawal from the market by 
manufactures GSK in 2000.  Out of 11,874 patients across 26 trials, the rate of serious 
constipation was 0.1% in patients receiving alosetron compared to 0.06% for those 
receiving placebo (Chang et al., 2006).  This is also true for the other 5-HT3 receptor 
antagonists previously discussed (Andresen et al., 2008; Ford et al., 2009; Fukudo et 
al., 2016; Zheng et al., 2017).  Given CSTI-300 is a partial 5-HT3 receptor agonist, it 
is predicted constipation or ischemic colitis is unlikely to occur. 
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What must be taken into consideration is the complication of ischemic colitis 
associated with 5-HT3 receptor antagonists appears to be unique with IBS-d patients.  
5-HT3 receptor antagonists are routinely used to treat emesis associated with 
chemotherapy or after surgery.  No serious adverse effects have been recorded, 
although constipation was noted from a variety of large clinical trials investigating the 
efficacy and safety of 5-HT3 receptor antagonists (i.e. ondansetron, granisetron or 
ramosetron) in CINV or PONV (Atkinson et al., 2006; Miura et al., 2013; Candiotti et 
al., 2014). 
 
The mechanism of action of CSTI-300 is shown in Figure 32.  Increasing 5-HT3 
receptor activity is correlated with increasing gut activity, thus IBS-d is associated with 
high levels of 5-HT3 receptor functioning.  Whereas alosetron (or indeed any 5-HT3 
receptor antagonist) potentially completely blocks 5-HT3 receptor activity and causes 
constipation, CSTI-300 is anticipated to reduce 5-HT3 receptor activity to such an 
extent it potentially restores normal gut functioning, and thus does not cause 
constipation.  In addition, the more modest affinity for the 5-HT3 receptor that CSTI-
300 has compared to alosetron will potentially allow local 5-HT to have more of an 
influence upon receptor activity.  This is a concept shared with ondansetron, which 
has similar affinity to CSTI-300, and for which ischemic colitis is not seen in IBS-d 
patients, possibly due to 5-HT being able to out-compete ondansetron and allow some 
5-HT3 receptor activity (Garsed et al., 2014).  However, ondansetron is known to 
activate the hERG ion channel (human ether-a-go-go-related gene), which in long-
term administration could lead to cardiac side effects (Kuryshev et al., 2000; 
Chandrakala et al., 2008).  This should not be an issue for CSTI-300, given it does not 
interact with hERG, meaning CSTI-300 should be a safe, effective, long-term 
treatment for IBS-d.  
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Previous studies have assessed 5-HT3 receptor partial agonists for treating IBS.  
Pumosetrag (DDP, MKC-733) was evaluated for constipation dominant IBS rather 
than diarrhoea predominant.  Interestingly, the intrinsic efficacy of pumosetrag varied 
depending on the species studied, with activity ranging from 20% to 100% of full 
agonist in rat or mouse colon (Evangelista, 2007; Chetty et al., 2008).  Similar to CSTI-
300, in the Bezold-Jarisch reflex in mouse, pumosetrag elicited transient bradycardia 
approximately 65% that of 5-HT.  In rats treated with dopamine to delay gastric 
emptying, pumosetrag increased the rate of gastric motility (Evangelista, 2007).  In 
healthy subjects, pumosetrag showed prokinetic activity, measured by an increase in 
migrating motor complexes in the duodenum (Coleman et al., 2003).  In IBS-c patients, 
pumosetrag improved symptoms associated with bowel motility by increasing percent 
elimination and frequency of defecation (Fujita et al., 2005; Evangelista, 2007).  As 
may have been anticipated with a 5-HT3 receptor partial agonist, a common side effect 
Figure 32.  Theoretical mode of CSTI-300 function. 
Elevated or reduced 5-HT3 receptor activity is thought to be responsible for diarrhoea 
or constipation, respectively. Alosetron, a 5-HT3 receptor antagonist, may cause 
constipation through 5-HT3 receptor blockade.  CSTI-300 is anticipated to reduce the 
activity of the 5-HT3 receptor, leading to normal gut function, without complete 
blockade and hence will less likely cause constipation. 
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experienced by those administered with pumosetrag was nausea and vomiting, which 
ultimately lead to its withdrawal from further research (Coleman et al., 2003; Fujita et 
al., 2005; Evangelista, 2007).  It may be of concern that this issue could arise when 
CSTI-300 is assessed in humans.  However, oral administration of CSTI-300 to dog 
failed to elicit emesis, despite plasma concentrations of the drug reaching levels that 
would saturate the 5-HT3 receptor.  Moreover, there was no suggestion of an increase 
in gastric motility, and the behaviour of the dogs was unaffected by the drug.  
Furthermore, in pharmacokinetic studies in a variety of species (mouse, dog and mini-
pig), CSTI-300 failed to evoke any emetic episodes, and these studies included 
supramaximal doses of CSTI-300 (up to 30 mg/kg).  This data supports the theory that 
CSTI-300 could treat IBS-d, without evoking emesis or increasing gastrointestinal 
motility associated with 5-HT3 receptor activation.  In addition, CSTI-300 failed to 
interact with a large number (100) of receptors/channels, suggesting this drug will have 
limited off-target adverse effects.  
 
As was mentioned previously (section 4.4.1, page 111), there is a case study 
demonstrating the efficacy of the 5-HT3 receptor partial agonist vortioxetine in treating 
a patient with IBS-d and concurrent depression (Aydin et al., 2018).  After 4 weeks of 
treatment, there was a global improvement in gastrointestinal symptoms (abdominal 
pain and frequency to defecate).  As CSTI-300 has similar intrinsic activity to 
vortioxetine (see section 3.1), this further implies that CSTI-300 will be efficacious in 
treating the pain and discomfort patients with IBS-d experience. 
 
Given the intrinsic activity of CSTI-300 at the 5-HT3 receptor, it is interesting to 
speculate whether this drug could show promise in treating IBS-c as well as IBS-d.  In 
contrast to IBS-d, 5-HT levels are lower in IBS-c patients.  Following meal ingestion, 
plasma levels of 5-HT will rise in healthy volunteers as well as IBS-d patients, but this 
is not recorded in IBS-c patients (Dunlop et al., 2005; Atkinson et al., 2006).  
Furthermore, plasma concentrations of the 5-HT breakdown product, 5-HIAA, were 
lower in IBS-c patients compared to control subjects; both under fasting conditions 
and following meal ingestion (Dunlop et al., 2005; Atkinson et al., 2006).  CSTI-300 
might therefore be beneficial in increasing 5-HT3 receptor activity to a level which 
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results in ‘normal gut functioning’ rather than constipation (Figure 32).  Currently, 
prucalopride, a selective 5-HT4 receptor agonist, is used to treat IBS-c when laxatives 
have failed (Thayalasekeran et al., 2013; Jiang et al., 2015).  However, it has been 
shown that less than 50% of IBS-c patients report relief from symptoms when taking 
prucalopride (Jadav et al., 2013).  Although speculative, CSTI-300 could show promise 
in treating IBS-c.  Furthermore, the ability of CSTI-300 to modulate 5-HT3 receptor 
such that it should result in normal gut functioning could lead to this drug 
demonstrating efficacy in IBS-m (mixed IBS).  In this condition, symptoms fluctuate 
between constipation and diarrhoea (Lacy et al., 2009).  By keeping 5-HT3 receptor 
activity relatively consistent, CSTI-300 be a viable therapeutic for IBS-m, where 
currently no effective treatments are indicated. 
 
4.2.3 Targeting the 5-HT3 receptor to treat carcinoid syndrome 
There is also potential for CSTI-300 to offer symptomatic relief to patients with 
carcinoid syndrome, whereby the associated diarrhoea is often debilitating.  
Gastrointestinal carcinoid tumours have an incidence rate of 1.5-2 per 100,000, with 
64% of tumours arising from the small intestine and rectum (ileal tumours being the 
most common cause of carcinoid syndrome) (Ha et al., 2012).  The frequency of 
carcinoid syndrome in patients with carcinoid tumours is increasing; with 11% of 
patients being diagnosed with carcinoid syndrome in 2000, compared to 19% of 
patients in 2011, perhaps due to improved diagnosis (Halperin et al., 2017).   Most 
symptoms of carcinoid syndrome are caused by a hypersecretion of amines (most 
commonly 5-HT), resulting in raised plasma 5-HT levels (Spiller, 2007).  The most 
common symptom experienced by patients with carcinoid syndrome is diarrhoea, 
which is reported in 83% of patients (49% also experience flushing) (Ha et al., 2012; 
Oronsky et al., 2017).  Diagnosis of carcinoid syndrome is based on clinical 
presentation and urinary 5-HIAA levels, which will be raised compared to a healthy 
control (Lauffer et al., 1999; Ha et al., 2012; Oronsky et al., 2017; Rastogi et al., 2018). 
 
A variety of treatments have been established for treating carcinoid syndrome.  
Traditionally, the first-line treatment for carcinoid syndrome was long acting forms of 
121 
 
somatostatin analogues (octreotide and lanreotide), both of which demonstrated a 
response rate of 50% (Riechelmann et al., 2017).  Somatostatin is known to reduce 
gut hormone secretion via interactions with somatostatin receptors (SST1-5) (Hoyer et 
al., 1995; Patel, 1999).  Indeed, it was established octreotide decreased 5-HT release 
from isolated human carcinoid tumour cells (Wängberg et al., 1991).  However, many 
patients receiving either of these drugs experience refractory carcinoid syndrome, 
whereby possibly due to tachyphylaxis, hormone related symptoms are no longer 
controlled by this treatment, and a new therapy is required (Riechelmann et al., 2017). 
 
PCPA, a TPH inhibitor, the rate-limiting enzyme in 5-HT synthesis, has been trialled 
for treatment with some efficacy (flushing and diarrhoea were relived in 50-60% of 
patients, and urinary 5-HIAA was decreased by 80%) (Kvols, 1986; Ha et al., 2012).  
However, associated neuropsychiatric side effects (including confusion and 
depression) made this treatment option unusable (Kvols, 1986).   
 
An oral peripherally acting TPH inhibitor, telotristat ethyl, was developed by Lexicon 
pharmaceuticals and approved to treat carcinoid syndrome in the USA and Europe in 
February and September 2017, respectively.  This pro-drug is metabolised to the 
active telotristat, which cannot cross the blood-brain barrier and so should limit any 
CNS based adverse effects (Chan et al., 2018).  Pre-clinical studies demonstrated that 
telotristat decreased plasma 5-HT in mice with experimental colitis, and also 
decreased levels of proinflammatory cytokines including IL-1β and IL-6 (Chan et al., 
2018).  In phase II clinical trials, telotristat decreased bowel movement in 23% of 
patients, and reduced urinary 5-HIAA by at least 50% (Masab et al., 2017; Chan et al., 
2018).  In these small studies, telotristat was well tolerated, with most side effects 
being gastrointestinal, and any serious adverse effects were not attributed to the drug 
(Masab et al., 2017). 
 
Two phase III trials have been conducted to investigate telotristat, TELESTAR and 
TELECAST.  Both examined the effects of 250 mg, 500 mg telotristat and placebo on 
135 patients with carcinoid syndrome (Kulke et al., 2017; Pavel et al., 2018).  In the 
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TELESTAR trials, at both doses of drug, bowel movement was reduced by 
approximately 40% (20% of patients receiving placebo responded) (Kulke et al., 2017).  
Urinary 5-HIAA was reduced by 78% and 87% respectively by 250 mg and 500 mg 
telotristat respectively; with placebo reducing urinary 5-HIAA in 10% of patients (Kulke 
et al., 2017).  These primary outcomes were also replicated in the TELECAST trials 
(Pavel et al., 2018).  Furthermore, 40% of patients receiving telotristat were defined 
as durable responders (they had over 30% decrease in bowel movement for more 
than 50% of the duration of the trial) in the TELECAST trials (Pavel et al., 2018).  
Patients receiving telotristat reported an improvement in quality of life compared to 
placebo, and although nausea was a reported side effect, no subject withdrew from 
the trial because of it, reinforcing the tolerability of this drug (Kulke et al., 2017; Masab 
et al., 2017).  Although telotristat appears safe in these trials, the effects of telotristat 
need to be monitored by long-term post marketing surveillance, just in case any issues 
arise, especially given it will be decreasing total gastrointestinal 5-HT.   As CSTI-300 
only targets the 5-HT3 receptor and has no off-target effects, it may be a safer long-
term option in carcinoid syndrome (although again that needs to be evaluated).  
 
A number of small studies have also been conducted to examine the impact of 5-HT3 
receptor antagonists to treat carcinoid syndrome.  Administration of tropisetron 
improved diarrhoea (smaller stool size and less frequent defecation) in three cases of 
carcinoid syndrome, whilst also being well tolerated (Anderson et al., 1987). 
Furthermore, ondansetron improved the diarrhoea and vomiting associated with 
carcinoid syndrome in a single patient (Platt et al., 1992).  This was also replicated in 
a separate study, whereby ondansetron improved diarrhoea (as well as nausea and 
vomiting) in 6 patients presenting with carcinoid syndrome (Wymenga et al., 1998).  In 
addition, ondansetron offered relief to patients with carcinoid syndrome for whom 
octreotide and lanreotide failed to work or had refractory carcinoid syndrome 
(Kiesewetter et al., 2013; Kiesewetter et al., 2018).  Clearly there is evidence that 5-
HT3 receptor antagonism has efficacy in treating carcinoid syndrome.  In the 
knowledge 5-HT levels in patients with carcinoid syndrome are highly elevated, it is 
even more likely that a partial agonist would be useful, by displaying activity as a full 
antagonist.  In addition, given the ability of CSTI-300 to reduce 5-HT3 receptor activity 
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in the presence of excess 5-HT, this drug could be a viable therapeutic for treating the 
diarrhoea associated with carcinoid syndrome. 
 
It may be of importance to further study the in vitro pharmacology of CSTI-300 at other 
5-HT3 receptor isoforms (5-HT3AC, 5-HT3AD, 5-HT3AE), especially given their 
expression in the gastrointestinal tract (Kapeller et al., 2011).  Moreover, CSTI-300 
(and for comparison, alosetron), may need to be validated in an animal model of 
diarrhoea (5-HTP induced diarrhoea) to further demonstrate its effectiveness in IBS-d 
(Pascual et al., 2002). Furthermore, it may be of interest to see what impact CSTI-300 
has upon experimentally-induced colitis, given alosetron appears to reduce 
inflammation (Motavallian et al., 2019).  Finally, the safety of CSTI-300 should be 
investigated in long-term animal toxicology studies.  
 
One limitation of this study is the use of only male rats in the colon distension model, 
which needs to be acknowledged given IBS-d impacts women more than men, and 
any possibly any sex differences in the gut of male and female rats (Afonso-Pereira et 
al., 2018).   The pharmacology of CSTI-300 at the other heteromeric 5-HT3 receptor 
complexes has not been considered, which may be crucial in the in vivo activity of 
CSTI-300, especially given expression of 5-HT3C, 5-HT3D and 5-HT3E subunits in 
human colon (Kapeller et al., 2011). The cell lines used to study the in vitro 
pharmacology of CSTI-300 are not clonal, i.e. each cell does not generate the same 
receptor density. Similarly, CSTI-300 may influence the 5-HT1P receptor, and any 
impact this has on gastrointestinal function should be appreciated.  
 
In summary, CSTI-300 is a potent, relatively high affinity, selective 5-HT3 receptor 
partial agonist.  In the mouse Bezold-Jarisch reflex, CSTI-300 was able to both elicit 
transient bradycardia (a response approximately 40% of 5-HT) and block 5-HT-
induced bradycardia, indicative of 5-HT3 receptor antagonistic properties in the 
presence of excess 5-HT.  Furthermore, CSTI-300 demonstrated comparable efficacy 
to alosetron, an approved therapeutic for IBS-d, in a rodent model of the visceral 
sensation experienced by many IBS-d patients.  Yet despite its intrinsic activity at the 
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5-HT3 receptor, CSTI-300 did not evoke emesis in a variety of species (mouse, dog 
and mini-pig) studied.  CSTI-300 could undergo further in vivo assays to determine if 
it slows or delays gastric motility (assessed by bead expulsion in rodent), with the 
animal having been first treated with a compound to increase colonic motility (e.g. 
dopamine).  The safety and tolerability of CSTI-300 will be further studied by long-term 
toxicology studies in mini-pig.  By maintaining basal 5-HT3 receptor activity, CSTI-300 
is predicted to increase the risk/benefit ratio.  By not fully inhibiting the 5-HT3 receptor, 
and therefore allowing some 5-HT signalling, CSTI-300 is predicted not to cause the 
constipation associated with 5-HT3 receptor antagonists when used to treat IBS-d.  
CSTI-300 is also anticipated to have success in treating the diarrhoea associated with 
carcinoid syndrome, which is thought to be 5-HT3 receptor mediated, and for which 
limited therapies are available.   
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4.3 The binding mechanism of Cl-indole at the h5-HT3 receptor 
 
4.3.1 Cl-indole has a unique binding model at the h5-HT3 receptor 
This study presents the findings from investigating the binding mechanism of the COM 
Cl-indole at the h5-HT3 receptor; and how understanding this mechanism may be of 
importance for identifying potential novel 5-HT3 receptor ligands for therapy.  Although 
Cl-indole appears to interact with the h5-HT3A receptor through a non-orthosteric 
binding site, it is apparent that in the presence of 5-HT3 receptor agonist, Cl-indole will 
compete for the orthosteric h5-HT3A receptor binding site.  This is true for a variety of 
structurally diverse 5-HT3 receptor agonists (with differing intrinsic efficacies), but this 
is not the case when a 5-HT3 receptor antagonist is present.  Interestingly, Cl-indole 
does not interact with the agonist binding site at the h5-HT3AB receptor, even when 5-
HT3 receptor agonist is present, suggesting Cl-indole has a different mechanism of 
action at this heteromeric receptor compared to the homomeric h5-HT3A receptor.    
 
In the absence of 5-HT3 receptor agonist, Cl-indole does not displace bound [3H]-
granisetron from h5-HT3A orthosteric binding sites.  However, the presence of 5-HT3 
receptor agonist (at sub-maximal concentrations) appears to impact the h5-HT3A 
receptor so that Cl-indole (at concentrations above 3.0 µM, which demonstrate 
functional activity in vitro) now competes out [3H]-granisetron in a concentration-
dependent manner, akin to an orthosteric agonist.  It is also interesting that the intrinsic 
activity of agonist, which range from 100% (5-HT) to 5% (s-zacopride) does not appear 
to correlate with ability to increase the affinity of Cl-indole for the h5-HT3A receptor 
(i.e. all agonists allow Cl-indole to interact with the orthosteric site of the h5-HT3A 
receptor).  Interestingly, the affinity of a weak 5-HT3 receptor partial agonist PBG is 
not impacted by 5-HT, suggesting this is a unique binding strategy for allosteric and 
not orthosteric ligands.  It is hypothesised that Cl-indole (in the presence of 5-HT or a 
5-HT3 receptor partial agonist) will bind to the h5-HT3A receptor and behave as a full 
agonist.  This is responsible for the increased functional response elicited by agonist 
in the presence of Cl-indole (Newman et al., 2013). 
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The ability of 5-HT3 receptor ligands to allow Cl-indole to interact with the orthosteric 
binding site of the h5-HT3A receptor appears to be unique to agonists, as two 5-HT3 
receptor antagonists (metoclopramide and ondansetron) fail to influence the binding 
of Cl-indole for the h5-HT3A receptor.  This may occur because when bound, 5-HT3 
receptor antagonists do not induce a conformational change in the 5-HT3 receptor; 
whilst it is predicted that this will occur when a 5-HT3 receptor agonist binds.  
Moreover, it is thought that this conformational change is also involved in the positive 
cooperativity which has been well established for 5-HT3 receptor agonists.  Given the 
structural similarities between Cl-indole and other 5-HT3 receptor agonists, it could 
transpire therefore that once agonist is bound, through positive cooperative 
mechanisms, Cl-indole is able to interact with other binding sites on the 5-HT3 receptor 
which would otherwise engage agonist. 
 
This mechanism of orthosteric binding may in part explain the functional activity of Cl-
indole.  It has been established that in in vitro and ex vivo functional assays Cl-indole 
behaves as a selective, relatively potent type I PAM at the 5-HT3 receptor, i.e. it does 
not impact upon receptor desensitisation (Newman et al., 2013; Powell et al., 2016).  
Cl-indole has no efficacy at (and does bind to) the h5-HT3A receptor in the absence of 
agonist, yet Cl-indole will increase the potency and efficacy of agonist (Newman et al., 
2013).  Further studies have elucidated the possible mechanism of Cl-indole action.  
In single cell electrophysiology, after removal of 5-HT following co-application of 5-HT 
and Cl-indole at the h5-HT3A receptor, a tail current is recorded (Powell et al., 2016).  
Cl-indole appears to be responsible for this tail current, as the amplitude of the current 
is independent of initial 5-HT concentration.  Furthermore, given the tail current can 
be blocked with prior application of ondansetron, it suggests Cl-indole has an 
orthosteric mechanism of action, which is only revealed when agonist is present 
(Powell et al., 2016).  This complements the findings that the presence of agonist 
allows Cl-indole to compete for orthosteric binding sites at the h5-HT3A receptor.  This 
led to reidentifying Cl-indole as a cryptic orthosteric modulator rather than a positive 
allosteric modulator. 
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Interestingly, the binding mode of Cl-indole is not replicated at the h5-HT3AB receptor.  
Even in the presence of 5-HT (300 nM), Cl-indole failed to interact with the orthosteric 
binding site of the h5-HT3AB receptor, and the affinity of Cl-indole remained unaltered 
by 5-HT.  This further strengthens the idea that the h5-HT3AB receptor only has one 
A-A binding site (which orthosteric agonists can interact with) (Lochner et al., 2010).  
Moreover, Cl-indole does demonstrate efficacy at the h5-HT3AB receptor, suggesting 
it may have activity as both an orthosteric ligand (at the h5-HT3A receptor in the 
presence of agonist) and an allosteric ligand at the h5-HT3AB receptor.  Cl-indole may, 
like mCPBG, interact with A-B binding sites at the h5-HT3AB receptor (Miles et al., 
2015).  Unlike at the 5-HT3A receptor, in competition binding assays, agonists do not 
display positive cooperativity (see competition binding assays in vortioxetine or CSTI-
300 results section) when interacting with the h5-HT3AB receptor.  Furthermore, 
despite Cl-indole demonstrating activity at the h5-HT3AB receptor (to increase agonist 
efficacy) Cl-indole failed to elicit tail currents (Powell et al., 2016).  This reiterates the 
principle that 5-HT allows Cl-indole to interact with an A-A orthosteric binding site at 
the h5-HT3A receptor allowing a functional effect of Cl-indole.  The unusual 
mechanism of action of Cl-indole is similar to the ago-allosteric modulator CGP7930 
at the GABAB receptor (Schwartz et al., 2007).  The main difference with Cl-indole 
however is the orthosteric activity is only revealed when agonist is present (Powell et 
al., 2016). 
 
At the 5-HTBP, which is generated by mutating the AChBP so it is able to bind [3H]-
granisetron, 5-HT failed to demonstrate the same impact upon Cl-indole binding as 
was shown at the h5-HT3A receptor.  This suggests that the 5-HTBP is not necessarily 
a good model to use for trying to elucidate 5-HT3 receptor binding interactions. 
 
Lummis and colleagues have also tried to determine the mechanism of action for Cl-
indole, using a chimera composed of the mouse 5-HT3A receptor extracellular domain 
and the transmembrane domain of the ELIC (Erwinia ligand-gated ion channel), which 
is a prokaryotic homologue of Cys-loop receptors (Thompson et al., 2012; Price et al., 
2018).  After demonstrating this chimera has similar pharmacology to wild-type mouse 
5-HT3A receptor, it was discovered that 5-HT elicited responses are inhibited by Cl-
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indole at this chimeric receptor, in contrast to what has been shown at the 5-HT3 
receptor.  This may suggest that although Cl-indole interacts with the N-terminus of 
the 5-HT3 receptor, the transmembrane is required for its functional activity.  However, 
this work must be replicated using a h5-HT3 receptor-ELIC chimera.  Perhaps the lack 
of a transmembrane domain in the 5-HTBP is also partially the reason Cl-indole fails 
to replicate its binding mechanism with it. 
 
4.3.2 Allosteric ligands interacting with other Cys-loop receptors 
Allosteric ligands with unusual mechanisms of action of been studied in depth at other 
Cys-loop receptors.  One of the best studied examples of ago-allosteric modulation is 
the compound 4BP-TQS, which demonstrates selective activity at the α7 nAChR.  
Initial characterisation of 4BP-TQS identified that this molecule, which unlike the 
compound it was based on (TQS, a type II PAM), demonstrates agonist activity at the 
α7 nAChR (TQS does not activate the α7 nAChR in the absence of agonist) (Gill et 
al., 2011).  Interestingly, whereas a current elicited by acetylcholine at the α7 nAChR 
has a rapid onset and fast desensitisation, the current evoked by 4BP-TQS has a 
slower onset, and doesn’t desensitise (Gill et al., 2011).  Single channel studies 
identified that whilst acetylcholine elicits infrequent, short openings; 4BP-TQS induced 
responses have a longer mean open time and a shorter close time (Palczynska et al., 
2012).  This suggests that 4BP-TQS fundamentally activates the α7 nAChR through a 
different mechanism compared to classic nicotinic agonists such as acetylcholine.  
This complements the studies involving Cl-indole by highlighting how distinct the 
mechanism of action for allosteric ligands is compared to receptor agonists. 
 
Mutational studies have attempted to pinpoint the binding site for 4BP-TQS (and it’s 
active isomer, GAT107) (Thakur et al., 2013).  Mutating methionine 253 to leucine 
(found in the transmembrane domain 2 region of the α7 nAChR) causes the effect of 
4BP-TQS (and TQS) to be lost, whilst acetylcholine still retains activity (Gill et al., 
2011).  Moreover, mutations to tryptophan 148, which is close to the acetylcholine 
binding site, appear to have no impact of 4BP-TQS activity whilst reducing the affinity 
of acetylcholine (Gill et al., 2011).  Mutations to other sites in the ligand binding domain 
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(e.g. tryptophan 55, tyrosine 93, cysteine 116) all render acetylcholine inactive, yet 
GAT107 activity is unaffected (Papke et al., 2014; Horenstein et al., 2016).  
Furthermore, the α7 nAChR selective antagonist methyllycaconitine blocks any 
response induced by 4BP-TQS, suggesting that the orthosteric binding site is still 
necessary for receptor activation by 4BP-TQS (Gill et al., 2011; Gill et al., 2013).  It 
appears that 4BP-TQS activity is dependent somewhat on an interaction between the 
allosteric transmembrane domain and the orthosteric binding site.  Indeed, modelling 
studies demonstrated that when GAT107 binds to the α7 nAChR, it triggers closure of 
loop C in the ligand binding domain, which is also seen when α7 nAChR agonists such 
as epibatidine bind (Grazioso et al., 2015). 
 
4.3.3 Allosteric ligands in in vivo models of disease 
Allosteric modulators (and ago-allosteric modulators or COMs) have many 
advantages as a clinical target compared to classic orthosteric ligands.  Whilst an 
orthosteric binding site at a transmembrane receptor may have similarity across a 
family (e.g. 5-HT receptors), allosteric binding sites are often unique to each receptor, 
allowing receptor sub-type specific selectivity (Wang et al., 2009; Rocheville et al., 
2010).  This may lead to allosteric ligands having less adverse effects due to fewer 
interactions with ‘off target’ receptors, channels or transporters, leading to a safer 
biological profile (Rocheville et al., 2010; Grover, 2013).  Ago-allosteric modulators will 
also have a dual effect, by having intrinsic efficacy and also being able to increase the 
efficacy and potency of endogenous ligand (Schwartz et al., 2006).  Furthermore, an 
additional level of receptor chemistry increases the diversity of drug-like chemical 
spaces available to exploit (Rocheville et al., 2010). 
 
There are several examples of allosteric (or ago-allosteric) modulators which 
demonstrate efficacy in in vitro assays and also display activity in in vivo models of 
various diseases.  The previously mentioned selective α7 nAChR ago-allosteric 
modulator GAT107 was investigated for its impact on inflammatory or neuropathic pain 
in mice.  In control conditions, GAT107 did not impact motor activity or coordination in 
mice, demonstrating a promising safety profile of GAT107 (Bagdas et al., 2016).  
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GAT107 reduced formalin induced nociceptive behaviour in mice; this response was 
blocked when mice were pre-treated with methyllycaconitine and was not apparent in 
α7 nAChR knock-out mice (Bagdas et al., 2016).  Furthermore, GAT107 reversed 
lipopolysaccharide induced inflammatory pain and also reduced neuropathic pain 
(caused by sciatic nerve injury) (Bagdas et al., 2016).  GAT107 does therefore appear 
to have potential to treat a plethora of different types of allodynia, with limited off-target 
effects.  Indeed, it may be of interest to investigate the effect of Cl-indole in an in vivo 
assay, for example an animal model of constipation, whereby increasing 5-HT3 
receptor activity should increase gastrointestinal function (Evangelista, 2007; Taschler 
et al., 2015). 
 
Allosteric ligands which display affinity for GPCRs have also been studied, including 
BQCA at the M1 muscarinic receptor.  In functional calcium assays, BQCA increased 
the potency of acetylcholine at the M1 muscarinic receptor without demonstrating 
activity at any other muscarinic receptors (Grover, 2013).  This translated in mouse 
models of schizophrenia, where for example BQCA reversed amphetamine induced 
hyperlocomotion (Grover, 2013).  Allosteric ligands do therefore appear to have 
potential to treat a complication conditions where orthosteric small molecules may 
have limited efficacy or adverse effects. 
 
Understanding the mechanism of action of Cl-indole at the h5-HT3 receptor may aid in 
developing more potent ligands (which may have therapeutic benefit in IBS-c).  
Moreover, it may lead to the synthesis of NAMs.  NAMs may have therapeutic potential 
in treating IBS-d, by subtly overactive reducing 5-HT3 receptors without complete 
blockade (which is thought to be responsible for the constipation experienced by 
patients receiving 5-HT3 receptor antagonists, see vortioxetine and CSTI-300 
discussion sections).   
 
Future experiments examining this unusual activity of Cl-indole include ligand docking 
computational studies to see if Cl-indole interacts with additional binding sites at the 
h5-HT3A receptor as well as the orthosteric binding site.  It may also be of interest to 
131 
 
see if mutations to the h5-HT3A receptor which ablate 5-HT activity or binding also 
have the same effect for Cl-indole binding, or indeed if there are any residues which 
not impact 5-HT function but do impact Cl-indole binding.  A photo-reactive Cl-indole 
(which covalently labels the 5-HT3 receptor under UV conditions) could be used to 
identify the exact amino acid residues Cl-indole interacts with in the presence of 5-HT. 
 
One limitation of this study is the binding mechanism of Cl-indole has been studied 
indirectly. To further cement how Cl-indole interacts with the h5-HT3 receptor, the 
binding of Cl-indole may need to be monitored directly, possibly using [3H]-labelled Cl-
indole or a photo-reactive version. 
 
Cl-indole demonstrates a unique pharmacological profile at the h5-HT3 receptor.  The 
presence of orthosteric agonist, not antagonist, allows Cl-indole to compete with [3H]-
granisetron for h5-HT3A receptor binding sites; a mechanism which may explain its 
functional activity.  To further elucidate the mechanism of Cl-indoles action, mutational 
studies to identify if specific residues within the orthosteric binding site of the h5-HT3A 
receptor impact not only agonist activity but the functioning and binding of Cl-indole.  
Understanding the mechanism of Cl-indole action may aid in developing other 
allosteric 5-HT3 receptor ligands, which could show therapeutic promise in IBS-d. 
 
To conclude, this present thesis provides a detailed pharmacological investigation into 
three structurally diverse 5-HT3 receptor ligands (vortioxetine, CSTI-300 and Cl-
indole), and how each through different mechanisms of action could provide 
therapeutical promise in treating a variety of conditions (schizophrenia, IBS, carcinoid 
syndrome) where malfunction of the 5-HT3 receptor is reported. 
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Appendix  
 
 
 
 
-10 mins  5 mins  20 mins  35 mins  50 mins  
A vs. B ns A vs. B **** A vs. B **** A vs. B **** A vs. B **** 
- 5 mins  10 mins  25 mins  40 mins  55 mins  
A vs. B ns A vs. B **** A vs. B **** A vs. B **** A vs. B **** 
0 mins  15 mins  30 mins  45 mins  60 mins  
A vs. B ns A vs. B **** A vs. B **** A vs. B **** A vs. B **** 
 
 
 
 
 
 
 
 
 
 
 
Supplementary Table 1: Statistical analysis for Figure 21A.   
Statistics were performed using 2-way ANOVA (p<0.05) with Tukey post-hoc test.  
ns=non-significant, *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001. 
A= Vehicle 
B=5-HTP (10 mg/kg) 
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5 mins  20 mins  35 mins  50 mins  
B vs. C ns B vs. C ns B vs. C * B vs. C * 
B vs. D ns B vs. D * B vs. D ** B vs. D *** 
B vs. E ns B vs. E ns B vs. E ** B vs. E * 
C vs. D ns C vs. D ns C vs. D ns C vs. D ns 
C vs. E ns C vs. E ns C vs. E ns C vs. E ns 
D vs. E ns D vs. E ns D vs. E ns D vs. E ns 
10 mins  25 mins  40 mins  55 mins  
B vs. C ns B vs. C ns B vs. C ns B vs. C * 
B vs. D ns B vs. D ns B vs. D ns B vs. D ** 
B vs. E ns B vs. E ns B vs. E *** B vs. E ns 
C vs. D ns C vs. D ns C vs. D ns C vs. D ns 
C vs. E ns C vs. E ns C vs. E ns C vs. E ns 
D vs. E ns D vs. E ns D vs. E ns D vs. E ns 
15 mins  30 mins  45 mins  60 mins  
B vs. C ns B vs. C ns B vs. C ns B vs. C ** 
B vs. D ns B vs. D ns B vs. D * B vs. D ns 
B vs. E ns B vs. E ns B vs. E * B vs. E ** 
Supplementary Table 2: Statistical analysis for Figure 21B.   
Statistics were performed using 2-way ANOVA (p<0.05) with Tukey post-hoc test.  
ns=non-significant, *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001. 
B=Vehicle 
C=Alosetron (0.01 mg/kg) 
D=Alosetron (0.1 mg/kg) 
E=Alosetron (1.0 mg/kg) 
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C vs. D ns C vs. D ns C vs. D ns C vs. D ns 
C vs. E ns C vs. E ns C vs. E ns C vs. E ns 
D vs. E ns D vs. E ns D vs. E ns D vs. E ns 
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5 mins  20 mins  35 mins  50 mins  
A vs. B ns A vs. B * A vs. B **** A vs. B **** 
A vs. C ns A vs. C ns A vs. C **** A vs. C ns 
A vs. D ns A vs. D ns A vs. D ns A vs. D ns 
A vs. E ns A vs. E * A vs. E **** A vs. E **** 
B vs. C ns B vs. C ns B vs. C ns B vs. C **** 
B vs. D ns B vs. D ns B vs. D * B vs. D **** 
B vs. E ns B vs. E ns B vs. E ns B vs. E ns 
C vs. D ns C vs. D ns C vs. D * C vs. D ns 
C vs. E ns C vs. E ns C vs. E ns C vs. E ** 
D vs. E ns D vs. E ns D vs. E * D vs. E **** 
10 mins  25 mins  40 mins  55 mins  
A vs. B ns A vs. B * A vs. B **** A vs. B **** 
A vs. C ns A vs. C ns A vs. C ns A vs. C ** 
A vs. D ns A vs. D ns A vs. D ns A vs. D ns 
A vs. E ns A vs. E * A vs. E ** A vs. E **** 
B vs. C ns B vs. C ns B vs. C ns B vs. C ns 
Supplementary Table 3: Statistical analysis for Figure 21C.   
Statistical analysis was performed using a 2-way ANOVA with Tukey post-hoc test.  
ns=non-significant, *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001. 
A= Vehicle 
B= CSTI-300 (1.0 mg/kg) 
C= CSTI-300 (0.1 mg/kg) 
D= CSTI-300 (0.01 mg/kg) 
E= Alosetron (0.1 mg/kg) 
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B vs. D ns B vs. D ns B vs. D *** B vs. D *** 
B vs. E ns B vs. E ns B vs. E ns B vs. E ns 
C vs. D ns C vs. D ns C vs. D ns C vs. D ns 
C vs. E ns C vs. E ns C vs. E ns C vs. E ns 
D vs. E ns D vs. E ns D vs. E * D vs. E **** 
15 mins  30 mins  45 mins  60 mins  
A vs. B ns A vs. B *** A vs. B **** A vs. B **** 
A vs. C ns A vs. C ns A vs. C ** A vs. C ns 
A vs. D ns A vs. D ns A vs. D ns A vs. D ns 
A vs. E ns A vs. E * A vs. E **** A vs. E **** 
B vs. C ns B vs. C ns B vs. C ** B vs. C * 
B vs. D ns B vs. D ns B vs. D **** B vs. D **** 
B vs. E ns B vs. E ns B vs. E ns B vs. E ns 
C vs. D ns C vs. D ns C vs. D * C vs. D ns 
C vs. E ns C vs. E ns C vs. E ns C vs. E *** 
D vs. E ns D vs. E ns D vs. E ** D vs. E **** 
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Supplementary Table 4: Pharmacological selectivity of CSTI-300. 
CSTI-300 (1.0 µM) tested for the ability to interact with a wide variety of named targets 
assessed by the screening assays performed by either Cerep (www.cerep.fr), ChanTest 
(www.criver.com) or MDS Pharma Services (www.mdsps.com).   
Target Company Species 
5-HT1A receptor 
Cerep and MDS Pharma 
Services 
Human 
5-HT1B receptor Cerep Rat 
5-HT1D receptor Cerep Rat 
5-HT2A receptor Cerep Human 
5-HT2B receptor Cerep Human 
5-HT2C receptor Cerep Human 
5-HT4e receptor Cerep Human 
5-ht5a receptor Cerep Human 
5-HT6 receptor Cerep Human 
5-HT7 receptor Cerep Human 
Adenosine A1 receptor MDS Pharma Services Human 
Adenosine A2A receptor MDS Pharma Services Human 
Adenosine A3 receptor MDS Pharma Services Human 
Adrenergic 1A receptor MDS Pharma Services Rat 
Adrenergic 1B receptor MDS Pharma Services Rat 
Adrenergic 1D receptor MDS Pharma Services Human 
Adrenergic 2A receptor MDS Pharma Services Human 
Adrenergic 1 receptor MDS Pharma Services Human 
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Adrenergic 2 receptor MDS Pharma Services Human 
Androgen (Testosterone) receptor MDS Pharma Services Rat 
BK (KCa1.1)  ChanTest Human 
Bradykinin B1 receptor MDS Pharma Services Human 
Bradykinin B2 receptor MDS Pharma Services Human 
Calcium Channel L-Type, Benzothiazepine  MDS Pharma Services Rat 
Calcium Channel L-Type, Dihydropyridine  MDS Pharma Services Rat 
Calcium Channel L-Type (Cav1.2) ChanTest Human 
Calcium Channel N-Type  MDS Pharma Services Rat 
Calcium Channel T-type (Cav3.2) ChanTest Human 
Chloride Channel-1 ChanTest Human 
Cysteinyl Leukotriene CysLT1 receptor MDS Pharma Services Human 
Cystic Fibrosis Transmembrane Conductance 
Regulator 
ChanTest Human 
Dopamine D1 receptor MDS Pharma Services Human 
Dopamine D2S receptor MDS Pharma Services Human 
Dopamine D3 receptor MDS Pharma Services Human 
Dopamine D4.2 receptor MDS Pharma Services Human 
Dopamine Transporter MDS Pharma Services Human 
Endothelin ETA receptor MDS Pharma Services Human 
Endothelin ETB receptor MDS Pharma Services Human 
Epidermal Growth Factor  MDS Pharma Services Human 
GABA Transporter  MDS Pharma Services Rat 
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GABAA, Flunitrazepam receptor MDS Pharma Services Rat 
GABAA, Muscimol receptor MDS Pharma Services Rat 
GABAB1A receptor MDS Pharma Services Human 
Glucocorticoid receptor MDS Pharma Services Human 
GPR103 receptor MDS Pharma Services Human 
HCN2  ChanTest Human 
HCN4 ChanTest Human 
hERG  
ChanTest and MDS 
Pharma Services 
Human 
Histamine H1 receptor MDS Pharma Services Human 
Histamine H2 receptor MDS Pharma Services Human 
Histamine H3 receptor MDS Pharma Services Human 
IK (KCa3.1) ChanTest Human 
Imidazoline I2 receptor MDS Pharma Services Rat 
Interleukin IL-1 receptor MDS Pharma Services Mouse 
Kainate receptor MDS Pharma Services Rat 
KATP  MDS Pharma Services Hamster 
Kir2.1 ChanTest Human 
Kir3.1/3.4 ChanTest Human 
Kir6.2/SUR2A ChanTest Human 
Kv1.3 ChanTest Human 
Kv1.5 ChanTest Human 
Kv4.3 ChanTest Human 
KvLQT/mink ChanTest Human 
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Melatonin MT1 receptor MDS Pharma Services Human 
Muscarinic M1 receptor MDS Pharma Services Human 
Muscarinic M2 receptor MDS Pharma Services Human 
Muscarinic M3 receptor MDS Pharma Services Human 
Nicotinic -BGTX-insensitive (42) receptor Cerep Rat 
Nicotinic -BGTX-sensitive (7) receptor Cerep Rat 
Nav1.5 Phasic ChanTest Human 
Nav1.5 Tonic  ChanTest Human 
Neuropeptide Y Y1 receptor MDS Pharma Services Human 
Neuropeptide Y Y2 receptor MDS Pharma Services Human 
Nicotinic Acetylcholine receptor MDS Pharma Services Human 
Nicotinic Acetylcholine  1 Bungarotoxin receptor MDS Pharma Services Human 
NMDA, Agonism receptor MDS Pharma Services Rat 
NMDA, Glycine receptor MDS Pharma Services Rat 
NMDA, Phencyclidine receptor MDS Pharma Services Rat 
Noradrenaline Transporter MDS Pharma Services Human 
Oestrogen ER receptor MDS Pharma Services Human 
Opiate  receptor MDS Pharma Services Human 
Opiate  receptor MDS Pharma Services Human 
Opiate  receptor MDS Pharma Services Human 
P2X1 receptor ChanTest Human 
P2X3 receptor ChanTest Human 
Phorbol Ester  MDS Pharma Services Mouse 
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Platelet Activating Factor  MDS Pharma Services Human 
Prostanoid EP4 receptor MDS Pharma Services Human 
Purinergic P2X receptor MDS Pharma Services Rabbit 
Purinergic P2Y receptor MDS Pharma Services Rat 
Rolipram  MDS Pharma Services Rat 
Serotonin Transporter MDS Pharma Services Human 
Sigma 1 receptor MDS Pharma Services Human 
Sigma 2 receptor MDS Pharma Services Rat 
Sodium Channel Site 2 MDS Pharma Services Rat 
Tachykinin NK1 receptor MDS Pharma Services Human 
Thyroid Hormone  MDS Pharma Services Rat 
TRPV1 ChanTest Human 
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